##fileformat=VCFv4.1
##source=VarScan2
##INFO=<ID=ADP,Number=1,Type=Integer,Description="Average per-sample depth of bases with Phred score >= 15">
##INFO=<ID=WT,Number=1,Type=Integer,Description="Number of samples called reference (wild-type)">
##INFO=<ID=HET,Number=1,Type=Integer,Description="Number of samples called heterozygous-variant">
##INFO=<ID=HOM,Number=1,Type=Integer,Description="Number of samples called homozygous-variant">
##INFO=<ID=NC,Number=1,Type=Integer,Description="Number of samples not called">
##INFO=<ID=bior.Clinvar.ClinicalSignificance,Number=.,Type=String,Description="comma-separated list of values of clinical significance reported for this variation">
##INFO=<ID=bior.Clinvar.RCVaccession,Number=.,Type=String,Description="list of RCV accessions that report this variant">
##INFO=<ID=bior.Clinvar.PhenotypeIDs,Number=.,Type=String,Description="list of db names and identifiers for phenotype(s) reported for this variant">
##INFO=<ID=bior.Clinvar.Guidelines,Number=.,Type=String,Description="ACMG only right now">
##INFO=<ID=bior.Clinvar.ReviewStatus,Number=.,Type=String,Description="highest review status for reporting this measure. For the key to the terms">
##INFO=<ID=bior.ExAC.Info.AC,Number=A,Type=Integer,Description="Allele count in genotypes, for each ALT allele, in the same order as listed">
##INFO=<ID=bior.ExAC.Info.AN,Number=1,Type=Integer,Description="Total number of alleles in called genotypes">
##INFO=<ID=bior.ExAC.Info.AF,Number=A,Type=Float,Description="Allele Frequency, for each ALT allele, in the same order as listed">
##INFO=<ID=bior.ExAC.Info.AC_Het,Number=1,Type=Integer,Description="Adjusted Heterozygous Count (AC_Het)">
##INFO=<ID=bior.ExAC.Info.AC_Hom,Number=1,Type=Integer,Description="Adjusted Homozygous Count">
##INFO=<ID=bior.hgmd_2014.2.CLASS,Number=1,Type=String,Description="CLASS. This field categorizes mutations and polymorphisms. There are seven possible values, DM, DM?, DP, DFP, FP, FTV and R. Details here -> http://bsiweb.mayo.edu/bior_catalog/hgmd">
##INFO=<ID=bior.hgmd_2014.2.PHEN,Number=1,Type=String,Description="The name for the disease or condition associated with the mutation. If the curator had some reservations about the adequacy of the evidence supporting the relationship to the disease, this name is followed by a question mark. Disease names are provided as reported in the literature.">
##INFO=<ID=bior.hgmd_2014.2.OMIM_ID,Number=1,Type=String,Description="Identifier for the OMIM database, http://www.ncbi.nlm.nih.gov/omim.">
##INFO=<ID=bior.hgmd_2014.2.PubMed,Number=1,Type=String,Description="Numeric PUBMED id for the reference in PubMed.">
##INFO=<ID=bior.cosmic68.Histology_subtype,Number=1,Type=String,Description="Further histological classifications of the sample Histology_subtype">
##INFO=<ID=bior.dbSNP139.ID,Number=.,Type=String,Description="Semi-colon separated list of unique identifiers.  If this is a dbSNP variant, the rs number(s) should be used.  (VCF field) ID">
##FILTER=<ID=str10,Description="Less than 10% or more than 90% of variant supporting reads on one strand">
##FILTER=<ID=indelError,Description="Likely artifact due to indel reads at this position">
##FORMAT=<ID=GT,Number=1,Type=String,Description="Genotype">
##FORMAT=<ID=GQ,Number=1,Type=Integer,Description="Genotype Quality">
##FORMAT=<ID=SDP,Number=1,Type=Integer,Description="Raw Read Depth as reported by SAMtools">
##FORMAT=<ID=DP,Number=1,Type=Integer,Description="Quality Read Depth of bases with Phred score >= 15">
##FORMAT=<ID=RD,Number=1,Type=Integer,Description="Depth of reference-supporting bases (reads1)">
##FORMAT=<ID=AD,Number=1,Type=Integer,Description="Depth of variant-supporting bases (reads2)">
##FORMAT=<ID=FREQ,Number=1,Type=String,Description="Variant allele frequency">
##FORMAT=<ID=PVAL,Number=1,Type=String,Description="P-value from Fisher's Exact Test">
##FORMAT=<ID=RBQ,Number=1,Type=Integer,Description="Average quality of reference-supporting bases (qual1)">
##FORMAT=<ID=ABQ,Number=1,Type=Integer,Description="Average quality of variant-supporting bases (qual2)">
##FORMAT=<ID=RDF,Number=1,Type=Integer,Description="Depth of reference-supporting bases on forward strand (reads1plus)">
##FORMAT=<ID=RDR,Number=1,Type=Integer,Description="Depth of reference-supporting bases on reverse strand (reads1minus)">
##FORMAT=<ID=ADF,Number=1,Type=Integer,Description="Depth of variant-supporting bases on forward strand (reads2plus)">
##FORMAT=<ID=ADR,Number=1,Type=Integer,Description="Depth of variant-supporting bases on reverse strand (reads2minus)">
#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO	FORMAT	s_F-23-_10_cells_neb_repair	s_F-24-_40_cells_neb_repair	s_F-25-_200_cells_100ng	s_F-25-_200_cells_12_5_ng	s_F-25-_200_cells_25_ng	s_F-25-_200_cells_50_ng	s_F-25-_200_cells_neb_repair	s_F-26-_1k_cells_100_ng	s_F-26-_1k_cells_12_5_ng	s_F-26-_1k_cells_25_ng	s_F-26-_1k_cells_50_ng	s_F-26-_1k_cells_neb_repair
chr2	48030629	.	G	A	.	PASS	ADP=98;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:70:37:37:37:0:0%:1E0:56:0:24:13:0:0	0/0:201:115:115:114:1:0.87%:5E-1:51:38:75:39:1:0	0/0:17:10:10:10:0:0%:1E0:51:0:7:3:0:0	0/0:145:78:78:78:0:0%:1E0:61:0:32:46:0:0	0/0:265:141:141:141:0:0%:1E0:54:0:84:57:0:0	0/0:29:15:15:15:0:0%:1E0:69:0:3:12:0:0	0/0:302:162:162:162:0:0%:1E0:67:0:78:84:0:0	0/0:558:297:297:297:0:0%:1E0:69:0:142:155:0:0	0/1:21:99:99:92:7:7.07%:7.0009E-3:69:73:46:46:3:4	0/0:308:174:173:172:1:0.58%:5E-1:58:15:81:91:1:0	0/0:96:52:52:52:0:0%:1E0:67:0:22:30:0:0
chr2	48030679	.	G	T	.	PASS	ADP=89;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:77:42:42:42:0:0%:1E0:62:0:18:24:0:0	0/0:33:17:17:17:0:0%:1E0:56:0:6:11:0:0	0/0:149:80:80:80:0:0%:1E0:33:0:1:79:0:0	0/0:44:34:34:31:2:5.88%:2.4615E-1:62:19:15:16:2:0	0/0:69:53:53:50:3:5.66%:1.2143E-1:50:19:13:37:3:0	0/0:69:44:44:43:1:2.27%:5E-1:38:31:5:38:1:0	0/0:236:162:162:157:5:3.09%:3.0287E-2:55:17:73:84:5:0	0/1:30:191:191:179:10:5.24%:8.6429E-4:64:19:111:68:10:0	0/0:196:114:114:113:1:0.88%:5E-1:70:19:54:59:1:0	0/0:285:204:203:195:7:3.45%:7.4105E-3:57:18:102:93:7:0	0/0:250:133:133:133:0:0%:1E0:67:0:72:61:0:0
chr2	48030708	.	T	G	.	PASS	ADP=154;WT=6;HET=5;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:104:56:56:56:0:0%:1E0:72:0:19:37:0:0	0/1:22:30:30:23:7:23.33%:5.2713E-3:59:30:9:14:1:6	0/1:255:264:264:97:167:63.26%:2.6954E-68:41:34:2:95:57:110	0/0:84:57:57:55:2:3.51%:2.4779E-1:65:39:13:42:1:1	0/1:255:139:139:61:76:54.68%:5.3275E-30:53:36:15:46:27:49	0/1:255:160:160:78:81:50.62%:3.7403E-31:51:35:12:66:26:55	0/0:377:219:219:217:2:0.91%:2.4943E-1:67:38:99:118:0:2	0/0:381:204:204:204:0:0%:1E0:67:0:103:101:0:0	0/0:352:197:197:196:1:0.51%:5E-1:67:19:110:86:0:1	0/1:64:279:279:258:21:7.53%:3.2259E-7:67:37:138:120:9:12	0/0:471:251:251:251:0:0%:1E0:69:0:135:116:0:0
chr2	48030721	.	A	T	.	PASS	ADP=174;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:104:56:56:56:0:0%:1E0:72:0:19:37:0:0	0/0:44:24:24:24:0:0%:1E0:58:0:10:14:0:0	0/1:47:101:101:86:15:14.85%:1.7422E-5:42:18:4:82:0:15	0/0:104:55:55:55:0:0%:1E0:66:0:13:42:0:0	0/0:81:65:65:61:4:6.15%:5.9604E-2:54:18:19:42:0:4	0/0:119:78:78:76:2:2.56%:2.4839E-1:53:18:12:64:0:2	0/0:587:314:314:314:0:0%:1E0:70:0:144:170:0:0	0/0:638:351:351:350:1:0.28%:5E-1:71:17:176:174:1:0	0/0:666:355:355:355:0:0%:1E0:71:0:180:175:0:0	0/0:518:333:333:326:7:2.1%:7.5676E-3:68:18:157:169:0:7	0/0:645:356:356:355:1:0.28%:5E-1:70:18:175:180:0:1
chr2	48030726	.	C	T	.	PASS	ADP=172;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:100:54:54:54:0:0%:1E0:69:0:19:35:0:0	0/0:44:24:24:24:0:0%:1E0:58:0:10:14:0:0	0/1:31:98:98:88:10:10.2%:7.6712E-4:41:19:4:84:0:10	0/0:97:51:51:51:0:0%:1E0:65:0:13:38:0:0	0/0:119:63:63:63:0:0%:1E0:53:0:19:44:0:0	0/0:116:75:75:73:2:2.67%:2.4832E-1:53:17:10:63:2:0	0/0:567:314:314:313:1:0.32%:5E-1:69:17:143:170:1:0	0/0:634:350:350:348:1:0.29%:5E-1:72:17:175:173:1:0	0/0:663:353:353:353:0:0%:1E0:72:0:182:171:0:0	0/0:625:333:333:333:0:0%:1E0:68:0:157:176:0:0	0/0:645:356:356:355:1:0.28%:5E-1:70:18:175:180:0:1
chr2	48030764	.	A	T	.	PASS	ADP=146;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:775:413:413:413:0:0%:1E0:48:0:197:216:0:0	0/0:17:10:10:10:0:0%:1E0:40:0:2:8:0:0	0/1:44:83:83:69:14:16.87%:3.3581E-5:28:19:4:65:0:14	0/0:21:15:15:14:1:6.67%:5E-1:56:16:4:10:1:0	0/0:37:34:34:31:3:8.82%:1.194E-1:34:19:4:27:0:3	0/0:57:42:42:40:2:4.76%:2.4699E-1:35:19:6:34:0:2	0/0:395:230:230:228:2:0.87%:2.4946E-1:66:20:106:122:0:2	0/0:362:194:194:194:0:0%:1E0:71:0:96:98:0:0	0/0:452:242:242:242:0:0%:1E0:73:0:133:109:0:0	0/0:439:253:253:251:2:0.79%:2.495E-1:60:20:118:133:0:2	0/0:445:247:247:246:1:0.4%:5E-1:70:16:117:129:0:1
chr2	48030766	.	C	T	.	PASS	ADP=144;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:718:415:384:384:0:0%:1E0:45:0:166:218:0:0	0/0:11:10:10:9:1:10%:5E-1:43:20:2:7:0:1	0/1:41:83:83:70:13:15.66%:7.3398E-5:27:20:4:66:0:13	0/0:21:14:12:12:0:0%:1E0:56:0:5:7:0:0	0/0:37:34:34:31:3:8.82%:1.194E-1:34:20:4:27:0:3	0/0:57:42:42:40:2:4.76%:2.4699E-1:33:29:6:34:0:2	0/0:381:230:230:227:3:1.3%:1.2418E-1:65:20:106:121:0:3	0/0:362:194:194:194:0:0%:1E0:71:0:96:98:0:0	0/0:433:242:242:241:1:0.41%:5E-1:73:20:133:108:0:1	0/0:399:254:254:249:5:1.97%:3.0635E-2:60:20:118:131:0:5	0/0:460:246:246:246:0:0%:1E0:69:0:117:129:0:0
chr2	48030811	.	C	T	.	PASS	ADP=224;WT=10;HET=1;HOM=0;NC=1;bior.ExAC.Info.AC=4;bior.ExAC.Info.AN=126702;bior.ExAC.Info.AF=3.157e-05;bior.ExAC.Info.AC_Het=4;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM?;bior.hgmd_2014.2.PHEN=Colorectal_cancer|_non-polyposis;bior.hgmd_2014.2.OMIM_ID=600678;bior.hgmd_2014.2.PubMed=23523604;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs267608089	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:749:420:412:411:1:0.24%:5E-1:56:26:186:225:0:1	0/0:29:16:16:16:0:0%:1E0:52:0:8:8:0:0	0/0:359:202:202:201:1:0.5%:5E-1:54:20:120:81:0:1	0/0:82:44:43:43:0:0%:1E0:44:0:23:20:0:0	0/0:160:85:85:85:0:0%:1E0:55:0:53:32:0:0	0/0:201:108:108:108:0:0%:1E0:56:0:69:39:0:0	0/0:661:374:374:372:2:0.53%:2.4967E-1:66:73:170:202:1:1	0/0:689:367:367:367:0:0%:1E0:68:0:174:193:0:0	0/1:77:340:340:315:25:7.35%:1.8856E-8:73:77:160:155:21:4	0/0:672:380:380:378:2:0.53%:2.4967E-1:65:78:192:186:2:0	0/0:537:363:363:353:10:2.75%:9.1711E-4:67:75:168:185:10:0
chr2	48030838	.	A	T	.	PASS	ADP=77;WT=4;HET=2;HOM=3;NC=3;bior.Clinvar.ClinicalSignificance=Benign;bior.Clinvar.RCVaccession=RCV000074853|RCV000126833|RCV000035324;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1211|MedGen:C0009405|SNOMED_CT:315058005|MedGen:CN169374|MedGen:CN221809;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=reviewed_by_expert_panel;bior.ExAC.Info.AC=51003;bior.ExAC.Info.AN=126674;bior.ExAC.Info.AF=0.403;bior.ExAC.Info.AC_Het=28810;bior.ExAC.Info.AC_Hom=11053;bior.dbSNP139.ID=rs2020911	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:6	0/0:11:9:9:8:1:11.11%:5E-1:41:35:8:0:1:0	0/0:261:139:139:139:0:0%:1E0:52:0:136:3:0:0	./.:.:1	0/0:111:60:60:60:0:0%:1E0:55:0:58:2:0:0	0/0:119:64:64:64:0:0%:1E0:54:0:64:0:0:0	1/1:255:146:146:35:111:76.03%:8.0676E-50:64:69:22:13:56:55	1/1:255:119:119:7:112:94.12%:3.6997E-60:52:77:7:0:49:63	0/1:255:132:132:46:86:65.15%:6.9677E-36:76:76:32:14:56:30	0/1:255:131:131:40:91:69.47%:4.9197E-39:68:77:34:6:52:39	1/1:255:120:120:29:91:75.83%:7.0842E-41:77:70:18:11:55:36
chr2	48030839	.	A	G	.	PASS	ADP=76;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:6	0/0:18:9:9:9:0:0%:1E0:31:0:9:0:0:0	0/1:24:138:136:128:8:5.88%:3.5138E-3:48:16:125:3:8:0	./.:.:1	0/0:79:60:60:57:3:5%:1.2185E-1:53:16:55:2:3:0	0/0:78:63:63:59:4:6.35%:5.9512E-2:50:17:59:0:4:0	0/0:255:146:146:145:1:0.68%:5E-1:68:16:77:68:1:0	0/0:224:119:119:119:0:0%:1E0:75:0:56:63:0:0	0/0:246:132:132:132:0:0%:1E0:76:0:88:44:0:0	0/0:247:131:131:131:0:0%:1E0:74:0:86:45:0:0	0/0:207:120:120:119:1:0.83%:5E-1:71:17:71:48:1:0
chr2	48030842	.	T	C	.	PASS	ADP=73;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:8:8:8:7:1:12.5%:5E-1:34:17:7:0:1:0	0/1:50:138:138:122:16:11.59%:9.6237E-6:48:18:119:3:16:0	./.:.:1	0/0:56:59:58:51:6:10.34%:1.3607E-2:55:17:49:2:6:0	0/0:78:63:63:59:4:6.35%:5.9512E-2:48:17:59:0:4:0	0/0:215:123:123:122:1:0.81%:5E-1:69:15:61:61:1:0	0/0:224:119:119:119:0:0%:1E0:75:0:56:63:0:0	0/0:239:128:128:128:0:0%:1E0:76:0:85:43:0:0	0/0:239:127:127:127:0:0%:1E0:74:0:82:45:0:0	0/0:183:120:120:117:3:2.5%:1.2343E-1:71:16:69:48:3:0
chr2	48030851	.	C	G	.	PASS	ADP=71;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:6	0/1:27:134:134:125:9:6.72%:1.7001E-3:47:16:122:3:9:0	./.:.:1	0/0:91:55:55:54:1:1.82%:5E-1:52:16:52:2:1:0	0/0:62:62:62:56:6:9.68%:1.3767E-2:51:16:56:0:6:0	0/0:212:114:114:114:0:0%:1E0:70:0:49:65:0:0	0/0:217:115:115:115:0:0%:1E0:77:0:52:63:0:0	0/0:239:128:128:128:0:0%:1E0:66:0:51:77:0:0	0/0:231:124:124:124:0:0%:1E0:74:0:75:49:0:0	0/0:176:116:116:113:3:2.59%:1.2338E-1:66:16:46:67:3:0
chr2	48030858	.	T	A	.	PASS	ADP=70;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:6	0/1:21:134:131:124:7:5.34%:7.196E-3:45:15:121:3:7:0	./.:.:1	0/0:77:55:54:52:2:3.7%:2.4766E-1:53:15:50:2:2:0	0/0:83:62:61:58:3:4.92%:1.219E-1:50:15:58:0:3:0	0/0:212:114:114:114:0:0%:1E0:70:0:49:65:0:0	0/0:217:115:115:115:0:0%:1E0:76:0:52:63:0:0	0/0:239:128:128:128:0:0%:1E0:65:0:51:77:0:0	0/0:231:124:124:124:0:0%:1E0:73:0:75:49:0:0	0/0:200:116:116:115:1:0.86%:5E-1:64:15:47:68:1:0
chr2	48030859	.	C	G	.	PASS	ADP=71;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:6	0/1:24:133:132:124:8:6.06%:3.5022E-3:47:15:121:3:8:0	./.:.:1	0/0:73:55:55:52:3:5.45%:1.2156E-1:53:15:50:2:3:0	0/0:91:62:62:60:2:3.23%:2.4797E-1:47:15:60:0:2:0	0/0:196:114:114:113:1:0.88%:5E-1:70:16:48:65:1:0	0/0:217:115:115:115:0:0%:1E0:76:0:52:63:0:0	0/0:239:128:128:128:0:0%:1E0:66:0:51:77:0:0	0/0:231:124:124:124:0:0%:1E0:73:0:75:49:0:0	0/0:200:116:116:115:1:0.86%:5E-1:65:15:48:67:1:0
chr2	48030863	.	T	A	.	PASS	ADP=71;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:6	0/1:37:133:133:121:12:9.02%:1.8835E-4:48:16:118:3:12:0	./.:.:1	0/0:91:55:55:54:1:1.82%:5E-1:53:16:52:2:1:0	0/0:68:62:62:57:5:8.06%:2.8741E-2:49:16:57:0:5:0	0/0:212:114:114:114:0:0%:1E0:70:0:49:65:0:0	0/0:217:115:115:115:0:0%:1E0:76:0:52:63:0:0	0/0:239:128:128:128:0:0%:1E0:66:0:51:77:0:0	0/0:231:124:124:124:0:0%:1E0:74:0:75:49:0:0	0/0:216:116:116:116:0:0%:1E0:66:0:49:67:0:0
chr2	212578280	.	C	A	.	PASS	ADP=552;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:780:456:456:452:4:0.88%:6.2089E-2:54:32:59:393:0:4	0/0:1254:681:681:680:1:0.15%:5E-1:38:16:2:678:0:1	0/0:781:448:448:445:3:0.67%:1.2458E-1:56:34:82:363:0:3	0/0:1132:656:656:651:5:0.76%:3.1012E-2:38:32:0:651:0:5	0/0:1212:660:660:659:1:0.15%:5E-1:38:38:3:656:0:1	0/1:64:384:384:362:21:5.47%:3.5976E-7:53:32:58:304:0:21	0/0:1207:667:667:665:2:0.3%:2.4981E-1:38:33:4:661:0:2	0/0:1214:671:671:669:2:0.3%:2.4981E-1:38:33:4:665:0:2	0/0:1262:673:673:673:0:0%:1E0:38:0:3:670:0:0	0/0:1262:673:673:673:0:0%:1E0:38:0:5:668:0:0	0/0:1173:660:660:657:3:0.45%:1.2472E-1:38:32:4:653:0:3
chr2	212812097	.	T	C	.	PASS	ADP=15;WT=1;HET=2;HOM=3;NC=6;bior.dbSNP139.ID=rs839541	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:105:19:19:0:19:100%:2.8292E-11:0:77:0:0:5:14	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/1:25:13:13:6:7:53.85%:2.6087E-3:73:77:2:4:3:4	1/1:52:10:10:0:10:100%:5.4125E-6:0:77:0:0:4:6	1/1:255:68:68:0:68:100%:1.6809E-40:0:77:0:0:36:32	0/1:64:64:64:45:19:29.69%:3.9716E-7:77:76:18:27:12:7	0/0:33:17:17:17:0:0%:1E0:77:0:7:10:0:0
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=lobular_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=papillary_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10183772	.	C	T	.	PASS	ADP=314;WT=0;HET=0;HOM=8;NC=4;bior.Clinvar.ClinicalSignificance=Likely_benign|Pathogenic|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000002321|RCV000115744;bior.Clinvar.PhenotypeIDs=GeneReviews:NBK1463|MedGen:C0019562|OMIM:193300|Orphanet:ORPHA892|SNOMED_CT:46659004|MedGen:C0027672;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=21;bior.ExAC.Info.AN=124664;bior.ExAC.Info.AF=1.685e-04;bior.ExAC.Info.AC_Het=20;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=8634692;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma;bior.dbSNP139.ID=rs104893829	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:339:339:0:339:100%:2.6031E-203:0:74:0:0:165:174	./.:.:0	./.:.:0	1/1:255:333:333:0:333:100%:1.0568E-199:0:74:0:0:180:153	1/1:93:17:17:0:17:100%:4.2852E-10:0:75:0:0:10:7	1/1:255:647:647:27:620:95.83%:0E0:36:36:0:27:5:615	1/1:255:515:515:0:515:100%:3.4969E-309:0:43:0:0:49:466	1/1:255:647:647:3:644:99.54%:0E0:35:36:0:3:4:640	1/1:255:638:638:12:626:98.12%:0E0:38:36:6:6:8:618	1/1:255:634:634:21:613:96.69%:0E0:38:36:2:19:2:611
chr3	10188214	.	C	G	.	PASS	ADP=122;WT=4;HET=2;HOM=2;NC=4;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=7728151;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:52:27:27:27:0:0%:1E0:77:0:27:0:0:0	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:60:0	./.:.:0	./.:.:0	1/1:255:218:218:0:218:100%:1.4756E-130:0:77:0:0:218:0	./.:.:0	0/1:129:568:568:526:42:7.39%:1.0352E-13:45:40:526:0:42:0	0/0:25:14:14:14:0:0%:1E0:77:0:14:0:0:0	0/0:373:200:200:200:0:0%:1E0:77:0:200:0:0:0	0/1:87:273:273:245:28:10.26%:1.7964E-9:76:74:243:2:28:0	0/0:213:113:113:113:0:0%:1E0:76:0:113:0:0:0
chr3	10188214	.	C	G	.	PASS	ADP=122;WT=4;HET=2;HOM=2;NC=4;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=7728151;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:52:27:27:27:0:0%:1E0:77:0:27:0:0:0	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:60:0	./.:.:0	./.:.:0	1/1:255:218:218:0:218:100%:1.4756E-130:0:77:0:0:218:0	./.:.:0	0/1:129:568:568:526:42:7.39%:1.0352E-13:45:40:526:0:42:0	0/0:25:14:14:14:0:0%:1E0:77:0:14:0:0:0	0/0:373:200:200:200:0:0%:1E0:77:0:200:0:0:0	0/1:87:273:273:245:28:10.26%:1.7964E-9:76:74:243:2:28:0	0/0:213:113:113:113:0:0%:1E0:76:0:113:0:0:0
chr3	10188214	.	C	G	.	PASS	ADP=122;WT=4;HET=2;HOM=2;NC=4;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Von_Hippel-Lindau_syndrome;bior.hgmd_2014.2.OMIM_ID=608537;bior.hgmd_2014.2.PubMed=7728151;bior.cosmic68.Histology_subtype=clear_cell_renal_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:52:27:27:27:0:0%:1E0:77:0:27:0:0:0	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:60:0	./.:.:0	./.:.:0	1/1:255:218:218:0:218:100%:1.4756E-130:0:77:0:0:218:0	./.:.:0	0/1:129:568:568:526:42:7.39%:1.0352E-13:45:40:526:0:42:0	0/0:25:14:14:14:0:0%:1E0:77:0:14:0:0:0	0/0:373:200:200:200:0:0%:1E0:77:0:200:0:0:0	0/1:87:273:273:245:28:10.26%:1.7964E-9:76:74:243:2:28:0	0/0:213:113:113:113:0:0%:1E0:76:0:113:0:0:0
chr3	138665152	.	A	C	.	PASS	ADP=441;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:82:43:43:43:0:0%:1E0:74:0:21:22:0:0	0/0:891:476:476:476:0:0%:1E0:52:0:233:243:0:0	0/0:735:404:403:402:1:0.25%:5E-1:62:32:205:197:0:1	0/0:627:345:345:344:1:0.29%:5E-1:72:72:170:174:1:0	0/0:752:403:402:402:0:0%:1E0:62:0:193:209:0:0	0/0:708:377:377:377:0:0%:1E0:66:0:203:174:0:0	0/0:1254:683:681:680:1:0.15%:5E-1:37:33:24:656:0:1	0/1:201:549:545:481:64:11.74%:7.5963E-21:44:49:100:381:21:43	0/0:1173:680:678:672:5:0.74%:3.1019E-2:36:37:116:556:2:3	0/0:1238:675:674:673:1:0.15%:5E-1:37:38:25:648:0:1	0/0:1250:680:679:678:1:0.15%:5E-1:37:77:14:664:1:0
chr3	138665170	.	G	C	.	PASS	ADP=438;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:82:43:43:43:0:0%:1E0:74:0:21:22:0:0	0/0:895:477:477:477:0:0%:1E0:52:0:233:244:0:0	0/1:184:400:397:339:58:14.61%:3.6689E-19:66:36:173:166:29:29	0/0:648:345:345:345:0:0%:1E0:72:0:171:174:0:0	0/0:749:401:399:399:0:0%:1E0:62:0:190:209:0:0	0/0:703:378:377:376:0:0%:1E0:66:0:201:175:0:0	0/0:1262:679:674:674:0:0%:1E0:37:0:18:656:0:0	0/0:1014:548:542:542:0:0%:1E0:45:0:123:419:0:0	0/0:1244:676:663:663:0:0%:1E0:37:0:116:547:0:0	0/0:1223:677:666:665:1:0.15%:5E-1:37:37:24:641:0:1	0/0:1262:682:674:674:0:0%:1E0:37:0:17:657:0:0
chr3	178916811	.	T	G	.	PASS	ADP=62;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:548:347:347:337:6:1.73%:1.5284E-2:32:18:37:300:0:6	./.:.:0	0/0:55:35:35:34:1:2.86%:5E-1:59:18:15:19:0:1	0/0:84:58:58:56:2:3.45%:2.4783E-1:30:17:0:56:0:2	0/0:17:10:10:10:0:0%:1E0:45:0:3:7:0:0	0/0:190:102:102:102:0:0%:1E0:52:0:18:84:0:0	0/1:21:72:72:65:7:9.72%:6.7056E-3:54:17:16:49:0:7	0/0:47:26:26:26:0:0%:1E0:77:0:13:13:0:0	0/0:80:49:49:48:1:2.04%:5E-1:44:16:7:41:0:1	0/0:89:48:48:48:0:0%:1E0:45:0:18:30:0:0
chr3	178916818	.	A	T	.	PASS	ADP=62;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:55:347:347:329:18:5.19%:3.0425E-6:34:16:37:292:0:18	./.:.:0	0/0:55:35:35:34:1:2.86%:5E-1:60:15:15:19:0:1	0/0:79:59:59:56:3:5.08%:1.2179E-1:28:16:0:56:0:3	0/0:17:10:10:10:0:0%:1E0:47:0:3:7:0:0	0/0:190:102:102:102:0:0%:1E0:52:0:18:84:0:0	0/0:91:72:72:68:4:5.56%:5.9887E-2:56:15:16:52:0:4	0/0:47:26:26:26:0:0%:1E0:77:0:13:13:0:0	0/0:93:49:49:49:0:0%:1E0:39:0:7:42:0:0	0/0:92:50:50:50:0:0%:1E0:46:0:19:31:0:0
chr3	178916828	.	G	C	.	PASS	ADP=61;WT=7;HET=2;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:106:347:340:304:34:10%:2.43E-11:36:17:37:267:0:34	./.:.:0	0/0:35:35:35:31:4:11.43%:5.7106E-2:66:17:15:16:0:4	0/1:21:59:56:49:7:12.5%:6.4016E-3:30:17:0:49:0:7	0/0:18:10:9:9:0:0%:1E0:51:0:3:6:0:0	0/0:141:102:102:98:4:3.92%:6.0657E-2:53:17:18:80:0:4	0/0:81:72:69:64:5:7.25%:2.8994E-2:58:16:16:48:0:5	0/0:47:26:26:26:0:0%:1E0:76:0:13:13:0:0	0/0:89:49:47:47:0:0%:1E0:39:0:7:40:0:0	0/0:92:51:50:50:0:0%:1E0:46:0:19:31:0:0
chr3	178916829	.	T	G	.	PASS	ADP=62;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:86:347:345:314:28:8.16%:2.0943E-9:37:18:37:277:0:28	./.:.:0	0/0:47:35:35:33:2:5.71%:2.4638E-1:63:18:15:18:0:2	0/0:65:59:59:54:5:8.47%:2.8614E-2:30:17:0:54:0:5	0/0:11:10:10:8:1:10%:5E-1:53:37:3:5:0:1	0/0:162:102:102:100:2:1.96%:2.4877E-1:52:19:18:82:0:2	0/0:77:72:72:66:6:8.33%:1.4021E-2:58:17:16:50:0:6	0/0:47:26:26:26:0:0%:1E0:76:0:13:13:0:0	0/0:63:49:49:46:3:6.12%:1.2113E-1:41:18:7:39:0:3	0/0:84:51:51:50:1:1.96%:5E-1:47:18:19:31:0:1
chr3	178916832	.	T	G	.	PASS	ADP=62;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:112:347:347:309:36:10.43%:5.5549E-12:34:18:37:272:0:36	./.:.:0	0/0:40:35:35:32:3:8.57%:1.1957E-1:63:18:15:17:0:3	0/0:79:59:59:56:3:5.08%:1.2179E-1:26:19:0:56:0:3	0/0:17:10:10:10:0:0%:1E0:46:0:3:7:0:0	0/0:162:102:102:100:2:1.96%:2.4877E-1:52:19:17:83:0:2	0/0:77:72:72:66:6:8.33%:1.4021E-2:56:18:16:50:0:6	0/0:47:26:26:26:0:0%:1E0:76:0:13:13:0:0	0/0:71:49:49:47:2:4.08%:2.4742E-1:40:18:7:40:0:2	0/0:84:51:51:50:1:1.96%:5E-1:46:19:19:31:0:1
chr3	178916840	.	A	G	.	PASS	ADP=62;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:55:348:348:330:18:5.17%:3.0445E-6:34:18:37:293:0:18	./.:.:0	0/0:55:35:35:34:1:2.86%:5E-1:60:18:15:19:0:1	0/0:98:60:60:59:1:1.67%:5E-1:27:31:0:59:0:1	0/0:17:10:10:10:0:0%:1E0:45:0:3:7:0:0	0/0:174:102:102:101:1:0.98%:5E-1:53:18:18:83:0:1	0/0:109:72:72:70:2:2.78%:2.4825E-1:54:19:16:54:0:2	0/0:47:26:26:26:0:0%:1E0:77:0:13:13:0:0	0/0:71:49:49:47:2:4.08%:2.4742E-1:39:17:7:40:0:2	0/0:74:51:51:49:2:3.92%:2.4752E-1:46:18:19:30:0:2
chr3	178916930	.	G	A	.	PASS	ADP=54;WT=7;HET=2;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:254:185:185:177:7:3.8%:7.3716E-3:51:19:137:40:7:0	./.:.:0	0/0:82:43:43:43:0:0%:1E0:64:0:24:19:0:0	0/0:247:161:161:157:4:2.48%:6.1334E-2:59:19:113:44:4:0	0/0:14:12:12:11:1:8.33%:5E-1:61:19:10:1:1:0	0/1:34:73:73:62:11:15.07%:3.2525E-4:33:18:56:6:11:0	0/1:21:56:56:49:7:12.5%:6.4016E-3:41:18:42:7:7:0	0/0:36:20:20:20:0:0%:1E0:77:0:10:10:0:0	0/0:67:48:48:46:2:4.17%:2.4737E-1:37:18:40:6:2:0	0/0:88:53:53:52:1:1.89%:5E-1:40:19:32:20:1:0
chr3	178916931	.	C	T	.	PASS	ADP=53;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:36:185:185:172:12:6.52%:2.0287E-4:50:18:132:40:12:0	./.:.:0	0/0:60:43:43:41:2:4.65%:2.4706E-1:67:18:22:19:2:0	0/0:243:160:160:156:4:2.5%:6.1326E-2:58:17:112:44:4:0	0/0:22:11:11:11:0:0%:1E0:62:0:10:1:0:0	0/0:120:71:71:70:1:1.41%:5E-1:30:18:64:6:1:0	0/0:81:56:56:54:2:3.57%:2.4775E-1:37:18:47:7:2:0	0/0:36:20:20:20:0:0%:1E0:76:0:10:10:0:0	0/0:53:45:44:41:3:6.82%:1.2069E-1:37:18:36:5:3:0	0/0:92:52:50:50:0:0%:1E0:40:0:32:18:0:0
chr3	178916942	.	A	T	.	PASS	ADP=47;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:33:160:154:141:11:7.14%:4.0483E-4:55:17:98:43:11:0	./.:.:0	0/0:66:42:42:41:1:2.38%:5E-1:68:18:22:19:1:0	0/0:240:160:158:153:4:2.53%:6.1304E-2:59:16:109:44:4:0	0/0:11:11:10:9:1:10%:5E-1:62:19:6:3:1:0	0/0:94:59:58:57:1:1.72%:5E-1:32:16:50:7:1:0	0/0:82:46:43:43:0:0%:1E0:41:0:36:7:0:0	0/0:36:20:20:20:0:0%:1E0:76:0:10:10:0:0	0/0:54:40:39:37:2:5.13%:2.4675E-1:39:17:31:6:2:0	0/0:80:49:49:48:1:2.04%:5E-1:44:16:28:20:1:0
chr3	178916952	.	C	A	.	PASS	ADP=47;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:24:160:154:146:8:5.19%:3.5587E-3:56:17:103:43:8:0	./.:.:0	0/0:57:42:42:40:2:4.76%:2.4699E-1:70:17:21:19:2:0	0/0:223:160:159:153:6:3.77%:1.4893E-2:60:18:109:44:6:0	0/0:11:11:10:9:1:9.09%:5E-1:60:19:6:3:1:0	0/0:94:58:58:57:1:1.72%:5E-1:35:15:50:7:1:0	0/0:49:46:46:42:4:8.7%:5.8402E-2:46:16:35:7:4:0	0/0:36:20:20:20:0:0%:1E0:74:0:10:10:0:0	0/0:50:40:38:36:2:5.26%:2.4667E-1:42:19:32:4:2:0	0/0:49:49:46:42:4:8.7%:5.8402E-2:46:17:23:19:4:0
chr3	178916956	.	C	A	.	PASS	ADP=48;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:30:160:160:150:10:6.25%:8.4479E-4:53:20:107:43:10:0	./.:.:0	0/0:57:42:42:40:2:4.76%:2.4699E-1:67:19:21:19:2:0	0/0:214:160:160:152:7:4.38%:7.3031E-3:59:18:108:44:7:0	0/0:14:11:11:10:1:9.09%:5E-1:57:19:7:3:1:0	0/0:95:58:57:56:1:1.75%:5E-1:34:19:50:6:1:0	0/0:73:46:46:45:1:2.17%:5E-1:40:19:38:7:1:0	0/0:36:20:20:20:0:0%:1E0:75:0:10:10:0:0	0/0:74:40:40:40:0:0%:1E0:38:0:34:6:0:0	0/0:89:49:48:48:0:0%:1E0:42:0:29:19:0:0
chr3	178916963	.	T	A	.	PASS	ADP=48;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:33:160:160:149:11:6.88%:4.0877E-4:54:17:106:43:11:0	./.:.:1	0/0:70:43:43:42:1:2.33%:5E-1:67:33:23:19:1:0	0/0:281:160:160:159:1:0.62%:5E-1:58:16:115:44:1:0	0/0:14:11:11:10:1:9.09%:5E-1:57:18:7:3:1:0	0/0:94:58:58:57:1:1.72%:5E-1:36:18:50:7:1:0	0/0:85:45:45:45:0:0%:1E0:49:0:38:7:0:0	0/0:36:20:20:20:0:0%:1E0:76:0:10:10:0:0	0/0:74:39:39:39:0:0%:1E0:42:0:33:6:0:0	0/0:89:47:47:47:0:0%:1E0:42:0:28:19:0:0
chr3	178947872	.	G	A	.	PASS	ADP=176;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:112:59:59:59:0:0%:1E0:76:0:6:53:0:0	0/0:659:351:351:351:0:0%:1E0:73:0:94:257:0:0	0/0:651:348:348:348:0:0%:1E0:74:0:90:258:0:0	0/0:734:391:391:391:0:0%:1E0:66:0:72:319:0:0	./.:.:0	0/0:197:133:133:129:4:3.01%:6.1088E-2:77:77:42:87:1:3	0/0:310:166:166:166:0:0%:1E0:77:0:70:96:0:0	0/0:377:202:202:202:0:0%:1E0:77:0:73:129:0:0	0/0:348:185:185:185:0:0%:1E0:77:0:77:108:0:0	0/1:160:284:284:234:50:17.61%:8.3345E-17:77:77:103:131:28:22
chr3	178952098	.	G	T	.	PASS	ADP=532;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:21:26:15:7:6:40%:7.4534E-3:29:19:7:0:6:0	0/0:1246:680:678:677:1:0.15%:5E-1:38:36:6:671:0:1	0/0:1192:671:660:658:2:0.3%:2.4981E-1:38:15:180:478:2:0	0/0:1146:675:664:659:5:0.75%:3.1015E-2:38:24:166:493:4:1	0/0:1270:678:677:677:0:0%:1E0:38:0:5:672:0:0	0/0:1177:673:665:659:3:0.45%:1.2472E-1:38:31:179:480:1:2	0/0:1209:656:646:646:0:0%:1E0:38:0:437:209:0:0	0/0:991:572:562:559:3:0.53%:1.2467E-1:42:15:365:194:3:0	0/0:1137:635:620:619:1:0.16%:5E-1:39:15:254:365:1:0	0/0:1213:661:648:648:0:0%:1E0:38:0:401:247:0:0	0/0:984:570:557:554:3:0.54%:1.2466E-1:43:52:475:79:1:2
chr4	1803662	.	C	T	.	PASS	ADP=87;WT=3;HET=2;HOM=2;NC=5;bior.ExAC.Info.AC=2;bior.ExAC.Info.AN=126096;bior.ExAC.Info.AF=1.586e-05;bior.ExAC.Info.AC_Het=2;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:4	./.:.:4	./.:.:3	0/0:25:14:14:14:0:0%:1E0:42:0:5:9:0:0	0/0:25:13:13:13:0:0%:1E0:70:0:8:5:0:0	0/0:488:377:370:353:16:4.34%:1.2924E-5:44:28:164:189:12:4	1/1:255:65:65:5:60:92.31%:1.2731E-31:44:34:2:3:52:8	1/1:255:132:132:23:109:82.58%:1.1391E-51:50:31:3:20:100:9	0/1:77:372:365:340:25:6.85%:1.9478E-8:38:33:123:217:18:7	0/1:88:80:80:54:26:32.5%:1.3105E-9:44:34:22:32:22:4
chr4	1807894	.	G	A	.	PASS	ADP=507;WT=0;HET=0;HOM=11;NC=1;bior.ExAC.Info.AC=124742;bior.ExAC.Info.AN=126342;bior.ExAC.Info.AF=0.987;bior.ExAC.Info.AC_Het=1362;bior.ExAC.Info.AC_Hom=60279;bior.dbSNP139.ID=rs7688609	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:124:122:0:122:100%:6.9324E-73:0:39:0:0:64:58	1/1:255:595:595:0:595:100%:0E0:0:38:0:0:3:592	1/1:255:540:539:0:539:100%:1.5E-323:0:45:0:0:35:504	1/1:255:560:557:0:557:100%:0E0:0:44:0:0:30:527	1/1:255:659:655:0:655:100%:0E0:0:38:0:0:6:649	1/1:255:385:385:0:385:100%:5.6021E-231:0:54:0:0:69:316	1/1:255:648:642:0:642:100%:0E0:0:38:0:0:26:616	1/1:255:653:652:0:652:100%:0E0:0:38:0:0:16:636	1/1:255:647:645:0:644:99.84%:0E0:0:38:0:0:22:622	1/1:255:651:643:0:643:100%:0E0:0:38:0:0:20:623	1/1:255:656:653:2:651:99.69%:0E0:16:38:0:2:12:639
chr4	55141055	.	A	G	.	PASS	ADP=370;WT=0;HET=0;HOM=10;NC=2;bior.ExAC.Info.AC=125219;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.988;bior.ExAC.Info.AC_Het=1360;bior.ExAC.Info.AC_Hom=61922;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs1873778	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:492:492:0:492:100%:2.4052E-295:0:52:0:0:77:415	1/1:255:202:202:0:202:100%:6.101E-121:0:75:0:0:83:119	1/1:255:450:450:0:450:100%:4.4494E-270:0:56:0:0:96:354	1/1:255:674:674:0:674:100%:0E0:0:38:0:0:4:670	1/1:99:18:18:0:18:100%:1.1019E-10:0:75:0:0:4:14	1/1:255:498:498:0:498:100%:5.9078E-299:0:51:0:0:76:422	1/1:255:642:642:0:642:100%:0E0:0:40:0:0:15:627	1/1:255:511:511:0:511:100%:8.9174E-307:0:50:0:0:85:426	1/1:255:545:545:0:545:100%:0E0:0:47:0:0:64:481	1/1:255:413:413:0:413:100%:8.052E-248:0:62:0:0:126:287
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=gliosarcoma;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=gliosarcoma;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=gliosarcoma;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=spindle;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=spindle;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=spindle_and_epithelioid;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=spindle;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=spindle;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=spindle;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55152040	.	C	T	.	PASS	ADP=504;WT=0;HET=1;HOM=9;NC=2;bior.ExAC.Info.AC=22883;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.181;bior.ExAC.Info.AC_Het=17843;bior.ExAC.Info.AC_Hom=2518;bior.cosmic68.Histology_subtype=endometrioid_carcinoma;bior.dbSNP139.ID=rs2228230	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:672:668:0:668:100%:0E0:0:38:0:0:4:664	1/1:255:459:459:3:456:99.35%:2.7991E-268:64:55:0:3:1:455	1/1:255:523:520:0:520:100%:3.4315E-312:0:49:0:0:2:518	1/1:255:670:669:3:665:99.4%:0E0:36:38:0:3:1:664	1/1:255:666:662:0:662:100%:0E0:0:38:0:0:0:662	1/1:255:587:585:140:445:76.07%:3.1788E-198:42:43:0:140:0:445	1/1:255:519:516:14:502:97.29%:1.1649E-282:52:49:2:12:0:502	1/1:255:659:655:134:521:79.54%:1.0201E-238:37:38:0:134:12:509	0/1:255:667:663:245:418:63.05%:7.9594E-170:37:38:0:245:0:418	1/1:255:668:662:111:551:83.23%:6.7742E-261:38:39:0:111:3:548
chr4	55561723	.	C	A	.	PASS	ADP=342;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:566:370:354:347:6:1.69%:1.5294E-2:31:17:16:331:0:6	0/0:17:10:10:10:0:0%:1E0:75:0:7:3:0:0	0/0:696:458:441:431:8:1.81%:3.7826E-3:41:16:69:362:0:8	0/1:67:425:405:383:22:5.42%:1.7787E-7:30:19:19:364:0:22	0/0:576:398:389:376:10:2.58%:9.206E-4:45:19:64:312:0:10	0/0:865:468:461:461:0:0%:1E0:49:0:113:348:0:0	0/0:929:499:496:495:0:0%:1E0:48:0:104:391:0:0	0/0:957:549:536:532:2:0.37%:2.4977E-1:37:18:58:474:0:2	0/0:882:548:538:529:7:1.3%:7.66E-3:39:17:82:447:0:7	0/0:858:490:479:477:2:0.42%:2.4974E-1:45:17:82:395:0:2
chr4	55561727	.	C	T	.	PASS	ADP=344;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:604:373:353:348:3:0.85%:1.2447E-1:31:16:17:331:0:3	0/0:17:10:10:10:0:0%:1E0:73:0:7:3:0:0	0/0:806:458:452:449:2:0.44%:2.4972E-1:44:16:69:380:0:2	0/1:118:425:413:369:38:9.2%:1.4707E-12:30:17:20:349:0:38	0/0:528:399:390:373:15:3.85%:2.6587E-5:44:17:65:308:0:15	0/0:814:471:466:463:3:0.64%:1.246E-1:50:29:112:351:1:2	0/0:773:503:492:481:9:1.83%:1.8821E-3:43:16:104:377:0:9	0/0:681:551:537:507:25:4.66%:2.2331E-8:36:17:58:449:0:25	0/0:811:551:536:520:12:2.24%:2.293E-4:38:20:83:437:0:12	0/0:837:492:480:474:3:0.62%:1.2461E-1:44:17:82:392:0:3
chr4	55561747	.	T	A	.	PASS	ADP=364;WT=7;HET=2;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:642:465:465:439:15:3.23%:2.7134E-5:34:41:12:427:5:10	./.:.:7	0/0:739:466:466:455:8:1.72%:3.789E-3:45:19:70:385:0:8	0/1:160:435:434:366:51:11.78%:8.7146E-17:33:54:3:363:16:35	0/1:255:399:399:278:107:26.82%:1.1527E-36:41:62:24:254:40:67	0/0:787:477:477:470:6:1.26%:1.5379E-2:48:18:115:355:0:6	0/0:872:509:509:501:4:0.79%:6.2129E-2:46:19:104:397:0:4	0/0:967:562:562:554:4:0.71%:6.2164E-2:40:18:58:496:0:4	0/0:964:558:557:551:4:0.72%:6.2162E-2:42:23:82:469:0:4	0/0:772:500:499:485:10:2%:9.3276E-4:46:20:84:401:0:10
chr4	55561757	.	C	A	.	PASS	ADP=354;WT=0;HET=9;HOM=0;NC=3;bior.dbSNP139.ID=rs72549301	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:117:465:442:404:38:8.6%:1.5851E-12:32:16:12:392:0:38	./.:.:7	0/1:70:468:457:434:23:5.03%:8.9753E-8:43:16:68:366:0:23	0/1:134:432:422:378:43:10.19%:3.6725E-14:28:16:3:375:0:43	0/1:76:398:391:366:25:6.39%:2.0055E-8:38:16:25:341:0:25	0/1:124:473:463:422:40:8.64%:3.7643E-13:27:16:3:419:0:40	0/1:130:505:490:447:42:8.57%:9.0642E-14:29:17:4:443:0:42	0/1:142:564:549:502:46:8.38%:5.304E-15:29:16:3:499:0:46	0/1:152:557:541:492:49:9.06%:5.6908E-16:29:17:1:491:0:49	0/1:111:502:490:453:36:7.35%:7.4568E-12:31:16:2:451:0:36
chr4	55561816	.	A	C	.	PASS	ADP=85;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:324:225:223:216:7:3.14%:7.448E-3:34:18:101:115:7:0	./.:.:7	0/0:182:110:106:105:1:0.94%:5E-1:39:18:55:50:1:0	0/0:204:143:138:134:4:2.9%:6.1139E-2:28:18:109:25:4:0	0/0:162:110:108:105:3:2.78%:1.2326E-1:27:18:99:6:3:0	0/0:159:117:113:108:4:3.54%:6.0822E-2:30:18:96:12:4:0	0/1:27:102:101:92:9:8.91%:1.6215E-3:32:18:79:13:9:0	0/0:91:72:72:68:4:5.56%:5.9887E-2:34:18:53:15:4:0	0/0:95:65:63:61:2:3.17%:2.48E-1:29:19:48:13:2:0	0/0:113:92:90:85:5:5.56%:2.9519E-2:32:18:75:10:5:0
chr4	55561833	.	A	G	.	PASS	ADP=50;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:236:162:162:157:5:3.09%:3.0287E-2:37:16:40:117:5:0	./.:.:4	0/0:134:72:71:71:0:0%:1E0:39:0:10:61:0:0	0/0:66:36:36:36:0:0%:1E0:34:0:11:25:0:0	0/0:21:25:25:21:4:16%:5.4928E-2:33:19:15:6:4:0	0/0:92:84:82:76:6:7.32%:1.4214E-2:31:16:64:12:6:0	0/0:62:61:61:55:6:9.84%:1.3737E-2:31:16:43:12:6:0	0/0:62:52:51:47:3:6%:1.2121E-1:36:16:32:15:3:0	0/0:47:41:39:36:3:7.69%:1.2013E-1:36:16:23:13:3:0	0/1:21:76:74:67:7:9.46%:6.7346E-3:31:18:57:10:7:0
chr4	55561840	.	A	G	.	PASS	ADP=54;WT=8;HET=1;HOM=0;NC=3;bior.ExAC.Info.AC=4;bior.ExAC.Info.AN=126702;bior.ExAC.Info.AF=3.157e-05;bior.ExAC.Info.AC_Het=4;bior.ExAC.Info.AC_Hom=0;bior.dbSNP139.ID=rs371353189	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:304:194:193:189:4:2.07%:6.1527E-2:39:20:56:133:4:0	./.:.:4	0/0:134:72:71:71:0:0%:1E0:39:0:10:61:0:0	0/0:66:36:36:36:0:0%:1E0:37:0:11:25:0:0	0/0:48:25:25:25:0:0%:1E0:36:0:19:6:0:0	0/0:201:115:115:114:1:0.87%:5E-1:37:18:80:34:1:0	0/0:69:48:45:43:1:2.22%:5E-1:33:16:34:9:1:0	0/0:56:54:54:48:5:9.26%:2.8317E-2:39:18:32:16:5:0	0/0:66:43:42:41:1:2.38%:5E-1:39:15:27:14:1:0	0/1:31:74:73:63:10:13.7%:7.0212E-4:32:17:54:9:10:0
chr4	55592121	.	C	T	.	PASS	ADP=91;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:78:41:41:41:0:0%:1E0:54:0:22:19:0:0	./.:.:1	0/0:14:8:8:8:0:0%:1E0:51:0:0:8:0:0	0/0:29:15:15:15:0:0%:1E0:76:0:15:0:0:0	0/0:29:15:15:15:0:0%:1E0:74:0:14:1:0:0	0/0:422:260:260:256:4:1.54%:6.1778E-2:61:22:179:77:0:4	0/0:134:91:91:88:3:3.3%:1.2293E-1:71:19:79:9:0:3	0/1:46:264:264:249:15:5.68%:2.4873E-5:55:35:146:103:4:11	0/0:331:223:223:215:6:2.69%:1.5097E-2:59:19:146:69:0:6	0/0:340:181:181:181:0:0%:1E0:63:0:134:47:0:0
chr4	55593453	.	G	C	.	PASS	ADP=242;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:89:48:48:48:0:0%:1E0:77:0:21:27:0:0	0/0:689:367:367:367:0:0%:1E0:68:0:161:206:0:0	0/1:33:217:217:206:11:5.07%:4.2881E-4:61:18:61:145:0:11	0/0:231:124:124:124:0:0%:1E0:58:0:36:88:0:0	0/0:579:395:394:383:11:2.79%:4.5493E-4:63:18:143:240:0:11	0/0:59:31:31:31:0:0%:1E0:70:0:16:15:0:0	0/0:658:352:352:352:0:0%:1E0:72:0:163:189:0:0	0/0:634:349:349:348:1:0.29%:5E-1:72:78:152:196:0:1	0/0:568:339:339:335:4:1.18%:6.1946E-2:73:20:168:167:0:4	0/0:666:356:356:356:0:0%:1E0:71:0:155:201:0:0	0/0:632:338:338:338:0:0%:1E0:68:0:188:150:0:0
chr4	55593539	.	A	G	.	PASS	ADP=68;WT=9;HET=2;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:77:0:71:66:0:0	0/1:27:91:91:82:9:9.89%:1.587E-3:33:16:67:15:9:0	0/0:168:129:128:122:6:4.69%:1.4717E-2:31:16:120:2:6:0	0/0:466:260:260:259:1:0.38%:5E-1:38:17:194:65:1:0	0/1:23:24:24:17:7:29.17%:4.7006E-3:20:17:16:1:7:0	0/0:59:31:31:31:0:0%:1E0:38:0:19:12:0:0	0/0:25:14:14:14:0:0%:1E0:41:0:10:4:0:0	0/0:29:31:31:27:4:12.9%:5.6405E-2:30:17:21:6:4:0	0/0:44:23:23:23:0:0%:1E0:35:0:18:5:0:0	0/0:34:28:28:26:2:7.14%:2.4545E-1:34:17:22:4:2:0	0/0:77:54:54:52:2:3.7%:2.4766E-1:39:16:45:7:2:0
chr4	55593541	.	A	T	.	PASS	ADP=67;WT=9;HET=2;HOM=0;NC=1;bior.ExAC.Info.AC=2;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=1.578e-05;bior.ExAC.Info.AC_Het=2;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:77:0:71:66:0:0	0/1:28:86:86:77:9:10.47%:1.567E-3:34:18:62:15:9:0	0/0:165:126:126:119:6:4.76%:1.4695E-2:31:19:117:2:6:0	0/0:486:260:260:260:0:0%:1E0:38:0:195:65:0:0	0/1:23:22:22:15:7:31.82%:4.4505E-3:21:18:14:1:7:0	0/0:59:31:31:31:0:0%:1E0:37:0:19:12:0:0	0/0:25:14:14:14:0:0%:1E0:42:0:10:4:0:0	0/0:26:30:30:26:4:13.33%:5.62E-2:32:19:20:6:4:0	0/0:44:23:23:23:0:0%:1E0:36:0:18:5:0:0	0/0:41:27:27:26:1:3.7%:5E-1:34:19:22:4:1:0	0/0:87:54:54:53:1:1.85%:5E-1:37:17:46:7:1:0
chr4	55593542	.	A	C	.	PASS	ADP=72;WT=8;HET=3;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:77:0:71:66:0:0	0/1:34:86:86:75:11:12.79%:3.4727E-4:33:18:60:15:11:0	0/1:47:126:126:110:15:11.9%:1.9534E-5:29:18:108:2:15:0	0/0:486:260:260:260:0:0%:1E0:37:0:195:65:0:0	0/1:50:22:22:9:13:59.09%:9.5813E-6:22:18:8:1:13:0	0/0:59:31:31:31:0:0%:1E0:35:0:19:12:0:0	0/0:29:15:15:15:0:0%:1E0:42:0:10:5:0:0	0/0:24:31:31:26:5:16.13%:2.6257E-2:32:18:19:7:5:0	0/0:119:63:63:63:0:0%:1E0:37:0:18:45:0:0	0/0:49:42:42:39:3:7.14%:1.2048E-1:36:17:20:19:3:0	0/0:84:58:58:56:2:3.45%:2.4783E-1:38:16:45:11:2:0
chr4	55593550	.	A	C	.	PASS	ADP=69;WT=8;HET=3;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:77:0:71:66:0:0	0/0:101:77:77:73:4:5.19%:6.0057E-2:31:18:62:11:4:0	0/1:43:126:126:112:14:11.11%:4.1666E-5:30:19:110:2:14:0	0/0:486:260:260:260:0:0%:1E0:38:0:195:65:0:0	0/1:27:21:21:13:8:38.1%:1.7241E-3:22:18:13:0:8:0	0/0:18:9:9:9:0:0%:1E0:41:0:8:1:0:0	0/0:29:15:15:15:0:0%:1E0:41:0:10:5:0:0	0/1:26:31:31:23:8:25.81%:2.3332E-3:33:18:16:7:8:0	0/0:119:63:63:63:0:0%:1E0:37:0:18:45:0:0	0/0:66:42:42:41:1:2.38%:5E-1:36:18:22:19:1:0	0/0:84:58:58:56:2:3.45%:2.4783E-1:36:17:45:11:2:0
chr4	55593555	.	G	T	.	PASS	ADP=63;WT=10;HET=1;HOM=0;NC=1;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=7.892e-06;bior.ExAC.Info.AC_Het=1;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:77:0:71:66:0:0	0/0:130:69:69:69:0:0%:1E0:38:0:39:30:0:0	0/1:24:140:140:130:8:5.71%:3.5194E-3:34:18:107:23:8:0	0/0:473:271:271:269:2:0.74%:2.4954E-1:36:17:193:76:2:0	0/0:25:14:14:14:0:0%:1E0:40:0:1:13:0:0	0/0:18:9:9:9:0:0%:1E0:41:0:8:1:0:0	0/0:14:12:12:11:1:8.33%:5E-1:41:16:5:6:1:0	0/0:22:11:11:11:0:0%:1E0:32:0:3:8:0:0	0/0:87:54:54:53:1:1.85%:5E-1:37:19:9:44:0:1	0/0:41:28:28:27:1:3.57%:5E-1:37:19:9:18:0:1	0/0:33:17:17:17:0:0%:1E0:34:0:4:13:0:0
chr4	55593562	.	T	G	.	PASS	ADP=142;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:77:0:71:66:0:0	0/0:130:69:69:69:0:0%:1E0:38:0:39:30:0:0	0/0:261:140:140:140:0:0%:1E0:35:0:117:23:0:0	0/0:508:272:272:272:0:0%:1E0:38:0:195:77:0:0	0/0:25:14:14:14:0:0%:1E0:39:0:1:13:0:0	0/0:14:8:8:8:0:0%:1E0:38:0:7:1:0:0	0/0:501:268:268:268:0:0%:1E0:37:0:6:262:0:0	0/0:160:85:85:85:0:0%:1E0:37:0:3:82:0:0	0/0:284:152:152:151:0:0%:1E0:38:0:9:142:0:0	0/1:255:416:416:326:90:21.63%:3.6227E-30:37:29:9:317:0:90	0/0:272:146:146:146:0:0%:1E0:37:0:4:142:0:0
chr4	55594211	.	G	A	.	PASS	ADP=193;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:606:324:324:324:0:0%:1E0:39:0:323:1:0:0	0/0:355:189:189:189:0:0%:1E0:77:0:189:0:0:0	0/0:149:80:80:80:0:0%:1E0:39:0:79:1:0:0	0/1:49:17:17:5:12:70.59%:1.1285E-5:78:77:5:0:12:0	0/0:313:168:168:168:0:0%:1E0:77:0:168:0:0:0	./.:.:2	0/0:591:316:316:316:0:0%:1E0:77:0:316:0:0:0	0/0:606:324:324:324:0:0%:1E0:51:0:324:0:0:0	0/0:977:521:521:521:0:0%:1E0:43:0:521:0:0:0	0/0:689:367:367:367:0:0%:1E0:61:0:366:1:0:0	0/0:17:10:10:10:0:0%:1E0:37:0:9:1:0:0
chr4	55597606	.	C	T	.	PASS	ADP=83;WT=4;HET=1;HOM=0;NC=7	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/1:21:135:135:128:7:5.19%:7.214E-3:37:38:3:125:0:7	0/0:402:235:234:232:2:0.85%:2.4946E-1:35:19:136:96:2:0	0/0:393:219:219:218:1:0.46%:5E-1:35:19:106:112:1:0	0/0:426:227:227:227:0:0%:1E0:33:0:137:90:0:0	0/0:340:182:182:182:0:0%:1E0:37:0:95:87:0:0
chr4	55946081	.	A	G	.	PASS	ADP=195;WT=0;HET=0;HOM=6;NC=6;bior.ExAC.Info.AC=126307;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.997;bior.ExAC.Info.AC_Het=395;bior.ExAC.Info.AC_Hom=62950;bior.dbSNP139.ID=rs4421048	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:703:701:0:701:100%:0E0:0:38:0:0:2:699	./.:.:0	./.:.:0	./.:.:0	./.:.:1	./.:.:3	1/1:255:422:422:0:422:100%:3.1049E-253:0:52:0:0:299:123	1/1:255:182:182:0:182:100%:6.3678E-109:0:50:0:0:144:38	1/1:255:239:239:0:239:100%:3.5129E-143:0:61:0:0:126:113	1/1:255:425:423:0:422:100%:3.1049E-253:0:53:0:0:242:180	1/1:255:370:370:0:370:100%:5.8969E-222:0:58:0:0:239:131
chr4	153259059	.	A	G	.	PASS	ADP=133;WT=6;HET=2;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/1:34:114:114:102:11:9.65%:3.7826E-4:49:20:102:0:11:0	0/1:30:158:158:148:10:6.33%:8.4319E-4:29:19:147:1:10:0	0/0:62:39:39:38:1:2.56%:5E-1:63:19:38:0:1:0	0/0:497:266:266:266:0:0%:1E0:38:0:123:143:0:0	0/0:651:348:348:348:0:0%:1E0:38:0:61:287:0:0	0/0:582:322:322:321:1:0.31%:5E-1:38:32:81:240:0:1	0/0:411:219:219:219:0:0%:1E0:38:0:81:138:0:0	0/0:242:130:130:130:0:0%:1E0:38:0:60:70:0:0
chr4	153259060	.	G	A	.	PASS	ADP=124;WT=6;HET=2;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/1:24:114:114:106:8:7.02%:3.4403E-3:46:17:106:0:8:0	0/1:66:154:154:133:21:13.64%:2.2955E-7:29:18:132:1:21:0	0/0:62:39:39:38:1:2.56%:5E-1:62:18:38:0:1:0	0/0:460:266:245:245:0:0%:1E0:37:0:123:122:0:0	0/0:535:349:314:310:3:0.96%:1.244E-1:37:16:61:249:0:3	0/0:552:323:305:304:1:0.33%:5E-1:37:16:81:223:0:1	0/0:377:219:202:202:0:0%:1E0:37:0:81:121:0:0	0/0:232:130:123:123:0:0%:1E0:37:0:60:63:0:0
chr4	153259061	.	C	T	.	PASS	ADP=132;WT=6;HET=2;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/1:40:113:113:100:13:11.5%:8.4695E-5:46:20:100:0:13:0	0/1:56:151:151:133:18:11.92%:2.2272E-6:27:18:132:1:18:0	0/0:54:39:39:37:2:5.13%:2.4675E-1:63:19:37:0:2:0	0/0:501:267:267:267:0:0%:1E0:37:0:123:144:0:0	0/0:634:349:349:348:1:0.29%:5E-1:36:19:61:287:0:1	0/0:586:323:323:322:1:0.31%:5E-1:36:18:79:243:1:0	0/0:392:220:220:219:1:0.45%:5E-1:36:19:81:138:0:1	0/0:242:130:130:130:0:0%:1E0:36:0:60:70:0:0
chr4	153259062	.	A	C	.	PASS	ADP=133;WT=6;HET=2;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/1:21:113:113:106:7:6.19%:7.0996E-3:47:18:106:0:7:0	0/1:24:151:151:143:8:5.3%:3.5519E-3:29:17:142:1:8:0	0/0:62:39:39:38:1:2.56%:5E-1:63:18:38:0:1:0	0/0:501:268:268:268:0:0%:1E0:38:0:123:145:0:0	0/0:659:351:351:351:0:0%:1E0:36:0:61:290:0:0	0/0:606:323:323:323:0:0%:1E0:36:0:81:242:0:0	0/0:411:220:220:220:0:0%:1E0:36:0:81:139:0:0	0/0:242:130:130:130:0:0%:1E0:36:0:60:70:0:0
chr4	153259063	.	A	G	.	PASS	ADP=133;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/1:21:113:112:105:7:6.25%:7.0934E-3:46:17:105:0:7:0	0/0:225:151:150:145:4:2.67%:6.124E-2:28:17:144:1:4:0	0/0:74:39:39:39:0:0%:1E0:62:0:39:0:0:0	0/0:501:268:268:268:0:0%:1E0:37:0:123:145:0:0	0/0:659:351:351:351:0:0%:1E0:36:0:61:290:0:0	0/0:582:323:323:321:1:0.31%:5E-1:36:37:81:240:0:1	0/0:411:220:220:220:0:0%:1E0:36:0:81:139:0:0	0/0:242:130:130:130:0:0%:1E0:37:0:60:70:0:0
chr4	153259065	.	C	A	.	PASS	ADP=132;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/1:21:113:108:101:7:6.48%:7.0672E-3:46:17:101:0:7:0	0/0:190:151:145:138:7:4.83%:7.2547E-3:28:17:137:1:7:0	0/0:74:39:39:39:0:0%:1E0:61:0:39:0:0:0	0/0:501:268:267:267:0:0%:1E0:36:0:122:145:0:0	0/0:590:351:351:347:4:1.14%:6.1965E-2:33:23:60:287:1:3	0/0:553:323:323:320:3:0.93%:1.2442E-1:33:24:81:239:0:3	0/0:373:220:218:216:2:0.92%:2.4943E-1:34:17:79:137:0:2	0/0:226:130:130:129:1:0.77%:5E-1:35:17:60:69:0:1
chr4	153259075	.	G	T	.	PASS	ADP=132;WT=6;HET=2;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/1:31:113:110:100:10:9.09%:7.8855E-4:51:19:100:0:10:0	0/1:73:148:147:124:23:15.65%:4.6897E-8:34:19:123:1:23:0	0/0:74:39:39:39:0:0%:1E0:63:0:39:0:0:0	0/0:481:268:268:267:1:0.37%:5E-1:36:18:123:144:0:1	0/0:617:351:350:347:2:0.57%:2.4964E-1:34:18:61:286:0:2	0/0:586:323:323:322:1:0.31%:5E-1:35:18:80:242:0:1	0/0:346:220:218:214:4:1.83%:6.1639E-2:35:18:80:134:0:4	0/0:243:130:130:129:0:0%:1E0:36:0:60:69:0:0
chr4	153259078	.	C	A	.	PASS	ADP=111;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:3	./.:.:0	0/0:162:103:102:99:2:1.96%:2.4876E-1:48:19:99:0:2:0	0/1:27:142:141:131:9:6.38%:1.7105E-3:28:19:130:1:9:0	0/0:70:38:38:38:0:0%:1E0:64:0:38:0:0:0	0/0:426:268:237:236:1:0.42%:5E-1:37:19:123:113:0:1	0/0:433:351:265:261:4:1.51%:6.1792E-2:35:20:61:200:0:4	0/0:460:323:255:254:1:0.39%:5E-1:36:16:80:174:0:1	0/0:321:220:171:171:0:0%:1E0:36:0:81:90:0:0	0/0:215:130:123:122:1:0.81%:5E-1:37:19:60:62:0:1
chr4	153259101	.	A	T	.	PASS	ADP=84;WT=6;HET=1;HOM=0;NC=5	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:5	./.:.:0	0/0:113:69:68:66:1:1.49%:5E-1:40:33:31:35:0:1	./.:.:6	0/0:66:36:36:36:0:0%:1E0:51:0:22:14:0:0	0/0:276:148:148:148:0:0%:1E0:34:0:2:146:0:0	0/0:530:293:293:292:1:0.34%:5E-1:37:16:1:291:0:1	0/1:52:247:247:229:17:6.88%:5.7313E-6:31:18:4:225:0:17	0/0:248:142:142:141:1:0.7%:5E-1:32:17:2:139:0:1	0/0:134:71:71:71:0:0%:1E0:34:0:2:69:0:0
chr4	153259105	.	G	T	.	PASS	ADP=84;WT=6;HET=1;HOM=0;NC=5	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:5	./.:.:0	0/0:105:69:69:67:2:2.9%:2.4818E-1:40:19:31:36:2:0	./.:.:6	0/0:66:36:36:36:0:0%:1E0:51:0:22:14:0:0	0/1:30:148:148:138:10:6.76%:8.3459E-4:31:19:2:136:0:10	0/0:550:293:293:293:0:0%:1E0:36:0:1:292:0:0	0/0:464:247:247:247:0:0%:1E0:31:0:4:243:0:0	0/0:252:143:143:142:1:0.7%:5E-1:34:16:1:141:1:0	0/0:134:71:71:71:0:0%:1E0:30:0:2:69:0:0
chr4	153259106	.	A	T	.	PASS	ADP=84;WT=6;HET=1;HOM=0;NC=5	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:5	./.:.:0	0/0:130:69:69:69:0:0%:1E0:39:0:33:36:0:0	./.:.:6	0/0:66:36:36:36:0:0%:1E0:51:0:22:14:0:0	0/0:276:148:148:148:0:0%:1E0:33:0:2:146:0:0	0/0:550:293:293:293:0:0%:1E0:37:0:1:292:0:0	0/1:49:247:247:231:16:6.48%:1.1874E-5:31:17:4:227:0:16	0/0:252:143:143:142:1:0.7%:5E-1:32:18:2:140:0:1	0/0:77:71:71:65:6:8.45%:1.3999E-2:31:18:2:63:0:6
chr4	153259107	.	A	T	.	PASS	ADP=84;WT=6;HET=1;HOM=0;NC=5	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:5	./.:.:0	0/0:130:69:69:69:0:0%:1E0:39:0:33:36:0:0	./.:.:6	0/0:66:36:36:36:0:0%:1E0:51:0:22:14:0:0	0/0:276:148:148:148:0:0%:1E0:36:0:2:146:0:0	0/0:530:293:293:292:1:0.34%:5E-1:36:16:1:291:0:1	0/1:42:247:247:233:14:5.67%:5.0503E-5:30:18:4:229:0:14	0/0:248:143:143:141:1:0.7%:5E-1:31:16:1:140:1:0	0/0:134:71:71:71:0:0%:1E0:31:0:2:69:0:0
chr5	112175416	.	C	T	.	PASS	ADP=323;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:18:10:9:9:0:0%:1E0:44:0:9:0:0:0	0/0:209:113:112:112:0:0%:1E0:76:0:106:6:0:0	0/0:21:13:12:12:0:0%:1E0:30:0:12:0:0:0	0/0:213:114:113:113:0:0%:1E0:72:0:113:0:0:0	0/0:22:12:11:11:0:0%:1E0:72:0:11:0:0:0	0/1:30:159:159:149:10:6.29%:8.44E-4:71:77:132:17:10:0	0/0:1267:699:699:697:2:0.29%:2.4982E-1:39:39:675:22:2:0	0/0:1259:697:696:694:2:0.29%:2.4982E-1:38:38:680:14:2:0	0/0:1219:693:693:689:4:0.58%:6.2229E-2:38:39:671:18:4:0	0/0:1167:692:692:685:7:1.01%:7.6943E-3:39:39:671:14:7:0	0/0:1167:693:691:684:7:1.01%:7.6941E-3:39:35:665:19:6:1
chr5	112175417	.	T	A	.	PASS	ADP=324;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:17:10:10:10:0:0%:1E0:41:0:10:0:0:0	0/0:213:113:113:113:0:0%:1E0:75:0:107:6:0:0	0/0:25:14:14:14:0:0%:1E0:28:0:14:0:0:0	0/0:213:114:113:113:0:0%:1E0:72:0:113:0:0:0	0/0:21:12:12:12:0:0%:1E0:67:0:12:0:0:0	0/1:30:159:159:149:10:6.29%:8.44E-4:71:75:132:17:10:0	0/0:1267:699:699:697:2:0.29%:2.4982E-1:38:39:675:22:2:0	0/0:1259:697:697:694:2:0.29%:2.4982E-1:38:39:681:13:2:0	0/0:1219:694:693:689:4:0.58%:6.2229E-2:38:39:670:19:4:0	0/0:1167:692:692:684:7:1.01%:7.6941E-3:39:38:671:13:7:0	0/0:1182:693:693:686:6:0.87%:1.5456E-2:39:35:667:19:5:1
chr5	112175418	.	A	G	.	PASS	ADP=324;WT=10;HET=1;HOM=0;NC=1;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126700;bior.ExAC.Info.AF=7.893e-06;bior.ExAC.Info.AC_Het=1;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:17:10:10:10:0:0%:1E0:41:0:10:0:0:0	0/0:213:113:113:113:0:0%:1E0:76:0:106:7:0:0	0/0:17:14:14:13:1:7.14%:5E-1:25:17:13:0:1:0	0/0:193:114:112:111:1:0.89%:5E-1:73:15:111:0:1:0	0/0:21:12:12:12:0:0%:1E0:69:0:12:0:0:0	0/1:33:159:159:148:11:6.92%:4.083E-4:71:75:131:17:11:0	0/0:1267:699:699:697:2:0.29%:2.4982E-1:38:39:675:22:2:0	0/0:1263:698:698:695:2:0.29%:2.4982E-1:38:39:681:14:2:0	0/0:1218:695:695:690:4:0.58%:6.223E-2:38:39:671:19:4:0	0/0:1152:692:692:684:8:1.16%:3.8276E-3:38:39:670:14:8:0	0/0:1186:693:693:687:6:0.87%:1.5456E-2:38:35:668:19:5:1
chr5	112175587	.	A	T	.	PASS	ADP=87;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:152:82:82:82:0:0%:1E0:43:0:78:4:0:0	./.:.:1	0/0:190:101:101:101:0:0%:1E0:38:0:101:0:0:0	0/0:22:11:11:11:0:0%:1E0:73:0:6:5:0:0	0/0:204:117:117:116:1:0.85%:5E-1:40:39:112:4:1:0	0/1:33:164:160:149:11:6.88%:4.0877E-4:32:18:15:134:0:11	0/0:175:94:93:93:0:0%:1E0:35:0:39:54:0:0	0/0:415:233:231:230:1:0.43%:5E-1:34:18:31:199:0:1	0/0:224:120:120:120:0:0%:1E0:35:0:2:118:0:0	0/0:241:140:138:137:1:0.72%:5E-1:38:37:66:71:0:1
chr5	112175588	.	C	A	.	PASS	ADP=84;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:152:82:82:82:0:0%:1E0:43:0:78:4:0:0	./.:.:0	0/0:190:101:101:101:0:0%:1E0:38:0:101:0:0:0	0/0:22:11:11:11:0:0%:1E0:71:0:6:5:0:0	0/0:220:117:117:117:0:0%:1E0:40:0:113:4:0:0	0/0:183:164:145:135:7:4.83%:7.2431E-3:30:16:15:120:0:7	0/0:152:94:91:89:1:1.1%:5E-1:34:15:39:50:0:1	0/1:62:233:220:193:20:9.09%:5.9749E-7:31:17:31:162:0:20	0/0:151:120:103:99:3:2.91%:1.2315E-1:32:16:2:97:0:3	0/0:258:140:137:137:0:0%:1E0:36:0:66:71:0:0
chr5	112175592	.	G	T	.	PASS	ADP=81;WT=8;HET=1;HOM=0;NC=3;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:152:82:82:82:0:0%:1E0:42:0:78:4:0:0	./.:.:0	0/0:190:101:101:101:0:0%:1E0:37:0:101:0:0:0	0/0:22:11:11:11:0:0%:1E0:72:0:6:5:0:0	0/0:220:117:117:117:0:0%:1E0:39:0:113:4:0:0	0/0:280:153:149:149:0:0%:1E0:35:0:11:138:0:0	0/0:138:74:73:73:0:0%:1E0:36:0:19:54:0:0	0/1:39:229:227:212:13:5.73%:1.0213E-4:35:18:26:186:1:12	0/0:187:99:99:99:0:0%:1E0:36:0:2:97:0:0	0/0:224:119:119:119:0:0%:1E0:38:0:45:74:0:0
chr5	112175605	.	A	C	.	PASS	ADP=64;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:21:12:12:12:0:0%:1E0:73:0:8:4:0:0	./.:.:0	./.:.:0	0/0:25:13:13:13:0:0%:1E0:72:0:6:7:0:0	0/0:18:9:9:9:0:0%:1E0:73:0:4:5:0:0	0/1:43:201:182:168:14:7.69%:4.7076E-5:39:15:27:141:0:14	0/0:96:73:71:67:3:4.29%:1.223E-1:34:15:19:48:0:3	0/0:350:284:263:251:11:4.2%:4.3868E-4:39:16:51:200:0:11	0/0:145:119:103:99:4:3.88%:6.0675E-2:36:16:8:91:0:4	0/0:190:131:123:120:3:2.44%:1.2347E-1:38:16:44:76:0:3
chr5	112175620	.	T	C	.	PASS	ADP=79;WT=5;HET=1;HOM=0;NC=6;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:25:14:14:14:0:0%:1E0:71:0:6:8:0:0	./.:.:0	./.:.:0	./.:.:3	./.:.:6	0/1:43:208:207:189:14:6.83%:4.8403E-5:39:15:27:162:0:14	0/0:87:74:74:68:5:6.85%:2.9117E-2:35:16:19:49:0:5	0/0:381:297:296:282:14:4.73%:5.215E-5:39:17:50:232:0:14	0/0:331:216:215:210:5:2.33%:3.0524E-2:46:16:57:153:0:5	0/0:226:143:143:140:3:2.1%:1.2368E-1:41:16:51:89:0:3
chr5	112175770	.	G	A	.	PASS	ADP=256;WT=4;HET=0;HOM=5;NC=3;bior.Clinvar.ClinicalSignificance=Benign|other;bior.Clinvar.RCVaccession=RCV000074234|RCV000035071;bior.Clinvar.PhenotypeIDs=MedGen:CN029768|OMIM:114500|MedGen:CN169374;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=81948;bior.ExAC.Info.AN=126686;bior.ExAC.Info.AF=0.647;bior.ExAC.Info.AC_Het=27789;bior.ExAC.Info.AC_Hom=26977;bior.dbSNP139.ID=rs41115	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:523:317:316:312:4:1.27%:6.1906E-2:52:61:207:105:4:0	0/0:52:33:33:32:1:3.03%:5E-1:52:16:27:5:0:1	0/0:27:24:24:22:2:8.33%:2.4468E-1:76:36:16:6:1:1	0/0:283:152:152:152:0:0%:1E0:50:0:99:53:0:0	./.:.:3	1/1:255:551:548:41:507:92.52%:1.3198E-265:66:43:23:18:46:461	1/1:255:486:486:27:459:94.44%:6.6778E-247:38:42:0:27:25:434	1/1:255:472:472:36:436:92.37%:5.0386E-228:69:51:16:20:108:328	1/1:255:535:535:16:519:97.01%:8.976E-291:57:47:10:6:124:395	1/1:255:511:511:17:494:96.67%:3.723E-275:70:49:8:9:195:299
chr5	112175970	.	A	T	.	PASS	ADP=181;WT=2;HET=9;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:114:247:247:211:36:14.57%:3.6778E-12:75:75:113:98:19:17	0/1:24:97:97:89:8:8.25%:3.3616E-3:72:76:59:30:4:4	0/1:158:340:340:290:50:14.71%:1.2701E-16:75:76:146:144:25:25	0/1:165:344:344:292:52:15.12%:2.7587E-17:73:76:145:147:21:31	0/1:75:179:179:155:24:13.41%:2.61E-8:76:76:99:56:10:14	0/1:176:336:336:281:55:16.37%:2.4979E-18:75:75:145:136:30:25	0/0:172:91:91:91:0:0%:1E0:75:0:53:38:0:0	0/1:59:149:149:130:19:12.75%:1.034E-6:75:76:70:60:10:9	0/1:40:123:123:110:13:10.57%:8.7391E-5:75:76:53:57:4:9	0/0:88:70:70:66:4:5.71%:5.9812E-2:76:71:36:30:1:3	0/1:82:200:200:174:26:13%:6.2523E-9:75:76:100:74:13:13
chr5	149433596	.	T	G	.	PASS	ADP=198;WT=4;HET=1;HOM=0;NC=7;bior.ExAC.Info.AC=97125;bior.ExAC.Info.AN=126632;bior.ExAC.Info.AF=0.767;bior.ExAC.Info.AC_Het=20824;bior.ExAC.Info.AC_Hom=35709;bior.dbSNP139.ID=rs2066934	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:1	./.:.:2	./.:.:3	./.:.:0	./.:.:0	0/0:715:498:497:481:15:3.02%:2.7409E-5:52:39:83:398:0:15	0/0:775:413:413:413:0:0%:1E0:62:0:119:294:0:0	0/0:740:533:533:514:19:3.56%:1.6201E-6:49:40:77:437:0:19	0/0:784:482:482:475:7:1.45%:7.643E-3:53:52:105:370:2:5	0/1:134:445:445:402:43:9.66%:3.9154E-14:58:51:96:306:5:38
chr5	149433597	.	G	A	.	PASS	ADP=197;WT=4;HET=1;HOM=0;NC=7;bior.ExAC.Info.AC=97065;bior.ExAC.Info.AN=126632;bior.ExAC.Info.AF=0.767;bior.ExAC.Info.AC_Het=20929;bior.ExAC.Info.AC_Hom=35797;bior.dbSNP139.ID=rs2066933	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:1	./.:.:2	./.:.:2	./.:.:0	./.:.:0	0/0:715:498:496:481:15:3.02%:2.7409E-5:51:38:83:398:0:15	0/0:775:413:413:413:0:0%:1E0:61:0:119:294:0:0	0/0:736:534:532:513:19:3.57%:1.6195E-6:48:40:77:436:0:19	0/0:798:482:481:475:6:1.25%:1.5382E-2:52:58:105:370:2:4	0/1:134:445:444:401:43:9.68%:3.9056E-14:58:51:96:305:5:38
chr7	55221830	.	G	A	.	PASS	ADP=392;WT=10;HET=1;HOM=0;NC=1;bior.dbSNP139.ID=rs150549265	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1328:724:722:721:1:0.14%:5E-1:38:20:42:679:0:1	0/0:404:215:215:215:0:0%:1E0:75:0:117:98:0:0	0/0:640:341:341:341:0:0%:1E0:74:0:165:176:0:0	0/0:287:154:154:154:0:0%:1E0:75:0:140:14:0:0	0/0:468:249:249:249:0:0%:1E0:75:0:183:66:0:0	0/0:576:309:308:308:0:0%:1E0:70:0:197:111:0:0	0/0:805:508:508:499:9:1.77%:1.8846E-3:50:43:80:419:0:9	0/0:839:469:469:467:2:0.43%:2.4973E-1:55:47:89:378:0:2	0/0:1277:681:681:681:0:0%:1E0:38:0:5:676:0:0	0/1:82:534:534:506:27:5.06%:5.3153E-9:48:47:69:437:4:23	0/0:996:532:531:531:0:0%:1E0:48:0:79:452:0:0
chr7	55242390	.	C	T	.	PASS	ADP=190;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:642:361:353:352:1:0.28%:5E-1:71:18:176:176:0:1	0/0:34:26:23:22:1:4.35%:5E-1:35:18:13:9:0:1	0/0:377:398:277:261:10:3.61%:8.9742E-4:35:17:6:255:0:10	0/0:34:27:24:23:1:4.17%:5E-1:37:17:11:12:0:1	0/0:63:36:33:33:0:0%:1E0:34:0:17:16:0:0	0/1:52:359:245:214:17:6.94%:5.6219E-6:35:17:6:208:0:17	0/0:185:112:108:107:1:0.93%:5E-1:37:18:7:100:0:1	0/0:580:424:365:356:6:1.64%:1.5302E-2:40:17:24:332:0:6	0/0:473:276:271:269:2:0.74%:2.4954E-1:38:18:19:250:0:2	0/0:366:211:206:205:1:0.49%:5E-1:37:18:8:197:0:1	0/0:508:459:383:366:16:4.18%:1.2998E-5:37:17:10:356:0:16
chr7	55242403	.	T	A	.	PASS	ADP=230;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:622:363:362:359:3:0.83%:1.2448E-1:70:17:176:183:0:3	0/0:44:24:24:24:0:0%:1E0:32:0:10:14:0:0	0/1:70:399:383:351:23:6.01%:8.4108E-8:28:18:6:345:0:23	0/0:30:27:26:24:2:7.69%:2.451E-1:36:19:10:14:0:2	0/0:59:38:37:36:1:2.7%:5E-1:32:19:15:21:0:1	0/0:429:358:346:323:17:4.91%:6.2153E-6:29:18:5:318:0:17	0/0:245:148:147:145:2:1.36%:2.4915E-1:43:16:24:121:0:2	0/0:603:425:414:397:11:2.66%:4.5605E-4:35:18:8:389:0:11	0/0:623:345:345:343:1:0.29%:5E-1:41:16:59:284:0:1	0/0:415:232:232:230:1:0.43%:5E-1:40:17:15:215:0:1	0/0:556:461:450:420:22:4.89%:1.8239E-7:34:18:11:409:0:22
chr7	55242407	.	T	G	.	PASS	ADP=236;WT=7;HET=4;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:643:363:363:361:2:0.55%:2.4966E-1:71:18:176:185:0:2	0/0:48:31:31:30:1:3.23%:5E-1:36:16:11:19:0:1	0/1:73:399:399:375:24:6.02%:4.1734E-8:33:18:6:369:0:24	0/0:52:27:27:27:0:0%:1E0:35:0:10:17:0:0	0/0:85:47:46:46:0:0%:1E0:36:0:15:31:0:0	0/1:64:358:358:336:21:5.87%:3.5224E-7:35:19:5:331:0:21	0/0:249:150:150:147:2:1.33%:2.4916E-1:44:17:24:123:0:2	0/1:67:429:429:406:22:5.13%:1.8076E-7:38:18:7:399:0:22	0/0:627:346:346:344:1:0.29%:5E-1:43:18:58:286:1:0	0/0:414:233:233:231:1:0.43%:5E-1:41:17:15:216:0:1	0/1:79:460:459:433:26:5.66%:1.0353E-8:37:18:12:421:0:26
chr7	55242488	.	C	T	.	PASS	ADP=570;WT=6;HET=2;HOM=3;NC=1;bior.ExAC.Info.AC=9;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=7.103e-05;bior.ExAC.Info.AC_Het=9;bior.ExAC.Info.AC_Hom=0;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:689:367:367:367:0:0%:1E0:66:0:176:191:0:0	1/1:255:681:681:29:651:95.59%:0E0:33:38:10:19:4:647	0/1:255:666:666:394:272:40.84%:7.199E-98:33:38:1:393:2:270	1/1:255:670:670:27:643:95.97%:0E0:33:38:6:21:3:640	1/1:255:681:681:40:641:94.13%:0E0:33:38:9:31:10:631	0/1:255:673:673:355:317:47.1%:1.1361E-117:33:38:3:352:2:315	0/0:1043:583:581:578:2:0.34%:2.4978E-1:40:20:90:488:0:2	0/0:1186:648:645:644:1:0.16%:5E-1:36:20:11:633:0:1	0/0:1186:654:646:644:1:0.15%:5E-1:37:33:22:622:0:1	0/0:999:568:565:562:3:0.53%:1.2467E-1:41:17:54:508:0:3	0/0:1203:666:665:663:2:0.3%:2.4981E-1:36:20:17:646:0:2
chr7	55242488	.	C	T	.	PASS	ADP=570;WT=6;HET=2;HOM=3;NC=1;bior.ExAC.Info.AC=9;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=7.103e-05;bior.ExAC.Info.AC_Het=9;bior.ExAC.Info.AC_Hom=0;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:689:367:367:367:0:0%:1E0:66:0:176:191:0:0	1/1:255:681:681:29:651:95.59%:0E0:33:38:10:19:4:647	0/1:255:666:666:394:272:40.84%:7.199E-98:33:38:1:393:2:270	1/1:255:670:670:27:643:95.97%:0E0:33:38:6:21:3:640	1/1:255:681:681:40:641:94.13%:0E0:33:38:9:31:10:631	0/1:255:673:673:355:317:47.1%:1.1361E-117:33:38:3:352:2:315	0/0:1043:583:581:578:2:0.34%:2.4978E-1:40:20:90:488:0:2	0/0:1186:648:645:644:1:0.16%:5E-1:36:20:11:633:0:1	0/0:1186:654:646:644:1:0.15%:5E-1:37:33:22:622:0:1	0/0:999:568:565:562:3:0.53%:1.2467E-1:41:17:54:508:0:3	0/0:1203:666:665:663:2:0.3%:2.4981E-1:36:20:17:646:0:2
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=mixed_adenosquamous_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=astrocytoma_Grade_IV;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249005	.	G	T	.	PASS	ADP=260;WT=3;HET=3;HOM=5;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs121913465	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:189:189:0:189:100%:3.9605E-113:0:75:0:0:85:104	0/1:255:158:158:77:81:51.27%:3.307E-31:71:76:37:40:43:38	1/1:255:227:227:0:226:99.56%:2.2925E-135:0:76:0:0:108:118	1/1:255:333:333:0:333:100%:1.0568E-199:0:76:0:0:177:156	1/1:255:243:243:58:185:76.13%:9.4062E-83:64:76:26:32:89:96	1/1:255:60:60:0:60:100%:1.035E-35:0:76:0:0:32:28	0/0:646:481:474:456:18:3.8%:3.2363E-6:51:76:127:329:6:12	0/1:255:339:339:236:103:30.38%:1.0199E-35:73:75:103:133:56:47	0/0:461:363:363:345:18:4.96%:3.0737E-6:68:75:185:160:8:10	0/1:58:359:359:340:19:5.29%:1.4937E-6:65:76:122:218:10:9	0/0:596:381:378:371:7:1.85%:7.5966E-3:61:73:106:265:2:5
chr7	55249009	.	G	T	.	PASS	ADP=260;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:355:189:189:189:0:0%:1E0:76:0:85:104:0:0	0/1:30:158:158:148:10:6.33%:8.4319E-4:74:77:75:73:5:5	0/0:426:227:227:227:0:0%:1E0:76:0:109:118:0:0	0/0:625:333:333:333:0:0%:1E0:76:0:177:156:0:0	0/0:456:243:243:243:0:0%:1E0:73:0:114:129:0:0	0/0:111:60:60:60:0:0%:1E0:77:0:32:28:0:0	0/0:899:482:479:479:0:0%:1E0:52:0:133:346:0:0	0/0:636:339:339:339:0:0%:1E0:74:0:159:180:0:0	0/0:681:363:363:363:0:0%:1E0:69:0:193:170:0:0	0/0:674:359:359:359:0:0%:1E0:65:0:132:227:0:0	0/0:715:381:381:381:0:0%:1E0:62:0:109:272:0:0
chr7	55249024	.	G	A	.	PASS	ADP=317;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:56:189:189:171:18:9.52%:2.495E-6:75:72:81:90:4:14	0/0:962:515:514:514:0:0%:1E0:48:0:80:434:0:0	0/0:438:233:233:233:0:0%:1E0:74:0:109:124:0:0	0/0:628:336:336:336:0:0%:1E0:75:0:177:159:0:0	0/0:824:439:439:439:0:0%:1E0:57:0:114:325:0:0	0/0:220:118:118:118:0:0%:1E0:57:0:32:86:0:0	0/0:898:484:480:480:0:0%:1E0:52:0:132:348:0:0	0/0:643:345:344:344:0:0%:1E0:73:0:160:184:0:0	0/0:689:367:367:367:0:0%:1E0:69:0:195:172:0:0	0/0:689:368:367:367:0:0%:1E0:66:0:138:229:0:0	0/0:797:426:426:426:0:0%:1E0:59:0:110:316:0:0
chr7	55249046	.	C	T	.	PASS	ADP=309;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:355:190:190:190:0:0%:1E0:76:0:86:104:0:0	0/0:962:515:514:514:0:0%:1E0:49:0:80:434:0:0	0/0:456:244:244:244:0:0%:1E0:76:0:113:131:0:0	0/0:628:336:336:336:0:0%:1E0:76:0:177:159:0:0	0/0:823:440:440:440:0:0%:1E0:58:0:114:326:0:0	0/1:40:118:118:105:13:11.02%:8.6093E-5:55:78:24:81:8:5	0/0:872:466:466:466:0:0%:1E0:52:0:86:380:0:0	0/0:497:275:275:274:1:0.36%:5E-1:73:78:120:154:0:1	0/0:693:369:369:369:0:0%:1E0:69:0:196:173:0:0	0/0:696:373:373:372:0:0%:1E0:64:0:132:240:0:0	0/0:708:390:390:389:1:0.26%:5E-1:58:78:89:300:1:0
chr7	55249063	.	G	A	.	PASS	ADP=310;WT=3;HET=3;HOM=5;NC=1;bior.ExAC.Info.AC=65961;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.521;bior.ExAC.Info.AC_Het=29485;bior.ExAC.Info.AC_Hom=18226;bior.hgmd_2014.2.CLASS=DP;bior.hgmd_2014.2.PHEN=Lung_cancer|_association_with;bior.hgmd_2014.2.OMIM_ID=131550;bior.hgmd_2014.2.PubMed=17409930;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs1050171	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:337:190:190:189:1:0.53%:5E-1:76:16:85:104:1:0	1/1:255:515:515:81:433:84.08%:4.3509E-207:76:40:43:38:13:420	0/0:373:246:246:240:6:2.44%:1.5151E-2:77:35:114:126:0:6	0/0:564:337:337:333:4:1.19%:6.1943E-2:77:38:177:156:0:4	0/1:255:440:440:186:254:57.73%:4.1065E-100:76:44:88:98:26:228	0/1:215:118:118:60:58:49.15%:2.7919E-22:77:38:32:28:0:58	1/1:255:468:468:18:450:96.15%:1.7158E-248:77:52:6:12:80:370	0/1:255:272:272:85:171:66.8%:1.5232E-71:76:72:46:39:63:108	1/1:255:368:368:18:350:95.11%:3.5563E-190:77:69:8:10:188:162	1/1:255:373:373:15:357:95.97%:1.4045E-196:77:64:9:6:123:234	1/1:255:401:401:7:393:98%:1.8533E-225:75:58:2:5:93:300
chr7	55249063	.	G	A	.	PASS	ADP=310;WT=3;HET=3;HOM=5;NC=1;bior.ExAC.Info.AC=65961;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=0.521;bior.ExAC.Info.AC_Het=29485;bior.ExAC.Info.AC_Hom=18226;bior.hgmd_2014.2.CLASS=DP;bior.hgmd_2014.2.PHEN=Lung_cancer|_association_with;bior.hgmd_2014.2.OMIM_ID=131550;bior.hgmd_2014.2.PubMed=17409930;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs1050171	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:337:190:190:189:1:0.53%:5E-1:76:16:85:104:1:0	1/1:255:515:515:81:433:84.08%:4.3509E-207:76:40:43:38:13:420	0/0:373:246:246:240:6:2.44%:1.5151E-2:77:35:114:126:0:6	0/0:564:337:337:333:4:1.19%:6.1943E-2:77:38:177:156:0:4	0/1:255:440:440:186:254:57.73%:4.1065E-100:76:44:88:98:26:228	0/1:215:118:118:60:58:49.15%:2.7919E-22:77:38:32:28:0:58	1/1:255:468:468:18:450:96.15%:1.7158E-248:77:52:6:12:80:370	0/1:255:272:272:85:171:66.8%:1.5232E-71:76:72:46:39:63:108	1/1:255:368:368:18:350:95.11%:3.5563E-190:77:69:8:10:188:162	1/1:255:373:373:15:357:95.97%:1.4045E-196:77:64:9:6:123:234	1/1:255:401:401:7:393:98%:1.8533E-225:75:58:2:5:93:300
chr7	55249072	.	G	T	.	PASS	ADP=327;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:355:189:189:189:0:0%:1E0:76:0:85:104:0:0	0/0:966:515:515:515:0:0%:1E0:46:0:56:459:0:0	0/1:55:246:246:228:18:7.32%:2.7631E-6:75:77:106:122:8:10	0/0:633:337:337:337:0:0%:1E0:75:0:177:160:0:0	0/0:823:440:440:440:0:0%:1E0:58:0:114:326:0:0	0/0:220:118:118:118:0:0%:1E0:57:0:32:86:0:0	0/0:902:482:482:482:0:0%:1E0:52:0:92:390:0:0	0/0:685:384:384:366:0:0%:1E0:65:0:166:200:0:0	0/0:692:370:370:370:0:0%:1E0:68:0:196:174:0:0	0/0:764:408:407:407:0:0%:1E0:62:0:151:256:0:0	0/0:816:436:436:436:0:0%:1E0:58:0:110:326:0:0
chr7	55249076	.	C	T	.	PASS	ADP=328;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:355:189:189:189:0:0%:1E0:75:0:85:104:0:0	0/0:966:515:515:515:0:0%:1E0:46:0:56:459:0:0	0/0:460:246:246:246:0:0%:1E0:75:0:114:132:0:0	0/0:633:337:337:337:0:0%:1E0:75:0:177:160:0:0	0/1:76:440:440:415:25:5.68%:2.0986E-8:56:73:100:315:14:11	0/0:220:118:118:118:0:0%:1E0:57:0:32:86:0:0	0/0:872:488:488:486:2:0.41%:2.4974E-1:52:27:89:397:0:2	0/0:689:385:385:367:0:0%:1E0:65:0:167:200:0:0	0/0:696:372:372:372:0:0%:1E0:68:0:192:180:0:0	0/0:771:412:411:411:0:0%:1E0:61:0:149:262:0:0	0/0:816:437:436:436:0:0%:1E0:57:0:111:325:0:0
chr7	55249082	.	C	T	.	PASS	ADP=329;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:355:189:189:189:0:0%:1E0:76:0:85:104:0:0	0/0:951:521:520:519:1:0.19%:5E-1:44:78:56:463:0:1	0/0:464:247:247:247:0:0%:1E0:74:0:115:132:0:0	0/1:61:337:337:317:20:5.93%:7.1336E-7:75:77:166:151:11:9	0/0:823:440:440:440:0:0%:1E0:57:0:114:326:0:0	0/0:207:120:120:119:1:0.83%:5E-1:56:78:33:86:0:1	0/0:924:495:494:494:0:0%:1E0:50:0:89:405:0:0	0/0:719:386:385:383:0:0%:1E0:65:0:176:207:0:0	0/0:700:377:373:373:0:0%:1E0:67:0:187:186:0:0	0/0:775:414:413:413:0:0%:1E0:61:0:150:263:0:0	0/0:802:440:439:438:1:0.23%:5E-1:57:39:112:326:0:1
chr7	116339672	.	C	T	.	PASS	ADP=387;WT=6;HET=4;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Benign;bior.Clinvar.RCVaccession=RCV000079497;bior.Clinvar.PhenotypeIDs=MedGen:CN169374;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.ExAC.Info.AC=7427;bior.ExAC.Info.AN=125276;bior.ExAC.Info.AF=0.059;bior.ExAC.Info.AC_Het=6706;bior.ExAC.Info.AC_Hom=345;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs35775721	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:741:397:396:396:0:0%:1E0:57:0:101:295:0:0	0/0:599:321:319:319:0:0%:1E0:68:0:117:202:0:0	0/0:741:397:396:396:0:0%:1E0:59:0:111:285:0:0	0/0:733:392:392:392:0:0%:1E0:62:0:134:258:0:0	0/0:329:175:175:175:0:0%:1E0:74:0:80:95:0:0	0/1:117:589:588:550:38:6.46%:1.9618E-12:42:41:37:513:4:34	0/0:1006:563:560:558:2:0.36%:2.4978E-1:44:57:47:511:0:2	0/1:183:647:643:584:59:9.18%:4.3017E-19:39:37:16:568:1:58	0/1:161:639:636:583:52:8.18%:7.4764E-17:39:37:19:564:2:50	0/1:139:544:540:495:45:8.33%:1.0922E-14:46:47:63:432:6:39
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=meningothelial;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=basal_cell_carcinoma;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=meningothelial;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850341	.	G	T	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2;bior.Clinvar.ClinicalSignificance=Pathogenic;bior.Clinvar.RCVaccession=RCV000008586;bior.Clinvar.PhenotypeIDs=-;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs121918347	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:113:307:0:0	0/0:55:30:29:29:0:0%:1E0:37:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:78:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:842:474:472:470:2:0.42%:2.4973E-1:55:78:95:375:0:2	0/0:928:508:508:507:1:0.2%:5E-1:51:32:85:422:0:1	0/0:999:547:546:545:1:0.18%:5E-1:48:38:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850346	.	T	C	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:59:0:112:308:0:0	0/0:55:30:30:30:0:0%:1E0:37:0:15:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:69:77:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1100:600:600:599:1:0.17%:5E-1:43:39:39:560:0:1	0/0:846:474:474:472:2:0.42%:2.4974E-1:54:78:95:377:0:2	0/0:951:508:508:508:0:0%:1E0:51:0:85:423:0:0	0/0:999:547:546:545:1:0.18%:5E-1:48:39:67:478:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850347	.	G	A	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:60:0:112:308:0:0	0/0:55:30:30:30:0:0%:1E0:37:0:15:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:69:77:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:76:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:72:0:13:20:0:0	0/0:1080:600:600:598:2:0.33%:2.4979E-1:43:39:39:559:0:2	0/0:846:474:474:472:2:0.42%:2.4974E-1:54:78:95:377:0:2	0/0:909:508:508:506:2:0.39%:2.4975E-1:51:46:84:422:1:1	0/0:984:547:547:545:2:0.37%:2.4977E-1:48:28:67:478:0:2	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr7	128850352	.	A	C	.	PASS	ADP=292;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:786:420:420:420:0:0%:1E0:60:0:112:308:0:0	0/0:55:30:29:29:0:0%:1E0:39:0:14:15:0:0	0/1:34:106:106:95:11:10.38%:3.716E-4:70:76:32:63:3:8	0/0:524:279:279:279:0:0%:1E0:77:0:123:156:0:0	0/0:63:33:33:33:0:0%:1E0:73:0:13:20:0:0	0/0:1081:600:599:597:2:0.33%:2.4979E-1:43:38:38:559:0:2	0/0:846:474:474:472:2:0.42%:2.4974E-1:55:77:95:377:0:2	0/0:925:508:506:505:1:0.2%:5E-1:51:16:83:422:0:1	0/0:1003:547:547:546:1:0.18%:5E-1:48:38:67:479:0:1	0/0:966:516:516:516:0:0%:1E0:50:0:71:445:0:0
chr9	21970964	.	C	T	.	PASS	ADP=68;WT=4;HET=1;HOM=0;NC=7	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:5	0/0:59:31:31:31:0:0%:1E0:74:0:31:0:0:0	0/0:1236:667:660:660:0:0%:1E0:37:0:658:2:0:0	0/1:54:31:31:16:15:48.39%:3.2298E-6:72:71:16:0:15:0	0/0:138:73:73:73:0:0%:1E0:72:0:72:1:0:0	0/0:32:18:18:18:0:0%:1E0:73:0:18:0:0:0
chr9	21971098	.	C	T	.	PASS	ADP=427;WT=5;HET=0;HOM=5;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Renal_cancer;bior.hgmd_2014.2.OMIM_ID=600160;bior.hgmd_2014.2.PubMed=12894891;bior.cosmic68.Histology_subtype=dysplastic	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:1247:666:666:666:0:0%:1E0:38:0:666:0:0:0	0/0:992:530:529:529:0:0%:1E0:43:0:524:5:0:0	0/0:1146:664:664:659:5:0.75%:3.1015E-2:37:38:656:3:5:0	0/0:1206:647:644:644:0:0%:1E0:38:0:640:4:0:0	0/0:351:189:187:187:0:0%:1E0:57:0:186:1:0:0	1/1:255:473:473:97:376:79.49%:2.4092E-172:43:52:96:1:176:200	1/1:255:307:267:41:226:84.64%:1.0177E-108:34:28:4:37:2:224	1/1:255:614:609:5:604:99.18%:0E0:33:38:0:5:38:566	1/1:255:536:526:16:510:96.96%:1.7861E-285:37:42:6:10:80:430	1/1:255:569:567:13:554:97.71%:2.1326E-314:49:42:12:1:88:466
chr10	89711919	.	C	T	.	PASS	ADP=222;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=7.892e-06;bior.ExAC.Info.AC_Het=1;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:1071:571:571:571:0:0%:1E0:38:0:565:6:0:0	0/0:597:330:330:329:1:0.3%:5E-1:42:19:324:5:1:0	0/0:709:389:389:388:1:0.26%:5E-1:37:18:377:11:0:1	0/0:708:377:377:377:0:0%:1E0:38:0:374:3:0:0	0/0:441:236:236:236:0:0%:1E0:39:0:229:7:0:0	0/0:281:169:169:166:2:1.18%:2.4925E-1:35:20:12:154:0:2	0/1:27:95:95:86:9:9.47%:1.6016E-3:30:18:0:86:0:9	0/0:476:304:304:298:6:1.97%:1.5241E-2:43:18:64:234:0:6	0/0:212:154:154:148:6:3.9%:1.4869E-2:39:20:31:117:0:6	0/0:89:47:47:47:0:0%:1E0:47:0:9:38:0:0
chr10	89717609	.	G	T	.	PASS	ADP=339;WT=10;HET=1;HOM=0;NC=1;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:129:675:669:624:42:6.29%:1.1666E-13:27:18:1:623:0:42	0/0:709:389:389:388:1:0.26%:5E-1:64:19:220:168:1:0	0/0:130:69:69:69:0:0%:1E0:56:0:31:38:0:0	0/0:698:399:393:391:2:0.51%:2.4968E-1:55:18:185:206:0:2	0/0:1009:631:629:617:10:1.59%:9.4188E-4:34:17:30:587:0:10	0/0:595:317:317:317:0:0%:1E0:55:0:175:142:0:0	0/0:838:450:448:448:0:0%:1E0:42:0:156:292:0:0	0/0:259:150:149:147:1:0.67%:5E-1:54:16:64:83:0:1	0/0:401:247:247:243:4:1.62%:6.174E-2:39:18:15:228:0:4	0/0:910:502:498:497:1:0.2%:5E-1:46:36:242:255:1:0	0/0:498:265:265:265:0:0%:1E0:46:0:109:156:0:0
chr10	89717609	.	G	T	.	PASS	ADP=339;WT=10;HET=1;HOM=0;NC=1;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:129:675:669:624:42:6.29%:1.1666E-13:27:18:1:623:0:42	0/0:709:389:389:388:1:0.26%:5E-1:64:19:220:168:1:0	0/0:130:69:69:69:0:0%:1E0:56:0:31:38:0:0	0/0:698:399:393:391:2:0.51%:2.4968E-1:55:18:185:206:0:2	0/0:1009:631:629:617:10:1.59%:9.4188E-4:34:17:30:587:0:10	0/0:595:317:317:317:0:0%:1E0:55:0:175:142:0:0	0/0:838:450:448:448:0:0%:1E0:42:0:156:292:0:0	0/0:259:150:149:147:1:0.67%:5E-1:54:16:64:83:0:1	0/0:401:247:247:243:4:1.62%:6.174E-2:39:18:15:228:0:4	0/0:910:502:498:497:1:0.2%:5E-1:46:36:242:255:1:0	0/0:498:265:265:265:0:0%:1E0:46:0:109:156:0:0
chr10	89717609	.	G	T	.	PASS	ADP=339;WT=10;HET=1;HOM=0;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:129:675:669:624:42:6.29%:1.1666E-13:27:18:1:623:0:42	0/0:709:389:389:388:1:0.26%:5E-1:64:19:220:168:1:0	0/0:130:69:69:69:0:0%:1E0:56:0:31:38:0:0	0/0:698:399:393:391:2:0.51%:2.4968E-1:55:18:185:206:0:2	0/0:1009:631:629:617:10:1.59%:9.4188E-4:34:17:30:587:0:10	0/0:595:317:317:317:0:0%:1E0:55:0:175:142:0:0	0/0:838:450:448:448:0:0%:1E0:42:0:156:292:0:0	0/0:259:150:149:147:1:0.67%:5E-1:54:16:64:83:0:1	0/0:401:247:247:243:4:1.62%:6.174E-2:39:18:15:228:0:4	0/0:910:502:498:497:1:0.2%:5E-1:46:36:242:255:1:0	0/0:498:265:265:265:0:0%:1E0:46:0:109:156:0:0
chr10	89717611	.	T	C	.	PASS	ADP=336;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:174:675:636:535:56:8.85%:3.5348E-18:23:17:1:534:0:56	0/0:709:389:389:388:1:0.26%:5E-1:62:15:223:165:0:1	0/0:130:69:69:69:0:0%:1E0:55:0:31:38:0:0	0/0:702:399:396:393:2:0.51%:2.4968E-1:54:16:189:204:0:2	0/0:840:630:627:601:25:3.99%:2.334E-8:29:17:30:571:0:25	0/0:557:317:317:315:2:0.63%:2.4961E-1:55:17:175:140:0:2	0/0:746:450:446:441:5:1.12%:3.09E-2:42:16:156:285:0:5	0/0:259:149:148:147:1:0.68%:5E-1:53:16:65:82:0:1	0/0:464:247:247:247:0:0%:1E0:45:0:14:233:0:0	0/0:940:502:501:501:0:0%:1E0:47:0:244:257:0:0	0/0:498:265:265:265:0:0%:1E0:46:0:109:156:0:0
chr10	89717612	.	C	T	.	PASS	ADP=333;WT=10;HET=1;HOM=0;NC=1;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:848:675:647:609:26:4.04%:1.1476E-8:22:18:1:608:0:26	0/0:726:390:388:388:0:0%:1E0:61:0:222:166:0:0	0/0:130:69:69:69:0:0%:1E0:55:0:31:38:0:0	0/0:720:399:395:394:1:0.25%:5E-1:57:19:189:205:0:1	0/0:1030:630:592:588:4:0.68%:6.2183E-2:33:19:30:558:0:4	0/0:588:317:313:313:0:0%:1E0:55:0:175:138:0:0	0/0:827:450:442:442:0:0%:1E0:42:0:156:286:0:0	0/0:215:150:149:144:5:3.36%:3.0203E-2:51:78:62:82:3:2	0/1:46:247:241:225:15:6.22%:2.4354E-5:43:28:14:211:0:15	0/0:936:502:499:499:0:0%:1E0:46:0:244:255:0:0	0/0:494:265:263:263:0:0%:1E0:45:0:109:154:0:0
chr10	89717613	.	C	G	.	PASS	ADP=340;WT=10;HET=1;HOM=0;NC=1;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:154:675:671:609:50:7.45%:3.3806E-16:25:18:1:608:0:50	0/0:730:390:390:390:0:0%:1E0:59:0:223:167:0:0	0/0:130:69:69:69:0:0%:1E0:57:0:31:38:0:0	0/0:705:399:399:396:2:0.5%:2.4969E-1:57:18:189:207:0:2	0/0:1136:630:630:627:2:0.32%:2.498E-1:36:16:30:597:0:2	0/0:595:317:317:317:0:0%:1E0:55:0:175:142:0:0	0/0:785:450:450:446:3:0.67%:1.2458E-1:41:18:153:293:1:2	0/0:280:150:149:149:0:0%:1E0:52:0:65:84:0:0	0/0:410:247:247:243:3:1.21%:1.2424E-1:36:18:14:229:0:3	0/0:917:502:502:501:1:0.2%:5E-1:46:20:243:258:1:0	0/0:433:265:265:261:4:1.51%:6.1792E-2:44:62:107:154:2:2
chr10	89717614	.	T	C	.	PASS	ADP=341;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:997:675:675:641:15:2.22%:2.8145E-5:29:19:1:640:0:15	0/0:691:390:390:387:2:0.51%:2.4968E-1:55:23:223:164:0:2	0/0:130:69:69:69:0:0%:1E0:56:0:31:38:0:0	0/0:659:399:398:392:5:1.26%:3.0857E-2:53:17:189:203:1:4	0/1:132:630:629:583:43:6.84%:5.3877E-14:30:17:30:553:0:43	0/0:502:317:317:311:6:1.89%:1.5256E-2:55:17:174:137:0:6	0/0:785:450:450:446:3:0.67%:1.2458E-1:42:18:156:290:0:3	0/0:249:150:150:147:2:1.33%:2.4916E-1:52:18:65:82:0:2	0/0:397:247:247:242:4:1.62%:6.1737E-2:39:18:14:228:0:4	0/0:864:502:502:498:4:0.8%:6.2126E-2:46:17:244:254:0:4	0/0:478:265:265:264:1:0.38%:5E-1:46:18:109:155:0:1
chr10	89717615	.	C	A	.	PASS	ADP=341;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1146:675:675:665:6:0.89%:1.5451E-2:32:18:1:664:0:6	0/0:670:392:391:385:3:0.77%:1.2452E-1:59:16:221:164:0:3	0/0:130:69:69:69:0:0%:1E0:56:0:31:38:0:0	0/0:723:399:398:397:1:0.25%:5E-1:60:18:188:209:0:1	0/0:1046:631:631:619:7:1.11%:7.6819E-3:32:19:31:588:0:7	0/0:575:317:317:316:1:0.32%:5E-1:55:20:175:141:0:1	0/0:846:451:451:451:0:0%:1E0:44:0:156:295:0:0	0/0:249:150:150:148:2:1.33%:2.4916E-1:53:18:65:83:0:2	0/1:71:248:248:225:23:9.27%:6.9851E-8:38:19:15:210:0:23	0/0:917:502:502:501:1:0.2%:5E-1:46:18:244:257:0:1	0/0:498:265:265:265:0:0%:1E0:45:0:109:156:0:0
chr10	89717616	.	A	T	.	PASS	ADP=341;WT=7;HET=4;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1165:675:675:669:5:0.74%:3.1018E-2:34:35:0:669:1:4	0/0:730:390:390:390:0:0%:1E0:63:0:223:167:0:0	0/0:130:69:69:69:0:0%:1E0:58:0:31:38:0:0	0/0:677:399:399:395:4:1%:6.203E-2:60:62:189:206:0:4	0/0:1184:631:631:631:0:0%:1E0:38:0:31:600:0:0	0/0:575:317:317:316:1:0.32%:5E-1:57:16:174:142:1:0	0/1:255:451:451:300:151:33.48%:9.0209E-53:48:38:81:219:75:76	0/1:171:150:150:100:50:33.33%:6.4666E-18:62:40:41:59:24:26	0/0:448:250:250:249:1:0.4%:5E-1:43:26:14:235:0:1	0/1:255:502:502:206:296:58.96%:1.9815E-117:60:38:96:110:148:148	0/1:255:265:265:103:162:61.13%:2.1356E-65:58:39:29:74:80:82
chr10	89717617	.	G	C	.	PASS	ADP=351;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:145:675:663:612:47:7.1%:3.0359E-15:29:17:1:611:0:47	0/0:730:390:390:390:0:0%:1E0:60:0:223:167:0:0	0/0:130:69:69:69:0:0%:1E0:56:0:31:38:0:0	0/0:720:399:395:394:1:0.25%:5E-1:57:18:187:207:0:1	0/0:863:632:629:605:23:3.66%:9.7102E-8:33:17:30:575:0:23	0/0:591:317:316:316:0:0%:1E0:55:0:175:141:0:0	0/0:879:512:509:505:4:0.79%:6.2131E-2:41:18:156:349:0:4	0/0:274:158:157:155:1:0.64%:5E-1:52:77:64:91:1:0	0/0:501:298:296:293:3:1.01%:1.2437E-1:37:17:14:279:0:3	0/0:984:528:526:526:0:0%:1E0:46:0:244:282:0:0	0/0:505:269:269:269:0:0%:1E0:46:0:109:160:0:0
chr10	89717619	.	T	C	.	PASS	ADP=350;WT=9;HET=2;HOM=0;NC=1;bior.cosmic68.Histology_subtype=ductal_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:255:675:656:499:154:23.51%:1.5444E-51:25:16:1:498:0:154	0/0:705:390:388:387:1:0.26%:5E-1:57:18:224:163:0:1	0/0:116:69:69:68:1:1.45%:5E-1:56:16:31:37:0:1	0/0:655:399:397:391:5:1.26%:3.0856E-2:54:15:188:203:0:5	0/1:222:632:620:549:71:11.45%:5.0525E-23:31:16:31:518:0:71	0/0:538:317:316:313:3:0.95%:1.2441E-1:55:16:175:138:0:3	0/0:892:513:507:504:3:0.59%:1.2463E-1:40:16:157:347:0:3	0/0:229:158:158:153:5:3.16%:3.0263E-2:51:15:65:88:0:5	0/0:386:300:294:281:13:4.42%:1.066E-4:35:16:14:267:0:13	0/0:950:529:529:527:2:0.38%:2.4976E-1:46:16:244:283:0:2	0/0:501:269:267:267:0:0%:1E0:46:0:109:158:0:0
chr10	89717619	.	T	C	.	PASS	ADP=350;WT=9;HET=2;HOM=0;NC=1;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:255:675:656:499:154:23.51%:1.5444E-51:25:16:1:498:0:154	0/0:705:390:388:387:1:0.26%:5E-1:57:18:224:163:0:1	0/0:116:69:69:68:1:1.45%:5E-1:56:16:31:37:0:1	0/0:655:399:397:391:5:1.26%:3.0856E-2:54:15:188:203:0:5	0/1:222:632:620:549:71:11.45%:5.0525E-23:31:16:31:518:0:71	0/0:538:317:316:313:3:0.95%:1.2441E-1:55:16:175:138:0:3	0/0:892:513:507:504:3:0.59%:1.2463E-1:40:16:157:347:0:3	0/0:229:158:158:153:5:3.16%:3.0263E-2:51:15:65:88:0:5	0/0:386:300:294:281:13:4.42%:1.066E-4:35:16:14:267:0:13	0/0:950:529:529:527:2:0.38%:2.4976E-1:46:16:244:283:0:2	0/0:501:269:267:267:0:0%:1E0:46:0:109:158:0:0
chr10	89717621	.	G	C	.	PASS	ADP=354;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:180:675:662:603:58:8.77%:9.3829E-19:30:15:1:602:0:58	0/0:734:391:391:391:0:0%:1E0:59:0:223:168:0:0	0/0:130:69:69:69:0:0%:1E0:57:0:31:38:0:0	0/0:724:399:397:396:1:0.25%:5E-1:55:16:189:207:0:1	0/0:952:633:623:609:14:2.25%:5.6691E-5:34:15:31:578:0:14	0/0:591:317:316:316:0:0%:1E0:56:0:175:141:0:0	0/0:981:523:523:523:0:0%:1E0:41:0:156:367:0:0	0/0:263:158:158:156:2:1.27%:2.4921E-1:53:15:65:91:0:2	0/0:535:309:307:304:2:0.65%:2.4959E-1:36:16:14:290:0:2	0/0:1004:535:535:535:0:0%:1E0:46:0:244:291:0:0	0/0:505:269:269:269:0:0%:1E0:46:0:109:160:0:0
chr10	89717625	.	T	C	.	PASS	ADP=280;WT=10;HET=1;HOM=0;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:180:672:656:593:58:8.9%:9.1877E-19:30:15:1:592:0:58	0/0:705:391:388:386:1:0.26%:5E-1:59:18:220:166:1:0	0/0:130:69:69:69:0:0%:1E0:55:0:31:38:0:0	0/0:702:396:395:393:2:0.51%:2.4968E-1:56:17:187:206:2:0	0/0:972:633:623:610:12:1.93%:2.3141E-4:33:15:31:579:0:12	0/0:591:317:315:315:0:0%:1E0:55:0:175:140:0:0	0/0:418:260:258:254:4:1.55%:6.1773E-2:42:16:31:223:0:4	0/0:166:112:109:106:3:2.75%:1.2327E-1:55:15:41:65:0:3	0/0:421:291:287:278:8:2.79%:3.7172E-3:34:15:14:264:0:8	0/0:311:175:175:174:1:0.57%:5E-1:60:15:64:110:0:1	0/0:179:96:96:96:0:0%:1E0:56:0:24:72:0:0
chr10	89717627	.	T	C	.	PASS	ADP=283;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:241:672:665:586:77:11.58%:6.3541E-25:26:16:1:585:0:77	0/0:734:391:391:391:0:0%:1E0:57:0:223:168:0:0	0/0:116:69:69:68:1:1.45%:5E-1:56:16:31:37:0:1	0/0:701:396:396:394:2:0.51%:2.4968E-1:55:17:189:205:0:2	0/0:943:633:632:615:16:2.53%:1.3858E-5:32:15:32:583:0:16	0/0:557:317:317:315:2:0.63%:2.4961E-1:56:15:175:140:0:2	0/0:466:260:260:259:1:0.38%:5E-1:41:16:31:228:0:1	0/0:173:113:113:110:3:2.65%:1.2333E-1:53:15:41:69:0:3	0/0:402:291:291:280:11:3.78%:4.4348E-4:32:15:14:266:0:11	0/0:283:175:175:172:3:1.71%:1.2393E-1:61:15:64:108:0:3	0/0:179:96:96:96:0:0%:1E0:55:0:24:72:0:0
chr10	89717629	.	C	A	.	PASS	ADP=283;WT=6;HET=5;HOM=0;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Cowden_disease;bior.hgmd_2014.2.OMIM_ID=601728;bior.hgmd_2014.2.PubMed=22970944;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:255:672:666:417:203:30.48%:1.7909E-70:22:23:1:416:0:203	0/0:630:390:385:377:5:1.3%:3.0841E-2:51:23:223:154:0:5	0/0:92:69:69:65:3:4.35%:1.2222E-1:55:20:31:34:0:3	0/0:554:396:395:379:13:3.29%:1.1033E-4:48:20:192:187:0:13	0/1:255:633:630:544:84:13.33%:2.6374E-27:30:22:31:513:0:84	0/0:490:317:317:310:7:2.21%:7.5554E-3:55:20:175:135:0:7	0/1:90:261:261:230:29:11.11%:8.123E-10:39:20:31:199:0:29	0/1:21:113:111:103:7:6.31%:7.0805E-3:54:19:41:62:0:7	0/1:130:292:291:247:41:14.09%:9.82E-14:29:22:14:233:0:41	0/0:247:175:175:167:6:3.43%:1.4952E-2:60:24:64:103:0:6	0/0:151:96:96:94:2:2.08%:2.4869E-1:55:20:24:70:0:2
chr10	89717629	.	C	A	.	PASS	ADP=283;WT=6;HET=5;HOM=0;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Cowden_disease;bior.hgmd_2014.2.OMIM_ID=601728;bior.hgmd_2014.2.PubMed=22970944;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:255:672:666:417:203:30.48%:1.7909E-70:22:23:1:416:0:203	0/0:630:390:385:377:5:1.3%:3.0841E-2:51:23:223:154:0:5	0/0:92:69:69:65:3:4.35%:1.2222E-1:55:20:31:34:0:3	0/0:554:396:395:379:13:3.29%:1.1033E-4:48:20:192:187:0:13	0/1:255:633:630:544:84:13.33%:2.6374E-27:30:22:31:513:0:84	0/0:490:317:317:310:7:2.21%:7.5554E-3:55:20:175:135:0:7	0/1:90:261:261:230:29:11.11%:8.123E-10:39:20:31:199:0:29	0/1:21:113:111:103:7:6.31%:7.0805E-3:54:19:41:62:0:7	0/1:130:292:291:247:41:14.09%:9.82E-14:29:22:14:233:0:41	0/0:247:175:175:167:6:3.43%:1.4952E-2:60:24:64:103:0:6	0/0:151:96:96:94:2:2.08%:2.4869E-1:55:20:24:70:0:2
chr10	89717630	.	C	A	.	PASS	ADP=284;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:126:672:669:623:41:6.13%:2.4051E-13:30:20:1:622:0:41	0/0:659:391:390:386:4:1.03%:6.2019E-2:62:19:223:163:1:3	0/0:130:69:69:69:0:0%:1E0:57:0:31:38:0:0	0/0:685:396:396:392:3:0.76%:1.2452E-1:59:17:189:203:1:2	0/0:1160:633:632:631:1:0.16%:5E-1:38:17:32:599:0:1	0/0:595:317:317:317:0:0%:1E0:57:0:175:142:0:0	0/0:490:262:262:262:0:0%:1E0:46:0:31:231:0:0	0/0:213:114:113:113:0:0%:1E0:55:0:41:72:0:0	0/0:509:293:293:290:2:0.68%:2.4957E-1:38:20:14:276:0:2	0/0:296:176:176:174:2:1.14%:2.4929E-1:61:20:64:110:0:2	0/0:179:96:96:96:0:0%:1E0:58:0:24:72:0:0
chr10	89717632	.	G	C	.	PASS	ADP=284;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:151:673:671:618:49:7.32%:7.1143E-16:30:16:1:617:0:49	0/0:713:391:391:390:1:0.26%:5E-1:61:18:223:167:0:1	0/0:130:69:69:69:0:0%:1E0:57:0:31:38:0:0	0/0:741:396:396:396:0:0%:1E0:57:0:189:207:0:0	0/0:1007:633:633:622:11:1.74%:4.6735E-4:34:17:32:590:0:11	0/0:595:317:317:317:0:0%:1E0:56:0:175:142:0:0	0/0:470:262:262:261:1:0.38%:5E-1:42:16:31:230:0:1	0/0:163:114:113:109:4:3.54%:6.0837E-2:55:17:41:68:0:4	0/0:467:293:292:287:5:1.71%:3.0715E-2:34:16:14:273:0:5	0/0:311:176:176:175:1:0.57%:5E-1:61:18:64:111:0:1	0/0:179:96:96:96:0:0%:1E0:56:0:24:72:0:0
chr10	89717633	.	C	G	.	PASS	ADP=284;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:255:673:669:553:97:14.5%:1.3126E-31:25:19:1:552:0:97	0/0:691:390:389:387:2:0.51%:2.4968E-1:57:20:221:166:0:2	0/0:116:69:69:68:1:1.45%:5E-1:54:20:31:37:0:1	0/0:681:396:395:391:3:0.76%:1.2452E-1:55:18:188:203:0:3	0/0:982:634:633:620:13:2.05%:1.1471E-4:32:19:32:588:0:13	0/0:571:317:316:314:1:0.32%:5E-1:55:20:174:140:0:1	0/0:413:262:262:257:5:1.91%:3.0654E-2:40:20:31:226:0:5	0/0:183:114:114:112:2:1.75%:2.489E-1:52:18:41:71:0:2	0/0:447:295:294:286:7:2.38%:7.5345E-3:31:19:14:272:0:7	0/0:311:176:176:175:1:0.57%:5E-1:59:20:64:111:0:1	0/0:179:96:95:95:0:0%:1E0:55:0:23:72:0:0
chr10	89717634	.	T	A	.	PASS	ADP=285;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:126:674:673:613:41:6.09%:2.381E-13:25:18:1:612:0:41	0/0:682:393:393:390:3:0.76%:1.2452E-1:60:18:226:164:0:3	0/0:130:70:70:70:0:0%:1E0:56:0:31:39:0:0	0/0:698:396:396:392:2:0.51%:2.4968E-1:57:19:189:203:0:2	0/0:1125:635:635:630:3:0.47%:1.247E-1:34:17:32:598:0:3	0/0:595:317:317:317:0:0%:1E0:56:0:175:142:0:0	0/0:490:262:262:262:0:0%:1E0:42:0:31:231:0:0	0/0:197:114:114:112:1:0.88%:5E-1:53:16:41:71:0:1	0/0:470:296:296:289:5:1.69%:3.0719E-2:33:19:14:275:0:5	0/0:300:177:177:175:2:1.13%:2.4929E-1:60:20:64:111:0:2	0/0:183:97:97:97:0:0%:1E0:56:0:24:73:0:0
chr10	89717641	.	G	T	.	PASS	ADP=286;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:119:675:673:634:39:5.79%:1.032E-12:30:19:1:633:0:39	0/0:737:394:394:394:0:0%:1E0:60:0:223:171:0:0	0/0:130:70:70:70:0:0%:1E0:56:0:31:39:0:0	0/0:724:397:397:396:1:0.25%:5E-1:57:16:187:209:0:1	0/0:1083:637:637:631:6:0.94%:1.5441E-2:35:19:32:599:0:6	0/0:595:317:317:317:0:0%:1E0:56:0:175:142:0:0	0/0:470:262:262:261:1:0.38%:5E-1:43:20:31:230:0:1	0/0:196:114:114:113:1:0.88%:5E-1:54:20:41:72:0:1	0/0:491:297:297:293:4:1.35%:6.1868E-2:35:19:14:279:0:4	0/0:304:179:179:177:2:1.12%:2.493E-1:60:16:64:113:0:2	0/0:167:98:98:97:1:1.02%:5E-1:57:20:24:73:0:1
chr10	89717705	.	C	A	.	PASS	ADP=210;WT=8;HET=2;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:5	0/0:456:256:253:252:1:0.4%:5E-1:39:38:62:190:0:1	0/0:1010:572:572:569:3:0.52%:1.2467E-1:38:24:569:0:3:0	0/0:445:239:238:238:0:0%:1E0:41:0:52:186:0:0	0/0:37:19:19:19:0:0%:1E0:38:0:16:3:0:0	0/0:491:282:282:280:2:0.71%:2.4956E-1:38:20:279:1:2:0	0/1:55:327:327:309:18:5.5%:2.9995E-6:34:24:309:0:18:0	0/0:145:103:103:99:4:3.88%:6.0675E-2:57:20:99:0:4:0	0/1:71:282:282:257:23:8.16%:7.4444E-8:31:24:256:1:23:0	0/0:503:312:312:307:5:1.6%:3.075E-2:43:23:307:0:5:0	0/0:241:138:138:137:1:0.72%:5E-1:61:20:137:0:1:0
chr10	89717721	.	T	G	.	PASS	ADP=201;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:385:210:206:206:0:0%:1E0:37:0:5:201:0:0	0/0:1041:556:556:556:0:0%:1E0:38:0:556:0:0:0	0/0:396:223:222:221:1:0.45%:5E-1:37:16:11:210:0:1	0/0:14:8:8:8:0:0%:1E0:40:0:5:3:0:0	0/0:340:182:182:182:0:0%:1E0:38:0:180:2:0:0	0/0:483:366:363:347:15:4.13%:2.6319E-5:36:16:303:44:15:0	0/0:155:105:105:101:3:2.88%:1.2319E-1:53:16:82:19:3:0	0/1:74:310:307:281:24:7.87%:3.7226E-8:35:16:250:31:24:0	0/0:503:327:326:319:7:2.15%:7.5624E-3:43:16:296:23:7:0	0/0:244:140:140:139:1:0.71%:5E-1:62:16:137:2:1:0
chr10	89717735	.	A	T	.	PASS	ADP=204;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:378:211:211:210:1:0.47%:5E-1:39:19:4:206:1:0	0/0:1041:556:556:556:0:0%:1E0:38:0:556:0:0:0	0/0:403:216:216:216:0:0%:1E0:38:0:4:212:0:0	0/0:14:8:8:8:0:0%:1E0:40:0:5:3:0:0	0/0:340:182:182:182:0:0%:1E0:38:0:180:2:0:0	0/0:648:385:384:379:4:1.04%:6.201E-2:36:19:315:64:4:0	0/0:178:103:103:102:1:0.97%:5E-1:53:19:82:20:1:0	0/1:52:320:319:302:17:5.33%:6.1298E-6:33:18:261:41:17:0	0/0:587:334:334:332:2:0.6%:2.4963E-1:43:19:303:29:2:0	0/0:244:140:140:139:1:0.71%:5E-1:63:19:136:3:1:0
chr10	89717739	.	T	G	.	PASS	ADP=204;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:396:211:211:211:0:0%:1E0:38:0:5:206:0:0	0/0:1041:556:556:556:0:0%:1E0:38:0:556:0:0:0	0/0:403:216:216:216:0:0%:1E0:38:0:4:212:0:0	0/0:14:8:8:8:0:0%:1E0:37:0:5:3:0:0	0/0:340:182:182:182:0:0%:1E0:38:0:180:2:0:0	0/0:580:385:384:372:9:2.34%:1.862E-3:33:17:308:64:9:0	0/0:171:103:101:99:1:0.99%:5E-1:52:17:79:20:1:0	0/1:61:320:317:297:20:6.31%:7E-7:30:18:256:41:20:0	0/0:571:334:334:331:3:0.9%:1.2444E-1:42:17:302:29:3:0	0/0:207:140:140:136:4:2.86%:6.1158E-2:64:16:133:3:4:0
chr11	534332	.	G	A	.	PASS	ADP=422;WT=0;HET=0;HOM=10;NC=2;bior.Clinvar.ClinicalSignificance=Benign;bior.Clinvar.RCVaccession=RCV000125380;bior.Clinvar.PhenotypeIDs=MedGen:CN221809;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_single_submitter;bior.ExAC.Info.AC=5514;bior.ExAC.Info.AN=126108;bior.ExAC.Info.AF=0.044;bior.ExAC.Info.AC_Het=5139;bior.ExAC.Info.AC_Hom=159;bior.dbSNP139.ID=rs41294870	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:255:707:699:3:696:99.57%:0E0:15:38:1:2:658:38	1/1:255:676:676:0:676:100%:0E0:0:38:0:0:667:9	1/1:255:451:451:0:450:100%:4.4494E-270:0:54:0:0:448:2	1/1:255:674:673:0:673:100%:0E0:0:38:0:0:666:7	1/1:255:112:112:0:112:100%:6.9655E-67:0:77:0:0:112:0	1/1:255:665:665:27:638:95.94%:0E0:38:38:27:0:638:0	1/1:255:49:49:0:49:100%:3.925E-29:0:76:0:0:49:0	1/1:255:409:409:7:402:98.29%:8.341E-231:65:62:7:0:401:1	1/1:255:668:668:29:639:95.66%:0E0:38:38:29:0:637:2	1/1:255:673:673:0:673:100%:0E0:0:38:0:0:672:1
chr11	108170484	.	C	T	.	PASS	ADP=148;WT=0;HET=5;HOM=0;NC=7	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/1:255:318:318:239:79:24.84%:6.4644E-27:75:38:113:126:39:40	0/1:255:247:247:154:93:37.65%:2.1625E-33:75:39:83:71:47:46	0/1:255:412:412:267:145:35.19%:4.2347E-51:75:38:140:127:73:72	0/1:255:368:368:247:121:32.88%:2.6273E-42:74:38:129:118:60:61	0/1:255:437:437:237:200:45.77%:6.1262E-74:76:38:122:115:99:101
chr11	108170583	.	C	A	.	PASS	ADP=68;WT=8;HET=1;HOM=0;NC=3	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:445:237:237:237:0:0%:1E0:32:0:237:0:0:0	0/0:232:123:123:123:0:0%:1E0:33:0:121:2:0:0	./.:.:1	0/0:149:80:80:80:0:0%:1E0:38:0:76:4:0:0	0/0:17:14:14:13:1:7.14%:5E-1:30:18:13:0:1:0	0/1:21:72:72:65:7:9.72%:6.7056E-3:56:18:47:18:7:0	0/0:134:72:72:72:0:0%:1E0:65:0:46:26:0:0	0/0:149:87:87:86:1:1.15%:5E-1:67:18:49:37:1:0	0/0:130:69:69:69:0:0%:1E0:67:0:40:29:0:0	0/0:102:67:67:65:2:2.99%:2.4812E-1:68:18:40:25:2:0
chr11	108170601	.	G	A	.	PASS	ADP=122;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:390:268:268:260:8:2.99%:3.7047E-3:36:17:243:17:8:0	0/1:21:135:135:128:7:5.19%:7.214E-3:33:18:120:8:7:0	0/0:51:28:28:28:0:0%:1E0:73:0:16:12:0:0	0/0:278:158:158:156:1:0.63%:5E-1:55:18:117:39:1:0	0/0:52:27:27:27:0:0%:1E0:50:0:19:8:0:0	0/0:259:147:147:146:1:0.68%:5E-1:73:18:69:77:1:0	0/0:183:120:120:117:3:2.5%:1.2343E-1:67:18:60:57:3:0	0/0:437:234:234:234:0:0%:1E0:75:0:106:128:0:0	0/0:460:246:246:246:0:0%:1E0:74:0:123:123:0:0	0/0:190:101:101:101:0:0%:1E0:76:0:53:48:0:0
chr11	108170607	.	A	C	.	PASS	ADP=122;WT=5;HET=4;HOM=1;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:100:268:268:236:32:11.94%:8.7053E-11:36:74:236:0:15:17	0/1:37:135:135:123:12:8.89%:1.8911E-4:35:73:122:1:5:7	1/1:144:28:28:1:27:96.43%:3.7915E-15:39:73:1:0:15:12	0/1:255:158:158:73:85:53.8%:3.6133E-33:36:74:73:0:46:39	0/1:52:27:27:13:14:51.85%:6.1806E-6:37:67:13:0:6:8	0/0:276:147:147:147:0:0%:1E0:73:0:71:76:0:0	0/0:224:120:120:120:0:0%:1E0:67:0:63:57:0:0	0/0:441:235:235:235:0:0%:1E0:75:0:106:129:0:0	0/0:460:246:246:246:0:0%:1E0:74:0:123:123:0:0	0/0:190:101:101:101:0:0%:1E0:75:0:53:48:0:0
chr11	108173672	.	T	C	.	PASS	ADP=366;WT=5;HET=3;HOM=3;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:185:126:126:73:52:41.27%:2.5815E-19:32:33:2:71:0:52	1/1:255:621:621:127:494:79.55%:2.1903E-226:35:34:3:124:0:494	0/1:255:369:369:157:212:57.45%:1.5897E-83:32:34:0:157:0:212	0/1:255:665:665:264:401:60.3%:3.6265E-160:32:35:0:264:0:401	1/1:255:557:557:70:487:87.43%:1.8462E-240:32:34:0:70:0:487	1/1:255:109:109:11:98:89.91%:5.1046E-50:30:34:0:11:0:98	0/0:722:386:386:386:0:0%:1E0:66:0:161:225:0:0	0/0:670:357:357:357:0:0%:1E0:72:0:170:187:0:0	0/0:614:444:444:428:16:3.6%:1.3298E-5:57:29:109:319:0:16	0/0:694:392:392:390:2:0.51%:2.4968E-1:65:17:149:241:0:2	0/0:649:368:368:366:2:0.54%:2.4966E-1:70:18:160:206:0:2
chr11	108200947	.	A	C	.	PASS	ADP=117;WT=0;HET=5;HOM=0;NC=7;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126700;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=4;bior.ExAC.Info.AC_Hom=0;bior.dbSNP139.ID=rs199909913	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	./.:.:3	./.:.:0	./.:.:0	./.:.:6	./.:.:0	0/1:194:299:299:194:59:19.73%:3.7494E-20:77:75:101:93:34:25	0/1:134:270:270:201:42:15.56%:3.268E-14:76:75:87:114:15:27	0/1:255:318:318:161:101:31.76%:2.3309E-36:74:76:75:86:58:43	0/1:255:318:318:177:87:27.36%:1.278E-30:75:76:90:87:45:42	0/1:211:189:189:94:60:31.75%:6.5252E-22:76:75:40:54:33:27
chr11	108200990	.	C	T	.	PASS	ADP=117;WT=4;HET=1;HOM=0;NC=7;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126700;bior.ExAC.Info.AF=7.893e-06;bior.ExAC.Info.AC_Het=1;bior.ExAC.Info.AC_Hom=0;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	./.:.:3	./.:.:0	./.:.:0	./.:.:6	./.:.:0	0/0:436:299:299:290:9:3.01%:1.8374E-3:76:77:152:138:6:3	0/1:229:271:271:202:69:25.46%:1.1738E-23:74:76:81:121:36:33	0/0:595:318:318:318:0:0%:1E0:75:0:169:149:0:0	0/0:599:319:319:319:0:0%:1E0:75:0:162:157:0:0	0/0:355:189:189:189:0:0%:1E0:75:0:92:97:0:0
chr11	108200990	.	C	T	.	PASS	ADP=117;WT=4;HET=1;HOM=0;NC=7;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126700;bior.ExAC.Info.AF=7.893e-06;bior.ExAC.Info.AC_Het=1;bior.ExAC.Info.AC_Hom=0;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	./.:.:3	./.:.:0	./.:.:0	./.:.:6	./.:.:0	0/0:436:299:299:290:9:3.01%:1.8374E-3:76:77:152:138:6:3	0/1:229:271:271:202:69:25.46%:1.1738E-23:74:76:81:121:36:33	0/0:595:318:318:318:0:0%:1E0:75:0:169:149:0:0	0/0:599:319:319:319:0:0%:1E0:75:0:162:157:0:0	0/0:355:189:189:189:0:0%:1E0:75:0:92:97:0:0
chr11	108205782	.	A	G	.	PASS	ADP=97;WT=5;HET=1;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	./.:.:1	./.:.:4	0/0:32:18:18:18:0:0%:1E0:77:0:18:0:0:0	./.:.:6	./.:.:6	0/0:711:379:379:379:0:0%:1E0:67:0:379:0:0:0	0/1:40:199:199:186:13:6.53%:9.9706E-5:77:76:186:0:13:0	0/0:269:143:143:143:0:0%:1E0:77:0:143:0:0:0	0/0:501:268:268:268:0:0%:1E0:77:0:267:1:0:0	0/0:261:140:140:140:0:0%:1E0:77:0:140:0:0:0
chr11	108218141	.	A	T	.	PASS	ADP=35;WT=4;HET=2;HOM=1;NC=5	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:46:9:9:0:9:100%:2.0568E-5:0:33:0:0:9:0	0/0:200:116:116:115:1:0.86%:5E-1:77:33:115:0:1:0	./.:.:1	0/0:155:103:103:100:3:2.91%:1.2317E-1:77:32:100:0:3:0	0/0:52:27:27:27:0:0%:1E0:77:0:27:0:0:0	0/1:95:68:68:41:27:39.71%:2.9254E-10:77:33:41:0:27:0	./.:.:2	./.:.:0	./.:.:1	0/0:130:69:69:69:0:0%:1E0:76:0:69:0:0:0	0/1:33:32:32:22:10:31.25%:4.259E-4:75:31:22:0:10:0
chr11	108236173	.	C	A	.	PASS	ADP=181;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:493:264:264:264:0:0%:1E0:33:0:0:264:0:0	0/0:148:116:116:110:6:5.17%:1.4624E-2:33:33:2:108:0:6	0/1:105:96:96:65:31:32.29%:2.571E-11:32:33:2:63:0:31	0/0:325:173:173:173:0:0%:1E0:33:0:2:171:0:0	0/0:171:130:130:124:6:4.62%:1.4731E-2:33:33:3:121:0:6	0/0:11:10:10:9:1:10%:5E-1:33:32:1:8:0:1	0/0:463:257:257:256:1:0.39%:5E-1:34:20:5:251:1:0	0/0:599:319:319:319:0:0%:1E0:33:0:0:319:0:0	0/0:696:372:372:372:0:0%:1E0:33:0:8:364:0:0	0/0:493:273:273:272:1:0.37%:5E-1:33:29:5:267:0:1	0/0:302:162:162:162:0:0%:1E0:33:0:6:156:0:0
chr12	112926931	.	G	A	.	PASS	ADP=615;WT=10;HET=0;HOM=1;NC=1;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	1/1:255:691:691:2:688:99.57%:0E0:37:38:2:0:662:26	0/0:1276:698:694:693:1:0.14%:5E-1:37:30:668:25:1:0	0/0:1205:657:655:654:1:0.15%:5E-1:38:19:644:10:0:1	0/0:1220:665:664:663:1:0.15%:5E-1:38:38:643:20:1:0	0/0:1244:696:688:686:2:0.29%:2.4982E-1:37:26:660:26:2:0	0/0:1212:662:660:659:1:0.15%:5E-1:38:15:649:10:1:0	0/0:1251:670:668:668:0:0%:1E0:38:0:666:2:0:0	0/0:1239:665:662:662:0:0%:1E0:38:0:661:1:0:0	0/0:1251:671:668:668:0:0%:1E0:38:0:666:2:0:0	0/0:1266:676:675:675:0:0%:1E0:38:0:669:6:0:0	0/0:1243:666:664:664:0:0%:1E0:38:0:662:2:0:0
chr12	121431383	.	C	A	.	PASS	ADP=384;WT=7;HET=3;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:852:669:667:630:30:4.5%:6.6481E-10:25:17:0:630:0:30	0/0:133:101:101:96:5:4.95%:2.9707E-2:61:17:4:92:0:5	0/1:53:157:157:139:17:10.83%:4.814E-6:37:19:14:125:0:17	0/1:170:668:667:608:55:8.25%:8.6293E-18:27:18:0:608:0:55	0/1:50:141:141:124:16:11.35%:9.6911E-6:30:17:2:122:0:16	0/0:1157:647:618:618:0:0%:1E0:37:0:20:598:0:0	0/0:557:317:317:315:2:0.63%:2.4961E-1:65:24:18:297:0:2	0/0:1247:669:666:666:0:0%:1E0:38:0:1:665:0:0	0/0:1162:662:644:642:2:0.31%:2.4981E-1:37:18:10:632:0:2	0/0:1154:653:640:638:2:0.31%:2.498E-1:37:24:3:635:0:2
chr12	121431384	.	C	A	.	PASS	ADP=390;WT=8;HET=2;HOM=0;NC=2;bior.ExAC.Info.AC=2;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=1.578e-05;bior.ExAC.Info.AC_Het=2;bior.ExAC.Info.AC_Hom=0;bior.dbSNP139.ID=rs150040269	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:1052:669:667:653:12:1.8%:2.3222E-4:28:17:0:653:0:12	0/0:158:101:101:98:2:1.98%:2.4874E-1:61:17:4:94:0:2	0/1:27:157:157:148:9:5.73%:1.736E-3:37:17:14:134:0:9	0/1:116:668:668:629:38:5.69%:2.1151E-12:28:17:0:629:0:38	0/0:192:141:141:135:6:4.26%:1.48E-2:32:17:2:133:0:6	0/0:1182:647:644:643:1:0.16%:5E-1:38:18:47:596:0:1	0/0:557:318:318:316:2:0.63%:2.4961E-1:66:15:18:298:0:2	0/0:1254:670:670:670:0:0%:1E0:38:0:4:666:0:0	0/0:1195:662:662:660:2:0.3%:2.4981E-1:37:17:28:632:0:2	0/0:1225:653:653:653:0:0%:1E0:38:0:16:637:0:0
chr12	121431394	.	C	A	.	PASS	ADP=310;WT=8;HET=2;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:61:666:379:359:20:5.28%:7.3731E-7:33:16:0:359:0:20	0/0:156:101:84:84:0:0%:1E0:67:0:4:80:0:0	0/0:116:155:92:87:5:5.43%:2.9557E-2:48:17:14:73:0:5	0/1:67:668:340:318:22:6.47%:1.6787E-7:34:17:0:318:0:22	0/0:102:141:67:65:2:2.99%:2.4812E-1:42:17:2:63:0:2	0/0:1059:619:577:576:1:0.17%:5E-1:37:17:14:562:0:1	0/0:572:322:306:306:0:0%:1E0:66:0:18:288:0:0	0/0:1213:668:659:658:1:0.15%:5E-1:37:39:2:656:0:1	0/0:1127:654:613:612:1:0.16%:5E-1:37:17:14:598:0:1	0/0:1087:646:604:602:2:0.33%:2.4979E-1:37:15:4:598:0:2
chr12	121431402	.	C	A	.	PASS	ADP=298;WT=6;HET=4;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:188:663:291:233:58:19.93%:1.475E-19:31:17:0:233:0:58	0/0:135:100:79:78:1:1.27%:5E-1:71:30:4:74:0:1	0/1:58:151:82:64:18:21.95%:1.3391E-6:55:15:14:50:0:18	0/1:218:663:325:258:67:20.62%:1.5198E-22:33:15:0:258:0:67	0/1:25:140:60:52:8:13.33%:3.045E-3:41:15:2:50:0:8	0/0:999:651:566:563:3:0.53%:1.2467E-1:36:15:16:547:0:3	0/0:612:375:348:346:2:0.57%:2.4964E-1:65:16:48:298:0:2	0/0:1221:675:651:651:0:0%:1E0:37:0:5:646:0:0	0/0:996:669:582:577:5:0.86%:3.0982E-2:36:15:11:566:0:5	0/0:999:653:600:593:7:1.17%:7.6762E-3:37:19:3:590:0:7
chr12	121431415	.	G	A	.	PASS	ADP=395;WT=8;HET=2;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:806:644:615:580:25:4.07%:2.3139E-8:24:18:4:576:0:25	0/0:201:118:115:114:1:0.87%:5E-1:56:15:9:105:0:1	0/0:545:305:301:300:1:0.33%:5E-1:38:18:30:270:0:1	0/1:180:654:615:554:58:9.43%:8.406E-19:26:17:2:552:0:58	0/1:46:177:163:146:15:9.2%:2.1687E-5:31:17:5:141:0:15	0/0:1080:610:601:598:2:0.33%:2.4979E-1:36:16:6:592:0:2	0/0:661:378:374:372:2:0.53%:2.4967E-1:64:18:49:323:1:1	0/0:1246:679:677:676:1:0.15%:5E-1:38:18:9:667:0:1	0/0:1183:650:644:642:1:0.16%:5E-1:37:18:7:635:0:1	0/0:1140:639:635:630:2:0.31%:2.498E-1:37:18:1:629:0:2
chr12	121431417	.	C	T	.	PASS	ADP=401;WT=8;HET=3;HOM=0;NC=1;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:112:60:59:59:0:0%:1E0:21:0:6:53:0:0	0/1:255:659:592:434:153:25.89%:9.5542E-52:23:17:4:430:0:153	0/0:220:118:117:117:0:0%:1E0:57:0:8:109:0:0	./0:71:305:285:261:23:8.07%:7.496E-8:32:16:29:232:0:23	0/0:904:653:636:613:20:3.14%:8.1884E-7:30:16:1:612:0:20	./0:36:178:177:162:12:6.78%:2.0065E-4:32:17:5:157:0:12	0/0:951:635:627:597:12:1.92%:2.3114E-4:34:18:10:587:0:12	0/0:622:379:369:365:4:1.08%:6.1992E-2:61:17:47:318:0:4	0/0:1207:677:669:666:2:0.3%:2.4981E-1:37:16:5:661:0:2	0/0:1068:658:645:631:7:1.09%:7.6843E-3:35:17:9:622:0:7	0/0:1019:653:644:624:10:1.56%:9.4226E-4:35:17:5:619:0:10
chr12	121431417	.	C	G	.	PASS	ADP=401;WT=8;HET=3;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:112:60:59:59:0:0%:1E0:21:0:6:53:0:0	./0:255:659:592:434:153:25.89%:9.5542E-52:23:17:4:430:0:153	0/0:220:118:117:117:0:0%:1E0:57:0:8:109:0:0	0/1:71:305:285:261:23:8.07%:7.496E-8:32:16:29:232:0:23	0/0:904:653:636:613:20:3.14%:8.1884E-7:30:16:1:612:0:20	./0:36:178:177:162:12:6.78%:2.0065E-4:32:17:5:157:0:12	0/0:951:635:627:597:12:1.92%:2.3114E-4:34:18:10:587:0:12	0/0:622:379:369:365:4:1.08%:6.1992E-2:61:17:47:318:0:4	0/0:1207:677:669:666:2:0.3%:2.4981E-1:37:16:5:661:0:2	0/0:1068:658:645:631:7:1.09%:7.6843E-3:35:17:9:622:0:7	0/0:1019:653:644:624:10:1.56%:9.4226E-4:35:17:5:619:0:10
chr12	121431417	.	C	A	.	PASS	ADP=401;WT=8;HET=3;HOM=0;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:112:60:59:59:0:0%:1E0:21:0:6:53:0:0	./0:255:659:592:434:153:25.89%:9.5542E-52:23:17:4:430:0:153	0/0:220:118:117:117:0:0%:1E0:57:0:8:109:0:0	./0:71:305:285:261:23:8.07%:7.496E-8:32:16:29:232:0:23	0/0:904:653:636:613:20:3.14%:8.1884E-7:30:16:1:612:0:20	0/1:36:178:177:162:12:6.78%:2.0065E-4:32:17:5:157:0:12	0/0:951:635:627:597:12:1.92%:2.3114E-4:34:18:10:587:0:12	0/0:622:379:369:365:4:1.08%:6.1992E-2:61:17:47:318:0:4	0/0:1207:677:669:666:2:0.3%:2.4981E-1:37:16:5:661:0:2	0/0:1068:658:645:631:7:1.09%:7.6843E-3:35:17:9:622:0:7	0/0:1019:653:644:624:10:1.56%:9.4226E-4:35:17:5:619:0:10
chr12	121431418	.	C	G	.	PASS	ADP=408;WT=9;HET=2;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:119:64:64:64:0:0%:1E0:25:0:6:58:0:0	0/1:239:660:608:521:76:12.5%:1.0334E-24:31:17:4:517:0:76	0/0:220:118:118:118:0:0%:1E0:59:0:8:110:0:0	0/1:49:305:300:284:16:5.33%:1.2426E-5:36:17:31:253:0:16	0/0:1158:653:652:649:3:0.46%:1.2471E-1:34:18:2:647:0:3	0/0:271:178:176:172:4:2.27%:6.1433E-2:33:22:5:167:0:4	0/0:946:636:627:600:13:2.08%:1.1447E-4:36:18:6:594:0:13	0/0:661:380:374:371:2:0.53%:2.4966E-1:62:17:48:323:0:2	0/0:1238:678:674:673:1:0.15%:5E-1:38:39:6:667:0:1	0/0:888:658:654:628:25:3.83%:2.3582E-8:36:18:4:624:0:25	0/0:1045:654:652:637:10:1.54%:9.4294E-4:36:19:5:632:0:10
chr12	121431419	.	C	T	.	PASS	ADP=411;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:123:65:65:65:0:0%:1E0:36:0:6:59:0:0	0/0:775:661:646:584:30:4.64%:6.4782E-10:24:18:4:580:0:30	0/0:216:117:116:116:0:0%:1E0:56:0:8:108:0:0	0/0:556:307:307:306:1:0.33%:5E-1:37:18:31:275:0:1	0/1:154:653:642:576:50:7.79%:3.2059E-16:26:18:2:574:0:50	0/0:234:178:172:165:7:4.07%:7.3412E-3:29:18:5:160:0:7	0/0:1187:637:633:633:0:0%:1E0:38:0:7:626:0:0	0/0:690:382:380:379:1:0.26%:5E-1:63:18:49:330:0:1	0/0:1239:678:673:672:1:0.15%:5E-1:38:18:4:668:0:1	0/0:1177:659:654:650:2:0.31%:2.4981E-1:36:17:3:647:0:2	0/0:1201:655:655:652:1:0.15%:5E-1:37:19:5:647:0:1
chr12	121431421	.	G	C	.	PASS	ADP=405;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:111:65:60:60:0:0%:1E0:34:0:1:59:0:0	0/0:849:663:624:597:23:3.71%:9.6841E-8:30:16:4:593:0:23	0/0:213:117:113:113:0:0%:1E0:59:0:7:106:0:0	0/0:528:307:302:299:2:0.66%:2.4958E-1:38:16:31:268:0:2	0/1:101:653:608:573:33:5.43%:7.44E-11:32:16:1:572:0:33	0/0:213:178:160:153:7:4.38%:7.3063E-3:35:16:2:151:0:7	0/0:1184:641:631:631:0:0%:1E0:38:0:9:622:0:0	0/0:711:383:379:379:0:0%:1E0:65:0:49:330:0:0	0/0:1270:682:677:677:0:0%:1E0:38:0:7:670:0:0	0/0:1184:662:656:654:2:0.3%:2.4981E-1:37:16:7:647:0:2	0/0:1173:656:650:648:2:0.31%:2.4981E-1:37:16:2:646:0:2
chr12	121431422	.	C	A	.	PASS	ADP=395;WT=9;HET=2;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:115:65:62:62:0:0%:1E0:33:0:5:57:0:0	0/1:158:663:586:527:51:8.76%:1.4009E-16:24:18:4:523:0:51	0/0:180:117:111:109:2:1.8%:2.4887E-1:58:24:8:101:0:2	0/0:415:307:287:278:9:3.14%:1.8327E-3:35:18:31:247:0:9	0/1:191:653:565:504:61:10.8%:7.8282E-20:26:18:2:502:0:61	0/0:236:178:155:151:4:2.58%:6.1288E-2:31:17:5:146:0:4	0/0:1140:642:631:629:2:0.32%:2.498E-1:36:17:15:614:0:2	0/0:700:382:373:373:0:0%:1E0:64:0:49:324:0:0	0/0:1262:683:674:674:0:0%:1E0:37:0:9:665:0:0	0/0:1158:662:653:649:3:0.46%:1.2471E-1:36:16:9:640:0:3	0/0:1147:657:645:642:3:0.47%:1.2471E-1:36:17:5:637:0:3
chr12	121431423	.	A	C	.	PASS	ADP=412;WT=6;HET=5;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:91:65:61:59:2:3.28%:2.4793E-1:32:16:2:57:0:2	0/1:255:663:651:504:141:21.79%:6.5528E-47:24:17:2:502:0:141	0/1:27:117:117:108:9:7.69%:1.6649E-3:58:16:7:101:0:9	0/1:74:307:305:280:24:7.87%:3.7167E-8:34:17:29:251:0:24	0/1:255:653:645:500:145:22.48%:2.4097E-48:27:17:2:498:0:145	0/1:99:178:171:140:31:18.13%:1.0441E-10:30:19:5:135:0:31	0/0:985:641:635:622:13:2.05%:1.1473E-4:37:16:10:612:0:13	0/0:708:384:377:377:0:0%:1E0:63:0:50:327:0:0	0/0:1242:682:676:675:1:0.15%:5E-1:38:16:8:667:0:1	0/0:1101:664:657:649:7:1.07%:7.6878E-3:36:16:8:641:0:7	0/0:1036:656:652:638:11:1.69%:4.6786E-4:37:16:2:636:0:11
chr12	121431424	.	T	G	.	PASS	ADP=415;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:123:65:65:65:0:0%:1E0:37:0:6:59:0:0	0/0:1208:664:659:657:1:0.15%:5E-1:34:16:4:653:0:1	0/0:220:117:117:117:0:0%:1E0:60:0:7:110:0:0	0/0:556:307:307:306:1:0.33%:5E-1:40:16:29:277:0:1	0/0:1166:653:648:644:2:0.31%:2.4981E-1:35:17:2:642:0:2	0/0:311:178:176:175:1:0.57%:5E-1:38:15:5:170:0:1	0/0:1178:643:643:641:1:0.16%:5E-1:38:16:17:624:0:1	0/1:83:384:379:352:27:7.12%:4.6106E-9:67:35:38:314:13:14	0/0:1277:683:681:681:0:0%:1E0:37:0:13:668:0:0	0/0:1236:660:659:659:0:0%:1E0:37:0:13:646:0:0	0/0:1224:656:654:654:0:0%:1E0:37:0:5:649:0:0
chr12	121431426	.	C	T	.	PASS	ADP=415;WT=9;HET=2;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:123:65:65:65:0:0%:1E0:29:0:6:59:0:0	0/1:142:665:653:567:46:7.06%:5.9123E-15:22:18:4:563:0:46	0/0:200:117:117:115:1:0.85%:5E-1:56:20:8:107:0:1	0/0:478:307:303:292:5:1.65%:3.0724E-2:32:17:31:261:0:5	0/1:126:661:647:579:41:6.34%:2.2952E-13:25:18:2:577:0:41	0/0:234:178:173:165:7:4.05%:7.3412E-3:29:17:5:160:0:7	0/0:1115:644:641:634:4:0.62%:6.2206E-2:36:19:17:617:0:4	0/0:715:384:382:382:0:0%:1E0:64:0:50:332:0:0	0/0:1285:686:685:685:0:0%:1E0:38:0:13:672:0:0	0/0:1192:662:660:657:2:0.3%:2.4981E-1:36:20:12:645:0:2	0/0:1141:656:654:647:4:0.61%:6.2212E-2:36:19:6:641:0:4
chr12	121431427	.	C	A	.	PASS	ADP=410;WT=8;HET=3;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:78:65:64:60:4:6.25%:5.9559E-2:33:31:6:54:0:4	0/1:255:666:640:520:86:13.5%:5.0231E-28:23:19:4:516:0:86	0/0:162:117:115:110:4:3.48%:6.0852E-2:58:20:8:102:0:4	0/1:55:307:302:284:18:5.96%:2.9387E-6:33:19:30:254:0:18	0/1:223:662:634:546:71:11.2%:4.9973E-23:25:19:2:544:0:71	0/0:236:178:170:162:6:3.53%:1.4932E-2:29:20:5:157:0:6	0/0:1050:644:637:627:8:1.26%:3.8206E-3:37:19:12:615:0:8	0/0:690:384:380:379:1:0.26%:5E-1:63:20:50:329:0:1	0/0:1270:685:677:677:0:0%:1E0:38:0:6:671:0:0	0/0:1148:663:656:652:4:0.61%:6.2214E-2:36:19:8:644:0:4	0/0:1125:656:654:646:5:0.76%:3.101E-2:37:19:6:640:0:5
chr12	121431429	.	G	C	.	PASS	ADP=413;WT=8;HET=3;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:109:65:65:64:1:1.54%:5E-1:32:20:6:58:0:1	0/1:232:666:639:555:74:11.65%:5.4054E-24:27:17:2:553:0:74	0/0:172:117:115:111:3:2.61%:1.2335E-1:59:20:8:103:0:3	0/0:464:307:305:297:7:2.3%:7.5444E-3:35:17:28:269:0:7	0/1:148:662:636:580:48:7.56%:1.3967E-15:29:17:2:578:0:48	0/1:59:178:170:151:19:11.18%:1.1202E-6:34:18:5:146:0:19	0/0:1106:644:643:637:5:0.78%:3.1007E-2:37:18:16:621:0:5	0/0:723:385:385:385:0:0%:1E0:64:0:51:334:0:0	0/0:1261:687:685:684:1:0.15%:5E-1:38:18:12:672:0:1	0/0:1199:664:664:662:2:0.3%:2.4981E-1:37:19:13:649:0:2	0/0:1113:656:654:647:6:0.92%:1.5446E-2:37:17:6:641:0:6
chr12	121431434	.	T	C	.	PASS	ADP=406;WT=7;HET=4;HOM=0;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Diabetes|_MODY3;bior.hgmd_2014.2.OMIM_ID=142410;bior.hgmd_2014.2.PubMed=19169489	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:94:65:64:62:2:3.12%:2.4803E-1:28:17:6:56:0:2	0/1:255:668:621:489:108:17.48%:1.4976E-35:22:17:4:485:0:108	0/0:169:117:117:113:4:3.42%:6.0894E-2:56:16:9:104:0:4	0/1:64:308:303:279:21:6.93%:3.3186E-7:32:16:31:248:0:21	0/1:255:663:617:493:103:16.72%:7.8862E-34:26:17:2:491:0:103	0/1:100:178:167:134:31:18.56%:9.8315E-11:30:16:5:129:0:31	0/0:1033:640:636:624:9:1.42%:1.898E-3:36:18:17:607:0:9	0/0:642:359:354:352:1:0.28%:5E-1:65:18:37:315:0:1	0/0:1265:688:687:686:1:0.15%:5E-1:37:16:14:672:0:1	0/0:1139:661:660:655:5:0.76%:3.1013E-2:36:17:14:641:0:5	0/0:1076:655:649:641:8:1.23%:3.8224E-3:36:17:5:636:0:8
chr12	121431435	.	C	A	.	PASS	ADP=406;WT=6;HET=5;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:78:65:64:60:4:6.25%:5.9559E-2:29:19:5:55:0:4	0/1:255:668:614:485:123:20.1%:9.7086E-41:33:19:4:481:0:123	0/1:24:118:118:109:8:6.78%:3.4519E-3:61:17:8:101:0:8	0/1:96:306:303:271:31:10.23%:2.0691E-10:37:19:26:245:0:31	0/1:255:664:632:508:119:18.86%:3.0705E-39:34:19:2:506:0:119	0/1:89:178:171:143:28:16.37%:1.1182E-9:36:19:5:138:0:28	0/0:907:640:635:615:20:3.15%:8.1924E-7:37:20:16:599:0:20	0/0:573:360:358:351:6:1.68%:1.5298E-2:66:23:37:314:0:6	0/0:1273:688:680:680:0:0%:1E0:37:0:11:669:0:0	0/0:1046:662:655:644:11:1.68%:4.6805E-4:36:19:13:631:0:11	0/0:979:656:646:630:15:2.32%:2.8106E-5:37:20:4:626:0:15
chr12	121431436	.	C	G	.	PASS	ADP=417;WT=9;HET=2;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:105:65:65:63:1:1.54%:5E-1:32:16:6:57:0:1	0/1:199:668:667:597:64:9.64%:1.0917E-20:26:16:4:593:0:64	0/0:204:118:118:117:1:0.85%:5E-1:57:17:8:109:0:1	0/0:450:308:308:298:9:2.92%:1.8404E-3:37:16:31:267:0:9	0/1:202:664:664:595:65:9.8%:5.1669E-21:29:16:2:593:0:65	0/0:271:178:178:172:4:2.25%:6.1433E-2:33:17:5:167:0:4	0/0:1136:642:640:636:3:0.47%:1.2471E-1:37:22:18:618:0:3	0/0:604:360:359:355:4:1.11%:6.1977E-2:66:15:37:318:0:4	0/0:1265:688:687:686:1:0.15%:5E-1:37:15:13:673:1:0	0/0:1163:663:663:659:4:0.6%:6.2217E-2:36:16:14:645:0:4	0/0:1105:657:657:650:7:1.07%:7.688E-3:37:16:6:644:0:7
chr12	121431437	.	T	G	.	PASS	ADP=414;WT=7;HET=4;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:123:65:65:65:0:0%:1E0:31:0:6:59:0:0	0/1:255:669:660:535:120:18.26%:1.8507E-39:33:16:2:533:0:120	0/0:191:118:117:115:2:1.71%:2.4893E-1:58:16:6:109:0:2	0/1:64:308:301:280:21:6.98%:3.3228E-7:38:16:24:256:0:21	0/1:255:664:658:550:102:15.53%:2.7064E-33:34:16:1:549:0:102	0/1:82:178:174:147:26:14.94%:5.3996E-9:37:15:4:143:0:26	0/0:1058:642:640:631:8:1.25%:3.8211E-3:37:15:17:614:0:8	0/0:635:360:360:358:2:0.56%:2.4965E-1:66:15:38:320:0:2	0/0:1284:688:686:686:0:0%:1E0:38:0:13:673:0:0	0/0:1116:663:663:656:7:1.06%:7.6891E-3:37:16:14:642:0:7	0/0:1059:657:655:645:10:1.53%:9.4335E-4:37:17:7:638:0:10
chr12	121431438	.	G	A	.	PASS	ADP=415;WT=8;HET=3;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:123:65:65:65:0:0%:1E0:32:0:6:59:0:0	0/1:164:669:659:603:53:8.08%:3.7164E-17:32:17:4:599:0:53	0/0:204:118:118:117:1:0.85%:5E-1:58:18:9:108:0:1	0/0:426:308:305:294:11:3.61%:4.4548E-4:38:17:31:263:0:11	0/1:132:664:659:613:43:6.55%:5.5813E-14:32:17:1:612:0:43	0/1:27:178:176:167:9:5.11%:1.7588E-3:34:16:5:162:0:9	0/0:1136:641:639:636:3:0.47%:1.2471E-1:37:16:16:620:0:3	0/0:677:363:362:362:0:0%:1E0:66:0:37:325:0:0	0/0:1288:687:687:687:0:0%:1E0:38:0:12:675:0:0	0/0:1195:663:663:660:2:0.3%:2.4981E-1:37:18:14:646:0:2	0/0:1166:657:656:652:3:0.46%:1.2471E-1:37:16:5:647:0:3
chr12	121431439	.	T	C	.	PASS	ADP=416;WT=7;HET=4;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:98:65:65:63:2:3.08%:2.4806E-1:32:15:6:57:0:2	0/1:255:669:666:527:136:20.48%:5.0558E-45:32:15:4:523:0:136	0/0:169:118:117:113:4:3.42%:6.0894E-2:59:15:8:105:0:4	0/1:64:308:307:286:21:6.84%:3.3471E-7:37:16:31:255:0:21	0/1:255:664:663:550:110:16.67%:5.4065E-36:33:15:1:549:0:110	0/1:92:178:177:148:29:16.38%:5.3424E-10:36:15:5:143:0:29	0/0:1054:640:639:630:8:1.25%:3.821E-3:37:15:16:614:0:8	0/0:623:363:362:358:3:0.83%:1.2448E-1:66:15:36:322:0:3	0/0:1261:685:685:684:1:0.15%:5E-1:38:16:12:672:0:1	0/0:1143:663:663:656:5:0.75%:3.1014E-2:37:16:13:643:0:5	0/0:1086:657:656:648:8:1.22%:3.8233E-3:37:15:6:642:0:8
chr12	121431440	.	T	G	.	PASS	ADP=416;WT=6;HET=5;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:68:65:65:59:6:9.23%:1.3851E-2:28:18:6:53:0:6	0/1:255:669:666:432:229:34.49%:4.1598E-80:25:17:4:428:0:229	0/1:40:118:117:104:13:11.11%:8.5821E-5:61:16:8:96:0:13	0/1:184:306:306:249:57:18.63%:3.9027E-19:33:16:29:220:0:57	0/1:255:664:660:470:185:28.16%:5.1552E-63:27:17:1:469:0:185	0/1:164:177:177:128:49:27.68%:3.721E-17:30:16:4:124:0:49	0/0:860:640:639:613:25:3.91%:2.345E-8:36:16:16:597:0:25	0/0:560:364:363:355:8:2.2%:3.7569E-3:66:16:38:317:0:8	0/0:1221:686:686:683:3:0.44%:1.2473E-1:37:16:13:670:0:3	0/0:1023:664:664:649:14:2.11%:5.6947E-5:36:16:15:634:0:14	0/0:942:657:657:635:20:3.04%:8.2311E-7:37:18:6:629:0:20
chr12	121431442	.	C	T	.	PASS	ADP=414;WT=7;HET=4;HOM=0;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Diabetes|_MODY;bior.hgmd_2014.2.OMIM_ID=142410;bior.hgmd_2014.2.PubMed=23348805	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:123:66:65:65:0:0%:1E0:31:0:6:59:0:0	0/1:190:670:658:588:61:9.34%:9.8784E-20:25:18:4:584:0:61	0/0:191:119:117:115:2:1.71%:2.4893E-1:57:18:8:107:0:2	0/1:55:310:307:288:18:5.88%:2.949E-6:34:17:30:258:0:18	0/1:219:665:655:579:70:10.79%:1.185E-22:27:17:1:578:0:70	0/1:43:179:177:162:14:7.95%:4.6644E-5:30:18:5:157:0:14	0/0:1099:641:638:632:5:0.78%:3.1005E-2:36:18:17:615:0:5	0/0:649:372:368:366:2:0.54%:2.4966E-1:64:23:39:327:0:2	0/0:1257:687:683:682:1:0.15%:5E-1:37:15:12:670:1:0	0/0:1139:665:662:655:5:0.76%:3.1013E-2:36:18:14:641:0:5	0/0:1101:658:648:642:6:0.93%:1.5444E-2:36:21:6:636:0:6
chr12	121431445	.	G	T	.	PASS	ADP=418;WT=9;HET=2;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:122:66:66:66:0:0%:1E0:33:0:6:60:0:0	0/1:113:673:665:627:37:5.57%:4.3441E-12:26:18:4:623:0:37	0/0:191:119:118:116:2:1.69%:2.4894E-1:56:16:8:108:0:2	0/0:460:313:313:304:9:2.88%:1.8425E-3:35:17:31:273:0:9	0/1:119:668:667:628:39:5.85%:1.0266E-12:28:16:1:627:0:39	0/0:257:179:179:173:6:3.35%:1.4974E-2:33:17:5:168:0:6	0/0:1140:643:641:638:3:0.47%:1.2471E-1:37:17:15:623:0:3	0/0:641:374:372:369:3:0.81%:1.245E-1:64:37:37:332:0:3	0/0:1261:688:685:684:1:0.15%:5E-1:38:39:10:674:0:1	0/0:1177:666:663:659:3:0.45%:1.2472E-1:37:18:11:648:0:3	0/0:1170:659:657:654:3:0.46%:1.2471E-1:37:16:5:649:0:3
chr12	121431448	.	T	G	.	PASS	ADP=423;WT=6;HET=5;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:85:67:67:63:4:5.97%:5.9691E-2:33:20:6:57:0:4	0/1:255:676:676:459:217:32.1%:4.548E-75:27:20:5:454:0:217	0/1:40:124:124:111:13:10.48%:8.764E-5:61:19:9:102:0:13	0/1:145:329:329:283:46:13.98%:2.6186E-15:38:19:32:251:0:46	0/1:255:670:670:537:133:19.85%:6.3025E-44:28:19:1:536:0:133	0/1:119:187:187:150:37:19.79%:1.0074E-12:33:19:5:145:0:37	0/0:964:644:644:628:16:2.48%:1.3886E-5:37:19:17:611:0:16	0/0:615:376:374:369:5:1.34%:3.0833E-2:65:20:37:332:0:5	0/0:1269:690:689:688:1:0.15%:5E-1:38:20:12:676:0:1	0/0:1147:666:665:658:5:0.75%:3.1014E-2:36:19:14:644:0:5	0/0:952:661:661:641:20:3.03%:8.2422E-7:37:19:6:635:0:20
chr12	121431451	.	G	C	.	PASS	ADP=424;WT=10;HET=1;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:127:67:67:67:0:0%:1E0:34:0:6:61:0:0	0/1:110:678:676:640:36:5.33%:9.0171E-12:26:17:5:635:0:36	0/0:215:125:124:123:1:0.81%:5E-1:56:18:9:114:0:1	0/0:523:331:329:323:6:1.82%:1.527E-2:37:18:32:291:0:6	0/0:946:672:670:647:22:3.28%:2.0005E-7:28:17:1:646:0:22	0/0:268:189:185:179:6:3.24%:1.4995E-2:31:17:5:174:0:6	0/0:1206:645:644:644:0:0%:1E0:37:0:17:627:0:0	0/0:683:376:375:374:1:0.27%:5E-1:65:18:38:336:0:1	0/0:1296:691:691:691:0:0%:1E0:38:0:13:678:0:0	0/0:1223:668:666:665:1:0.15%:5E-1:37:18:15:650:0:1	0/0:1220:663:663:662:1:0.15%:5E-1:37:18:6:656:0:1
chr12	121431452	.	A	T	.	PASS	ADP=426;WT=8;HET=3;HOM=0;NC=1	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:127:67:67:67:0:0%:1E0:34:0:6:61:0:0	0/1:255:679:679:593:86:12.67%:7.2955E-28:27:18:5:588:0:86	0/0:205:126:126:124:2:1.59%:2.49E-1:56:27:9:115:0:2	0/0:454:334:334:321:13:3.89%:1.0837E-4:38:19:32:289:0:13	0/1:180:673:673:615:58:8.62%:9.6145E-19:29:18:1:614:0:58	0/1:62:191:191:171:20:10.47%:5.645E-7:33:18:6:165:0:20	0/0:1113:646:646:641:5:0.77%:3.1008E-2:38:20:17:624:0:5	0/0:686:377:377:376:1:0.27%:5E-1:64:16:38:338:0:1	0/0:1252:691:691:689:2:0.29%:2.4982E-1:38:18:13:676:0:2	0/0:1094:668:668:659:9:1.35%:1.9009E-3:37:17:15:644:0:9	0/0:1200:663:663:661:2:0.3%:2.4981E-1:37:26:6:655:0:2
chr12	121432005	.	C	A	.	PASS	ADP=138;WT=5;HET=1;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:59:32:32:32:0:0%:1E0:76:0:20:12:0:0	./.:.:0	0/0:966:516:516:516:0:0%:1E0:44:0:81:435:0:0	0/0:634:412:411:402:9:2.19%:1.8686E-3:55:17:132:270:0:9	0/1:55:276:274:255:18:6.57%:2.8557E-6:30:17:8:247:0:18	0/0:393:243:243:239:4:1.65%:6.1728E-2:31:17:6:233:0:4	0/0:311:185:183:181:2:1.09%:2.4932E-1:32:17:6:175:0:2
chr12	121432006	.	A	T	.	PASS	ADP=138;WT=5;HET=1;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:59:32:32:32:0:0%:1E0:77:0:20:12:0:0	./.:.:0	0/0:832:516:516:508:8:1.55%:3.8009E-3:45:16:81:427:0:8	0/0:621:413:412:402:10:2.43%:9.2407E-4:57:16:132:270:0:10	0/0:383:278:277:266:10:3.61%:8.9882E-4:33:16:8:258:0:10	0/0:348:244:244:236:8:3.28%:3.6851E-3:33:16:6:230:0:8	0/1:49:185:184:168:16:8.7%:1.0855E-5:34:17:6:162:0:16
chr12	121432013	.	C	A	.	PASS	ADP=109;WT=5;HET=1;HOM=0;NC=6;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Diabetes|_MODY;bior.hgmd_2014.2.OMIM_ID=142410;bior.hgmd_2014.2.PubMed=11942313	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	0/0:59:32:32:32:0:0%:1E0:76:0:20:12:0:0	./.:.:0	0/0:535:520:315:310:3:0.95%:1.244E-1:54:18:83:227:0:3	0/0:502:415:303:299:4:1.32%:6.1881E-2:66:17:132:167:0:4	0/1:24:278:127:119:8:6.3%:3.4868E-3:38:18:8:111:0:8	0/0:257:342:180:173:6:3.33%:1.4974E-2:40:17:9:164:0:6	0/0:653:550:360:358:1:0.28%:5E-1:47:16:56:302:0:1
chr12	121432019	.	T	G	.	PASS	ADP=176;WT=5;HET=1;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	0/0:59:32:32:32:0:0%:1E0:77:0:20:12:0:0	./.:.:0	0/0:743:526:513:487:13:2.53%:1.128E-4:39:17:79:408:0:13	0/0:600:416:411:399:12:2.92%:2.2505E-4:53:17:132:267:0:12	0/1:42:280:272:248:14:5.15%:5.1069E-5:26:17:8:240:0:14	0/0:478:347:337:324:11:3.26%:4.4921E-4:28:19:9:315:0:11	0/0:838:556:545:529:11:2.02%:4.6381E-4:36:18:56:473:0:11
chr12	121432117	.	G	C	.	PASS	ADP=25;WT=0;HET=0;HOM=5;NC=7;bior.Clinvar.ClinicalSignificance=Benign;bior.Clinvar.RCVaccession=RCV000125372|RCV000117234;bior.Clinvar.PhenotypeIDs=MedGen:CN169374|MedGen:CN221809;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.hgmd_2014.2.CLASS=DM?;bior.hgmd_2014.2.PHEN=Diabetes|_MODY3;bior.hgmd_2014.2.OMIM_ID=142410;bior.hgmd_2014.2.PubMed=16834925;bior.dbSNP139.ID=rs56348580	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	1/1:121:34:34:7:27:79.41%:7.9014E-13:34:36:0:7:21:6	1/1:121:24:24:1:23:95.83%:7.7525E-13:37:38:0:1:17:6	1/1:255:134:104:3:101:97.12%:8.7318E-57:34:42:0:3:42:59	1/1:255:124:105:4:101:96.19%:6.1477E-56:33:37:3:1:44:57	1/1:167:33:32:1:31:96.88%:1.8007E-17:37:32:0:1:27:4
chr13	28592641	.	T	G	.	PASS	ADP=142;WT=6;HET=0;HOM=2;NC=4;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:76:0:31:106:0:0	1/1:82:19:19:2:17:89.47%:5.9414E-9:78:74:1:1:10:7	./.:.:0	./.:.:0	1/1:76:14:14:0:14:100%:2.4927E-8:0:76:0:0:5:9	./.:.:0	0/0:670:359:358:358:0:0%:1E0:71:0:154:204:0:0	0/0:250:134:134:134:0:0%:1E0:76:0:71:63:0:0	0/0:655:349:349:349:0:0%:1E0:73:0:159:190:0:0	0/0:640:343:342:342:0:0%:1E0:74:0:139:203:0:0	0/0:662:354:354:354:0:0%:1E0:72:0:163:191:0:0
chr13	28592641	.	T	G	.	PASS	ADP=142;WT=6;HET=0;HOM=2;NC=4;bior.cosmic68.Histology_subtype=acute_lymphoblastic_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:76:0:31:106:0:0	1/1:82:19:19:2:17:89.47%:5.9414E-9:78:74:1:1:10:7	./.:.:0	./.:.:0	1/1:76:14:14:0:14:100%:2.4927E-8:0:76:0:0:5:9	./.:.:0	0/0:670:359:358:358:0:0%:1E0:71:0:154:204:0:0	0/0:250:134:134:134:0:0%:1E0:76:0:71:63:0:0	0/0:655:349:349:349:0:0%:1E0:73:0:159:190:0:0	0/0:640:343:342:342:0:0%:1E0:74:0:139:203:0:0	0/0:662:354:354:354:0:0%:1E0:72:0:163:191:0:0
chr13	28592641	.	T	G	.	PASS	ADP=142;WT=6;HET=0;HOM=2;NC=4;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:258:137:137:137:0:0%:1E0:76:0:31:106:0:0	1/1:82:19:19:2:17:89.47%:5.9414E-9:78:74:1:1:10:7	./.:.:0	./.:.:0	1/1:76:14:14:0:14:100%:2.4927E-8:0:76:0:0:5:9	./.:.:0	0/0:670:359:358:358:0:0%:1E0:71:0:154:204:0:0	0/0:250:134:134:134:0:0%:1E0:76:0:71:63:0:0	0/0:655:349:349:349:0:0%:1E0:73:0:159:190:0:0	0/0:640:343:342:342:0:0%:1E0:74:0:139:203:0:0	0/0:662:354:354:354:0:0%:1E0:72:0:163:191:0:0
chr13	28602358	.	G	T	.	PASS	ADP=329;WT=4;HET=2;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1266:682:675:675:0:0%:1E0:38:0:649:26:0:0	./.:.:2	./.:.:0	./.:.:0	./.:.:0	./.:.:2	0/0:857:665:659:629:29:4.4%:1.3588E-9:38:37:615:14:29:0	0/1:239:645:638:562:76:11.91%:1.2303E-24:37:36:557:5:76:0	0/0:1051:669:666:654:12:1.8%:2.3224E-4:37:35:643:11:12:0	0/0:977:666:658:641:17:2.58%:6.8713E-6:37:34:628:13:17:0	0/1:119:662:656:617:39:5.95%:1.0165E-12:37:36:606:11:39:0
chr13	28610183	.	A	G	.	PASS	ADP=133;WT=4;HET=2;HOM=1;NC=5;bior.ExAC.Info.AC=88815;bior.ExAC.Info.AN=126702;bior.ExAC.Info.AF=0.701;bior.ExAC.Info.AC_Het=23809;bior.ExAC.Info.AC_Hom=32473;bior.dbSNP139.ID=rs2491231	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:541:299:299:298:1:0.33%:5E-1:77:78:129:169:1:0	./.:.:0	./.:.:0	./.:.:7	0/0:272:146:146:146:0:0%:1E0:77:0:78:68:0:0	0/1:40:198:197:184:13:6.6%:9.9495E-5:77:77:69:115:4:9	0/0:613:328:328:328:0:0%:1E0:77:0:85:243:0:0	0/0:635:360:360:358:2:0.56%:2.4965E-1:71:77:106:252:2:0	1/1:255:67:67:6:61:91.04%:1.1362E-31:78:76:1:5:17:44	0/1:255:203:203:87:116:57.14%:6.7312E-46:77:77:31:56:41:75
chr13	49039374	.	C	T	.	PASS	ADP=203;WT=6;HET=3;HOM=2;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=2594029;bior.cosmic68.Histology_subtype=astrocytoma_Grade_IV;bior.dbSNP139.ID=rs137853293	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1227:673:668:667:1:0.15%:5E-1:37:16:0:667:0:1	0/1:255:365:365:190:175:47.95%:1.6323E-65:65:75:16:174:86:89	1/1:255:114:114:0:114:100%:4.392E-68:0:77:0:0:66:48	1/1:255:333:333:16:317:95.2%:1.7258E-172:76:76:1:15:164:153	0/1:255:377:376:200:176:46.81%:1.7032E-65:60:76:25:175:92:84	0/1:255:207:207:110:97:46.86%:2.1355E-36:76:76:22:88:45:52	0/0:212:114:114:114:0:0%:1E0:76:0:43:71:0:0	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:76:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039374	.	C	T	.	PASS	ADP=203;WT=6;HET=3;HOM=2;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=2594029;bior.cosmic68.Histology_subtype=astrocytoma_Grade_IV;bior.dbSNP139.ID=rs137853293	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1227:673:668:667:1:0.15%:5E-1:37:16:0:667:0:1	0/1:255:365:365:190:175:47.95%:1.6323E-65:65:75:16:174:86:89	1/1:255:114:114:0:114:100%:4.392E-68:0:77:0:0:66:48	1/1:255:333:333:16:317:95.2%:1.7258E-172:76:76:1:15:164:153	0/1:255:377:376:200:176:46.81%:1.7032E-65:60:76:25:175:92:84	0/1:255:207:207:110:97:46.86%:2.1355E-36:76:76:22:88:45:52	0/0:212:114:114:114:0:0%:1E0:76:0:43:71:0:0	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:76:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039374	.	C	T	.	PASS	ADP=203;WT=6;HET=3;HOM=2;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=2594029;bior.cosmic68.Histology_subtype=serous_carcinoma;bior.dbSNP139.ID=rs137853293	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1227:673:668:667:1:0.15%:5E-1:37:16:0:667:0:1	0/1:255:365:365:190:175:47.95%:1.6323E-65:65:75:16:174:86:89	1/1:255:114:114:0:114:100%:4.392E-68:0:77:0:0:66:48	1/1:255:333:333:16:317:95.2%:1.7258E-172:76:76:1:15:164:153	0/1:255:377:376:200:176:46.81%:1.7032E-65:60:76:25:175:92:84	0/1:255:207:207:110:97:46.86%:2.1355E-36:76:76:22:88:45:52	0/0:212:114:114:114:0:0%:1E0:76:0:43:71:0:0	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:76:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039374	.	C	T	.	PASS	ADP=203;WT=6;HET=3;HOM=2;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=2594029;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs137853293	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1227:673:668:667:1:0.15%:5E-1:37:16:0:667:0:1	0/1:255:365:365:190:175:47.95%:1.6323E-65:65:75:16:174:86:89	1/1:255:114:114:0:114:100%:4.392E-68:0:77:0:0:66:48	1/1:255:333:333:16:317:95.2%:1.7258E-172:76:76:1:15:164:153	0/1:255:377:376:200:176:46.81%:1.7032E-65:60:76:25:175:92:84	0/1:255:207:207:110:97:46.86%:2.1355E-36:76:76:22:88:45:52	0/0:212:114:114:114:0:0%:1E0:76:0:43:71:0:0	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:76:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039374	.	C	T	.	PASS	ADP=203;WT=6;HET=3;HOM=2;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=2594029;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs137853293	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1227:673:668:667:1:0.15%:5E-1:37:16:0:667:0:1	0/1:255:365:365:190:175:47.95%:1.6323E-65:65:75:16:174:86:89	1/1:255:114:114:0:114:100%:4.392E-68:0:77:0:0:66:48	1/1:255:333:333:16:317:95.2%:1.7258E-172:76:76:1:15:164:153	0/1:255:377:376:200:176:46.81%:1.7032E-65:60:76:25:175:92:84	0/1:255:207:207:110:97:46.86%:2.1355E-36:76:76:22:88:45:52	0/0:212:114:114:114:0:0%:1E0:76:0:43:71:0:0	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:76:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039374	.	C	T	.	PASS	ADP=203;WT=6;HET=3;HOM=2;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=2594029;bior.cosmic68.Histology_subtype=astrocytoma_Grade_IV;bior.dbSNP139.ID=rs137853293	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1227:673:668:667:1:0.15%:5E-1:37:16:0:667:0:1	0/1:255:365:365:190:175:47.95%:1.6323E-65:65:75:16:174:86:89	1/1:255:114:114:0:114:100%:4.392E-68:0:77:0:0:66:48	1/1:255:333:333:16:317:95.2%:1.7258E-172:76:76:1:15:164:153	0/1:255:377:376:200:176:46.81%:1.7032E-65:60:76:25:175:92:84	0/1:255:207:207:110:97:46.86%:2.1355E-36:76:76:22:88:45:52	0/0:212:114:114:114:0:0%:1E0:76:0:43:71:0:0	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:76:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039374	.	C	T	.	PASS	ADP=203;WT=6;HET=3;HOM=2;NC=1;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=2594029;bior.cosmic68.Histology_subtype=adenocarcinoma;bior.dbSNP139.ID=rs137853293	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1227:673:668:667:1:0.15%:5E-1:37:16:0:667:0:1	0/1:255:365:365:190:175:47.95%:1.6323E-65:65:75:16:174:86:89	1/1:255:114:114:0:114:100%:4.392E-68:0:77:0:0:66:48	1/1:255:333:333:16:317:95.2%:1.7258E-172:76:76:1:15:164:153	0/1:255:377:376:200:176:46.81%:1.7032E-65:60:76:25:175:92:84	0/1:255:207:207:110:97:46.86%:2.1355E-36:76:76:22:88:45:52	0/0:212:114:114:114:0:0%:1E0:76:0:43:71:0:0	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:76:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039375	.	G	A	.	PASS	ADP=204;WT=10;HET=1;HOM=0;NC=1;bior.ExAC.Info.AC=11;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=8.682e-05;bior.ExAC.Info.AC_Het=12;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=15605413;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1262:673:673:673:0:0%:1E0:38:0:0:673:0:0	0/0:685:365:365:365:0:0%:1E0:70:0:102:263:0:0	0/0:212:114:114:114:0:0%:1E0:76:0:66:48:0:0	0/0:625:333:333:333:0:0%:1E0:76:0:165:168:0:0	0/0:708:377:377:377:0:0%:1E0:67:0:117:260:0:0	0/0:389:207:207:207:0:0%:1E0:76:0:68:139:0:0	0/1:34:114:114:103:11:9.65%:3.7915E-4:76:78:41:62:2:9	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:75:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr13	49039375	.	G	A	.	PASS	ADP=204;WT=10;HET=1;HOM=0;NC=1;bior.ExAC.Info.AC=11;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=8.682e-05;bior.ExAC.Info.AC_Het=12;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Retinoblastoma;bior.hgmd_2014.2.OMIM_ID=614041;bior.hgmd_2014.2.PubMed=15605413;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:1262:673:673:673:0:0%:1E0:38:0:0:673:0:0	0/0:685:365:365:365:0:0%:1E0:70:0:102:263:0:0	0/0:212:114:114:114:0:0%:1E0:76:0:66:48:0:0	0/0:625:333:333:333:0:0%:1E0:76:0:165:168:0:0	0/0:708:377:377:377:0:0%:1E0:67:0:117:260:0:0	0/0:389:207:207:207:0:0%:1E0:76:0:68:139:0:0	0/1:34:114:114:103:11:9.65%:3.7915E-4:76:78:41:62:2:9	0/0:137:74:74:74:0:0%:1E0:76:0:39:35:0:0	0/0:179:96:96:96:0:0%:1E0:76:0:38:58:0:0	0/0:164:87:87:87:0:0%:1E0:75:0:43:44:0:0	0/0:25:13:13:13:0:0%:1E0:76:0:7:6:0:0
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=myelofibrosis	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_leukaemic_transformation_of_primary_myelofibrosis	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=acute_myeloid_leukaemia	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr15	90631935	.	G	A	.	PASS	ADP=238;WT=2;HET=3;HOM=0;NC=7;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:996:663:663:646:16:2.41%:1.3922E-5:38:51:2:644:3:13	0/1:255:616:616:411:205:33.28%:2.4633E-71:38:48:0:411:24:181	0/1:255:495:495:351:144:29.09%:2.2067E-49:50:56:18:333:21:123	0/0:757:588:588:561:27:4.59%:5.4899E-9:43:45:28:533:4:23	0/1:188:497:497:437:60:12.07%:1.3034E-19:50:55:132:305:3:57
chr16	68835624	.	A	G	.	PASS	ADP=147;WT=6;HET=1;HOM=0;NC=5	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:4	./.:.:0	./.:.:0	0/1:33:35:35:25:10:28.57%:4.6276E-4:75:75:10:15:5:5	0/0:22:11:11:11:0:0%:1E0:76:0:2:9:0:0	0/0:616:339:339:338:1:0.29%:5E-1:74:33:166:172:1:0	0/0:670:357:357:357:0:0%:1E0:70:0:165:192:0:0	0/0:636:339:339:339:0:0%:1E0:74:0:164:175:0:0	0/0:648:346:345:345:0:0%:1E0:72:0:170:175:0:0	0/0:636:340:340:340:0:0%:1E0:74:0:161:179:0:0
chr17	7576612	.	T	A	.	PASS	ADP=67;WT=6;HET=1;HOM=0;NC=5	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:46:141:141:126:15:10.64%:2.0606E-5:60:35:126:0:15:0	0/0:101:62:62:61:1:1.61%:5E-1:55:32:61:0:1:0	0/0:403:226:226:225:1:0.44%:5E-1:53:18:225:0:1:0	0/0:521:336:336:329:7:2.08%:7.5698E-3:31:17:201:128:7:0	./.:.:1	./.:.:6	0/0:1:10:10:5:5:50%:1.6254E-2:37:20:3:2:5:0	0/0:3:10:10:6:4:40%:4.3344E-2:35:16:4:2:4:0	./.:.:4	0/0:3:10:10:6:4:40%:4.3344E-2:38:27:3:3:4:0
chr17	7577155	.	A	T	.	PASS	ADP=29;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:32:18:18:18:0:0%:1E0:34:0:6:12:0:0	0/0:17:10:10:10:0:0%:1E0:29:0:4:6:0:0	0/0:62:34:34:34:0:0%:1E0:36:0:3:31:0:0	0/0:25:13:13:13:0:0%:1E0:34:0:5:8:0:0	0/1:27:132:129:119:9:6.98%:1.6887E-3:28:15:5:114:0:9	0/0:62:34:34:34:0:0%:1E0:38:0:3:31:0:0	0/0:22:11:11:11:0:0%:1E0:41:0:5:6:0:0	0/0:97:51:51:51:0:0%:1E0:39:0:2:49:0:0	0/0:36:20:20:20:0:0%:1E0:40:0:3:17:0:0	0/0:55:30:30:30:0:0%:1E0:39:0:3:27:0:0
chr17	7577474	.	T	G	.	PASS	ADP=277;WT=7;HET=3;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:802:452:450:447:2:0.44%:2.4972E-1:55:17:250:197:2:0	0/0:981:537:536:535:1:0.19%:5E-1:44:15:264:271:0:1	0/0:1132:662:657:650:5:0.76%:3.1012E-2:33:16:306:344:3:2	0/0:1162:647:643:641:2:0.31%:2.4981E-1:34:16:329:312:1:1	0/0:988:550:549:547:2:0.36%:2.4977E-1:43:16:286:261:1:1	0/0:172:131:129:123:6:4.65%:1.4724E-2:34:15:39:84:0:6	0/1:31:101:101:90:10:9.9%:7.7103E-4:30:15:18:72:0:10	0/1:61:87:87:68:19:21.84%:6.3346E-7:26:16:4:64:0:19	0/1:27:127:127:118:9:7.09%:1.6867E-3:25:15:2:116:0:9	0/0:87:55:54:53:1:1.85%:5E-1:27:15:4:49:0:1
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=serous_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=ductal_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577575	.	A	G	.	PASS	ADP=149;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=serous_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:59:31:31:31:0:0%:1E0:30:0:31:0:0:0	0/1:24:111:111:103:8:7.21%:3.4281E-3:29:21:103:0:8:0	0/0:289:204:204:196:7:3.43%:7.4124E-3:25:22:196:0:7:0	0/1:36:216:216:202:12:5.56%:2.0836E-4:27:19:202:0:12:0	0/0:62:34:34:34:0:0%:1E0:38:0:32:2:0:0	0/0:372:279:279:267:12:4.3%:2.1637E-4:55:18:168:99:12:0	0/0:358:273:273:259:12:4.4%:2.1558E-4:56:19:162:97:12:0	0/0:300:216:216:207:8:3.7%:3.6558E-3:56:19:96:111:8:0	0/0:361:267:267:256:11:4.12%:4.3958E-4:48:19:183:73:11:0	0/1:24:159:159:151:8:5.03%:3.5694E-3:55:19:107:44:8:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=astrocytoma_Grade_II	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=neoplasm	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=hepatocellular_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=astrocytoma_Grade_II	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=astrocytoma_Grade_II	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=astrocytoma_Grade_II	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577586	.	A	C	.	PASS	ADP=142;WT=5;HET=4;HOM=0;NC=3;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:25:27:26:23:3:11.54%:1.1765E-1:28:15:22:1:3:0	0/1:27:93:92:83:9:9.78%:1.5908E-3:28:15:82:1:9:0	0/1:68:204:202:180:22:10.89%:1.3029E-7:28:15:180:0:22:0	0/1:46:216:214:198:15:7.01%:2.3643E-5:29:16:198:0:15:0	./.:.:6	0/0:343:269:268:255:13:4.85%:1.0517E-4:53:15:132:123:13:0	0/0:346:271:269:256:13:4.83%:1.0523E-4:54:15:150:106:13:0	0/0:327:215:214:209:5:2.34%:3.0521E-2:56:16:98:111:5:0	0/0:366:263:260:251:9:3.46%:1.8204E-3:49:16:178:73:9:0	0/1:66:156:153:131:21:13.82%:2.2719E-7:59:15:85:46:21:0
chr17	7577596	.	A	G	.	PASS	ADP=144;WT=8;HET=1;HOM=0;NC=3;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:52:27:27:27:0:0%:1E0:30:0:26:1:0:0	0/0:157:91:91:90:1:1.1%:5E-1:30:16:89:1:1:0	0/0:333:204:204:201:3:1.47%:1.2408E-1:30:16:201:0:3:0	0/0:343:216:215:211:4:1.86%:6.1627E-2:31:16:211:0:4:0	./.:.:6	0/0:433:270:266:262:4:1.5%:6.1794E-2:55:16:137:125:4:0	0/0:461:275:274:271:3:1.09%:1.2431E-1:55:16:161:110:3:0	0/0:385:216:216:215:1:0.46%:5E-1:57:16:103:112:1:0	0/0:493:275:273:272:1:0.37%:5E-1:51:16:186:86:1:0	0/1:30:158:157:147:10:6.37%:8.4238E-4:58:16:99:48:10:0
chr17	7577596	.	A	G	.	PASS	ADP=144;WT=8;HET=1;HOM=0;NC=3;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:52:27:27:27:0:0%:1E0:30:0:26:1:0:0	0/0:157:91:91:90:1:1.1%:5E-1:30:16:89:1:1:0	0/0:333:204:204:201:3:1.47%:1.2408E-1:30:16:201:0:3:0	0/0:343:216:215:211:4:1.86%:6.1627E-2:31:16:211:0:4:0	./.:.:6	0/0:433:270:266:262:4:1.5%:6.1794E-2:55:16:137:125:4:0	0/0:461:275:274:271:3:1.09%:1.2431E-1:55:16:161:110:3:0	0/0:385:216:216:215:1:0.46%:5E-1:57:16:103:112:1:0	0/0:493:275:273:272:1:0.37%:5E-1:51:16:186:86:1:0	0/1:30:158:157:147:10:6.37%:8.4238E-4:58:16:99:48:10:0
chr17	7578175	.	A	C	.	PASS	ADP=118;WT=7;HET=1;HOM=0;NC=4;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Li-Fraumeni_syndrome;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=14656244	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:40:22:22:22:0:0%:1E0:43:0:21:1:0:0	0/0:14:8:8:8:0:0%:1E0:41:0:6:2:0:0	0/0:29:15:15:15:0:0%:1E0:47:0:13:2:0:0	0/0:430:266:265:259:4:1.51%:6.1786E-2:60:17:98:161:0:4	0/0:462:298:296:289:6:2.03%:1.5229E-2:51:18:101:188:0:6	0/0:287:178:178:174:3:1.69%:1.2394E-1:53:17:56:118:0:3	0/0:441:245:245:244:1:0.41%:5E-1:49:18:77:167:0:1	0/1:92:390:387:355:30:7.75%:5.175E-10:54:38:129:226:15:15
chr17	7578285	.	C	T	.	PASS	ADP=255;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:1045:559:557:557:0:0%:1E0:42:0:145:412:0:0	0/0:694:475:447:437:9:2.01%:1.8751E-3:45:15:96:341:0:9	0/1:96:388:388:356:31:7.99%:2.491E-10:63:66:131:225:15:16	0/0:734:392:391:391:0:0%:1E0:64:0:182:209:0:0	0/0:657:381:371:369:2:0.54%:2.4966E-1:64:15:140:229:0:2	0/0:407:229:229:227:1:0.44%:5E-1:44:19:32:195:0:1	0/0:253:137:136:136:0:0%:1E0:41:0:33:103:0:0	0/0:392:212:210:210:0:0%:1E0:57:0:89:121:0:0	0/0:337:207:206:203:3:1.46%:1.2409E-1:50:15:89:114:3:0	0/0:235:127:126:126:0:0%:1E0:37:0:5:121:0:0
chr17	7578303	.	G	A	.	PASS	ADP=286;WT=6;HET=4;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:2	0/0:1071:578:571:571:0:0%:1E0:45:0:149:422:0:0	0/0:876:522:480:479:1:0.21%:5E-1:47:16:100:379:0:1	0/0:745:399:398:398:0:0%:1E0:66:0:144:254:0:0	0/0:768:410:409:409:0:0%:1E0:65:0:186:223:0:0	0/0:726:402:387:387:0:0%:1E0:64:0:139:248:0:0	0/1:246:287:286:211:74:25.87%:2.2515E-25:51:45:62:149:6:68	0/1:255:182:182:95:87:47.8%:7.1937E-33:45:44:54:41:9:78	0/1:255:231:231:105:126:54.55%:4.5373E-49:54:65:65:40:36:90	0/1:255:252:252:174:78:30.95%:2.7844E-27:50:57:96:78:25:53	0/0:417:243:241:239:2:0.83%:2.4948E-1:44:39:55:184:0:2
chr17	7578322	.	G	A	.	PASS	ADP=369;WT=9;HET=1;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:1043:582:580:577:2:0.34%:2.4978E-1:45:16:152:425:0:2	0/0:849:523:519:511:7:1.35%:7.6548E-3:45:16:106:405:0:7	0/0:763:408:408:408:0:0%:1E0:64:0:152:256:0:0	0/0:775:418:413:413:0:0%:1E0:64:0:186:227:0:0	0/0:713:395:391:390:1:0.26%:5E-1:63:17:144:246:0:1	0/0:832:536:530:519:10:1.89%:9.3554E-4:39:38:75:444:5:5	0/0:348:248:245:235:8:3.27%:3.6842E-3:40:39:57:178:4:4	0/0:596:458:455:431:19:4.18%:1.571E-6:43:38:97:334:10:9	0/0:655:485:468:447:15:3.21%:2.719E-5:41:37:114:333:7:8	0/1:67:427:421:398:22:5.23%:1.7979E-7:39:37:67:331:11:11
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578390	.	C	A	.	PASS	ADP=249;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:408:229:228:226:1:0.44%:5E-1:38:16:29:197:0:1	0/0:701:399:397:394:2:0.5%:2.4968E-1:40:16:24:370:0:2	0/0:377:203:202:202:0:0%:1E0:39:0:32:170:0:0	0/0:367:205:205:204:1:0.49%:5E-1:37:15:33:171:0:1	0/0:245:147:147:145:2:1.36%:2.4915E-1:38:16:15:130:0:2	0/0:723:404:398:397:1:0.25%:5E-1:41:16:45:352:0:1	0/0:419:310:308:296:12:3.9%:2.1889E-4:44:16:56:240:0:12	0/0:561:321:321:318:2:0.62%:2.4961E-1:39:16:25:293:0:2	0/0:619:367:367:363:4:1.09%:6.1989E-2:40:16:45:318:0:4	0/1:80:415:415:386:26:6.27%:9.9181E-9:44:16:60:326:0:26
chr17	7578405	.	G	A	.	PASS	ADP=246;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:300:390:231:220:11:4.74%:4.3228E-4:38:16:26:194:0:11	0/0:705:474:397:395:2:0.5%:2.4968E-1:39:16:23:372:0:2	0/0:336:295:199:196:2:1.01%:2.4937E-1:39:16:29:167:0:2	0/1:33:304:207:195:11:5.31%:4.2577E-4:37:16:29:166:0:11	0/0:263:176:149:148:1:0.67%:5E-1:38:15:15:133:1:0	0/0:716:488:395:393:1:0.25%:5E-1:40:17:41:352:0:1	0/0:502:438:304:299:4:1.32%:6.1881E-2:44:17:55:244:0:4	0/0:535:442:330:325:5:1.52%:3.0777E-2:37:16:21:304:0:5	0/0:587:458:366:360:6:1.64%:1.5306E-2:40:17:43:317:0:6	0/0:630:471:373:369:4:1.07%:6.1997E-2:44:21:59:310:0:4
chr17	7578405	.	G	A	.	PASS	ADP=246;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:300:390:231:220:11:4.74%:4.3228E-4:38:16:26:194:0:11	0/0:705:474:397:395:2:0.5%:2.4968E-1:39:16:23:372:0:2	0/0:336:295:199:196:2:1.01%:2.4937E-1:39:16:29:167:0:2	0/1:33:304:207:195:11:5.31%:4.2577E-4:37:16:29:166:0:11	0/0:263:176:149:148:1:0.67%:5E-1:38:15:15:133:1:0	0/0:716:488:395:393:1:0.25%:5E-1:40:17:41:352:0:1	0/0:502:438:304:299:4:1.32%:6.1881E-2:44:17:55:244:0:4	0/0:535:442:330:325:5:1.52%:3.0777E-2:37:16:21:304:0:5	0/0:587:458:366:360:6:1.64%:1.5306E-2:40:17:43:317:0:6	0/0:630:471:373:369:4:1.07%:6.1997E-2:44:21:59:310:0:4
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=astrocytoma_Grade_IV	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=mucoepidermoid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=transitional_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=transitional_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578407	.	G	A	.	PASS	ADP=253;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=3;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=2.368e-05;bior.ExAC.Info.AC_Het=3;bior.ExAC.Info.AC_Hom=0;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Ovarian_carcinoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=22006311;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:360:411:264:251:10:3.79%:8.9447E-4:36:19:23:228:0:10	0/0:684:475:404:400:4:0.99%:6.2036E-2:38:20:25:375:0:4	0/0:299:302:205:198:6:2.93%:1.5053E-2:39:18:26:172:0:6	0/1:39:316:214:199:13:6.07%:1.0099E-4:36:18:30:169:0:13	0/0:263:178:150:148:1:0.67%:5E-1:38:15:15:133:0:1	0/0:699:491:412:407:4:0.97%:6.2044E-2:39:20:43:364:0:4	0/0:488:439:304:299:5:1.64%:3.0736E-2:44:17:56:243:0:5	0/0:509:445:341:332:9:2.64%:1.8515E-3:36:21:21:311:0:9	0/0:644:460:374:371:3:0.8%:1.245E-1:39:20:44:327:0:3	0/0:641:474:371:368:3:0.81%:1.2449E-1:44:19:59:309:0:3
chr17	7578409	.	C	G	.	PASS	ADP=341;WT=2;HET=8;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:196:444:431:367:62:14.39%:2.0139E-20:30:17:32:335:0:62	0/1:114:488:485:446:37:7.63%:3.5533E-12:36:17:26:420:0:37	0/1:113:317:313:276:36:11.5%:4.9856E-12:32:16:30:246:0:36	0/1:125:329:326:285:40:12.27%:2.5324E-13:31:16:35:250:0:40	0/1:46:184:181:166:15:8.29%:2.2557E-5:36:17:16:150:0:15	0/1:82:502:501:472:27:5.39%:5.1911E-9:36:16:50:422:0:27	0/0:570:452:450:427:22:4.89%:1.8318E-7:36:17:58:369:0:22	0/1:140:463:459:414:45:9.8%:9.1458E-15:32:16:20:394:0:45	0/1:92:470:469:438:30:6.4%:5.7631E-10:35:16:44:394:0:30	0/0:674:486:483:466:17:3.52%:6.6112E-6:38:16:61:405:0:17
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=intestinal_adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578413	.	C	G	.	PASS	ADP=373;WT=9;HET=1;HOM=0;NC=2;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/0:681:531:518:493:22:4.25%:1.8961E-7:27:17:35:458:0:22	0/0:855:539:536:527:9:1.68%:1.8881E-3:34:17:27:500:0:9	0/0:538:360:351:343:8:2.28%:3.7519E-3:30:17:36:307:0:8	0/1:70:398:394:370:23:5.84%:8.5581E-8:28:17:39:331:0:23	0/0:330:205:201:198:3:1.49%:1.2406E-1:34:17:20:178:0:3	0/0:882:530:528:522:6:1.14%:1.5403E-2:35:16:52:470:0:6	0/0:726:467:465:455:9:1.94%:1.8781E-3:36:17:59:396:0:9	0/0:708:493:492:476:15:3.05%:2.7379E-5:31:16:22:454:0:15	0/0:828:508:506:499:7:1.38%:7.651E-3:34:16:46:453:0:7	0/0:902:497:494:493:1:0.2%:5E-1:38:16:63:430:0:1
chr17	7578422	.	T	A	.	PASS	ADP=452;WT=0;HET=10;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:255:643:639:486:146:22.88%:8.4718E-49:27:20:38:448:0:146	0/1:255:630:630:544:82:13.02%:1.2088E-26:31:20:28:516:0:82	0/1:255:505:505:405:97:19.21%:3.6957E-32:27:19:35:370:0:97	0/1:255:546:544:413:125:22.98%:6.6642E-42:26:19:37:376:0:125	0/1:84:240:239:211:27:11.34%:3.4109E-9:31:20:19:192:0:27	0/1:206:624:623:556:66:10.59%:2.1936E-21:32:19:50:506:0:66	0/1:198:525:525:459:63:12%:1.4803E-20:35:19:60:399:0:63	0/1:255:571:571:466:103:18.04%:6.1258E-34:29:20:21:445:0:103	0/1:255:615:615:522:91:14.8%:1.0924E-29:31:20:46:476:0:91	0/1:126:541:541:499:41:7.58%:2.0658E-13:36:19:65:434:0:41
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=basal_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578423	.	C	T	.	PASS	ADP=446;WT=7;HET=3;HOM=0;NC=2;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:116:644:611:567:38:6.22%:1.9972E-12:27:17:42:525:0:38	0/0:861:631:611:590:20:3.27%:8.1407E-7:31:18:28:562:0:20	0/1:120:532:497:455:39:7.85%:8.3332E-13:28:18:34:421:0:39	0/1:149:566:534:484:48:8.99%:1.1707E-15:26:18:37:447:1:47	0/0:304:247:241:228:12:4.98%:2.1206E-4:31:17:20:208:0:12	0/0:879:625:614:594:19:3.09%:1.6555E-6:32:18:50:544:0:19	0/0:733:530:524:505:18:3.44%:3.2874E-6:36:19:59:446:0:18	0/0:816:587:575:554:18:3.13%:3.3302E-6:28:18:22:532:0:18	0/0:832:625:609:586:23:3.78%:9.6471E-8:30:18:46:540:0:23	0/0:842:549:543:530:11:2.03%:4.6385E-4:36:17:64:466:1:10
chr17	7578424	.	A	C	.	PASS	ADP=486;WT=7;HET=3;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	0/1:129:644:630:588:42:6.67%:1.1215E-13:28:18:26:562:2:40	0/0:886:632:630:608:21:3.33%:4.0241E-7:31:17:26:582:0:21	0/1:113:621:617:580:37:6%:4.1717E-12:26:18:29:551:1:36	0/1:107:652:649:613:35:5.39%:1.8159E-11:26:16:35:578:0:35	0/0:393:266:264:257:7:2.65%:7.5041E-3:30:19:17:240:1:6	0/0:957:624:619:606:13:2.1%:1.1454E-4:33:16:46:560:0:13	0/0:919:567:564:556:8:1.42%:3.8098E-3:35:18:56:500:0:8	0/0:1030:656:654:642:12:1.83%:2.3202E-4:29:18:20:622:0:12	0/0:932:632:631:614:17:2.69%:6.8402E-6:31:18:45:569:0:17	0/0:932:581:578:568:9:1.56%:1.8927E-3:36:20:63:505:0:9
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=hepatocellular_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=hepatocellular_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=non_small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=small_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=intestinal_adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=hepatocellular_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=diffuse_adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=hepatocellular_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=NS	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=squamous_cell_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7578469	.	C	A	.	PASS	ADP=503;WT=2;HET=8;HOM=0;NC=2;bior.hgmd_2014.2.CLASS=DM;bior.hgmd_2014.2.PHEN=Glioblastoma;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=7664239;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/1:206:629:608:541:66:10.86%:2.0916E-21:38:42:14:527:7:59	0/1:255:633:619:494:124:20.03%:4.8879E-41:39:39:14:480:5:119	0/0:859:641:627:603:23:3.67%:9.7037E-8:38:37:21:582:1:22	0/1:255:643:628:521:106:16.88%:9.6272E-35:37:38:14:507:10:96	0/1:254:560:551:471:80:14.52%:3.7504E-26:42:47:87:384:40:40	0/1:113:603:585:546:37:6.32%:4.0343E-12:37:37:12:534:1:36	0/1:132:591:580:537:43:7.41%:5.0663E-14:40:40:34:503:1:42	0/0:1144:650:633:631:2:0.32%:2.498E-1:37:58:11:620:2:0	0/1:98:630:614:581:32:5.21%:1.537E-10:37:36:15:566:1:31	0/1:91:602:592:562:30:5.07%:6.3892E-10:39:36:39:523:1:29
chr17	7579363	.	A	C	.	PASS	ADP=125;WT=7;HET=1;HOM=0;NC=4	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:647:348:346:346:0:0%:1E0:62:0:190:156:0:0	./.:.:0	./.:.:0	0/0:299:159:159:159:0:0%:1E0:70:0:97:62:0:0	0/0:590:326:325:324:1:0.31%:5E-1:64:15:168:156:0:1	0/0:220:119:117:117:0:0%:1E0:62:0:53:64:0:0	0/0:157:91:91:90:1:1.1%:5E-1:55:15:41:49:0:1	0/0:250:167:163:159:4:2.45%:6.1348E-2:39:19:119:40:0:4	0/1:49:228:227:210:16:7.08%:1.159E-5:43:15:50:160:0:16	0/0:97:79:77:72:4:5.19%:6.0025E-2:35:19:4:68:0:4
chr17	7579419	.	A	G	.	PASS	ADP=159;WT=3;HET=3;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	0/0:59:31:31:31:0:0%:1E0:74:0:11:20:0:0	./.:.:4	0/1:67:334:332:309:22:6.63%:1.6622E-7:24:16:307:2:22:0	0/0:530:382:377:364:13:3.45%:1.0988E-4:22:16:364:0:13:0	0/1:115:394:389:351:37:9.51%:2.9553E-12:24:16:351:0:37:0	0/0:355:284:272:257:12:4.41%:2.1537E-4:27:16:255:2:12:0	0/1:92:524:512:482:30:5.86%:6.0133E-10:26:16:481:1:30:0
chr17	7579421	.	G	T	.	PASS	ADP=156;WT=2;HET=4;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	0/0:59:31:31:31:0:0%:1E0:72:0:11:20:0:0	./.:.:4	0/1:106:314:313:278:34:10.86%:2.2499E-11:23:18:276:2:34:0	0/1:86:365:361:333:28:7.76%:2.1613E-9:21:17:333:0:28:0	0/1:77:376:375:349:25:6.67%:1.9685E-8:23:18:349:0:25:0	0/0:343:276:268:255:13:4.85%:1.0517E-4:26:19:252:3:13:0	0/1:114:533:524:487:37:7.06%:3.766E-12:26:19:474:13:37:0
chr17	7579422	.	G	C	.	PASS	ADP=151;WT=1;HET=5;HOM=0;NC=6	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	0/0:59:31:31:31:0:0%:1E0:71:0:11:20:0:0	./.:.:4	0/1:123:313:302:261:39:12.91%:4.8557E-13:22:16:259:2:39:0	0/1:128:364:352:311:41:11.65%:1.3204E-13:21:16:311:0:41:0	0/1:171:373:358:303:54:15.08%:6.345E-18:24:16:303:0:54:0	0/1:58:274:262:243:19:7.25%:1.3598E-6:27:15:240:3:19:0	0/1:133:530:501:458:43:8.58%:4.4346E-14:26:16:446:12:43:0
chr17	7579425	.	C	A	.	PASS	ADP=147;WT=1;HET=4;HOM=0;NC=7	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/1:87:303:296:266:28:9.46%:1.8974E-9:30:23:264:2:28:0	0/1:80:356:351:325:26:7.41%:9.2157E-9:28:22:325:0:26:0	0/1:61:362:350:327:20:5.71%:7.1953E-7:29:22:327:0:20:0	0/1:61:270:260:240:20:7.69%:6.5237E-7:31:21:238:2:20:0	0/0:740:519:509:494:15:2.95%:2.7486E-5:32:21:482:12:15:0
chr17	7579429	.	T	G	.	PASS	ADP=145;WT=0;HET=5;HOM=0;NC=7	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/1:100:302:296:263:32:10.81%:9.5751E-11:27:15:261:2:32:0	0/1:96:353:344:311:31:9.01%:2.2853E-10:26:16:311:0:31:0	0/1:138:362:343:298:44:12.83%:1.2964E-14:27:16:298:0:44:0	0/1:71:267:260:237:23:8.85%:7.1677E-8:30:16:235:2:23:0	0/1:114:521:502:465:37:7.37%:3.6548E-12:30:16:451:14:37:0
chr17	7579438	.	C	T	.	PASS	ADP=87;WT=3;HET=2;HOM=0;NC=7;bior.ExAC.Info.AC=2;bior.ExAC.Info.AN=126682;bior.ExAC.Info.AF=1.579e-05;bior.ExAC.Info.AC_Het=2;bior.ExAC.Info.AC_Hom=0;bior.dbSNP139.ID=rs55754907	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/1:30:256:164:154:10:6.1%:8.4787E-4:31:45:148:6:10:0	0/0:298:289:160:160:0:0%:1E0:31:0:160:0:0:0	0/0:348:321:203:201:2:0.99%:2.4938E-1:32:16:201:0:2:0	0/1:69:248:189:166:22:11.64%:1.2421E-7:33:37:155:11:22:0	0/0:502:464:332:324:8:2.41%:3.7431E-3:35:37:315:9:8:0
chr17	7579447	.	A	G	.	PASS	ADP=31;WT=3;HET=1;HOM=0;NC=8;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:77:43:42:42:0:0%:1E0:38:0:35:7:0:0	./.:.:0	0/1:27:123:106:95:9:8.65%:1.6306E-3:27:15:95:0:9:0	0/0:204:137:132:129:3:2.27%:1.2357E-1:34:15:116:13:3:0	0/0:162:106:101:99:2:1.98%:2.4876E-1:38:15:80:19:2:0
chr17	7579447	.	A	G	.	PASS	ADP=31;WT=3;HET=1;HOM=0;NC=8;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:77:43:42:42:0:0%:1E0:38:0:35:7:0:0	./.:.:0	0/1:27:123:106:95:9:8.65%:1.6306E-3:27:15:95:0:9:0	0/0:204:137:132:129:3:2.27%:1.2357E-1:34:15:116:13:3:0	0/0:162:106:101:99:2:1.98%:2.4876E-1:38:15:80:19:2:0
chr17	7579447	.	A	G	.	PASS	ADP=31;WT=3;HET=1;HOM=0;NC=8;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:2	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:77:43:42:42:0:0%:1E0:38:0:35:7:0:0	./.:.:0	0/1:27:123:106:95:9:8.65%:1.6306E-3:27:15:95:0:9:0	0/0:204:137:132:129:3:2.27%:1.2357E-1:34:15:116:13:3:0	0/0:162:106:101:99:2:1.98%:2.4876E-1:38:15:80:19:2:0
chr17	7579472	.	G	C	.	PASS	ADP=158;WT=0;HET=0;HOM=6;NC=6;bior.Clinvar.ClinicalSignificance=Benign|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000144668|RCV000013144|RCV000034639|RCV000079202|RCV000132165;bior.Clinvar.PhenotypeIDs=|GeneReviews:NBK1311|MedGen:C1835398|OMIM:151623|Orphanet:ORPHA524|MedGen:C0027672|MedGen:CN169374|MedGen:CN221809;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=83571;bior.ExAC.Info.AN=126650;bior.ExAC.Info.AF=0.660;bior.ExAC.Info.AC_Het=26245;bior.ExAC.Info.AC_Hom=28558;bior.hgmd_2014.2.CLASS=DFP;bior.hgmd_2014.2.PHEN=Lung_cancer|_association_with;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=8625447;bior.cosmic68.Histology_subtype=astrocytoma_Grade_IV;bior.dbSNP139.ID=rs1042522	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:105:19:19:0:19:100%:2.8292E-11:0:45:0:0:2:17	./.:.:2	./.:.:0	./.:.:0	./.:.:0	1/1:255:411:406:0:405:99.75%:5.2256E-243:0:60:0:0:175:230	1/1:255:352:345:2:343:99.42%:3.8488E-202:17:69:1:1:153:190	1/1:255:411:358:1:356:99.44%:1.3916E-211:32:61:0:1:206:150	1/1:255:417:398:0:398:100%:8.4874E-239:0:59:0:0:257:141	1/1:255:381:368:0:364:98.91%:2.3957E-218:0:63:0:0:219:145
chr17	7579472	.	G	C	.	PASS	ADP=158;WT=0;HET=0;HOM=6;NC=6;bior.Clinvar.ClinicalSignificance=Benign|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000144668|RCV000013144|RCV000034639|RCV000079202|RCV000132165;bior.Clinvar.PhenotypeIDs=|GeneReviews:NBK1311|MedGen:C1835398|OMIM:151623|Orphanet:ORPHA524|MedGen:C0027672|MedGen:CN169374|MedGen:CN221809;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=83571;bior.ExAC.Info.AN=126650;bior.ExAC.Info.AF=0.660;bior.ExAC.Info.AC_Het=26245;bior.ExAC.Info.AC_Hom=28558;bior.hgmd_2014.2.CLASS=DFP;bior.hgmd_2014.2.PHEN=Lung_cancer|_association_with;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=8625447;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs1042522	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:105:19:19:0:19:100%:2.8292E-11:0:45:0:0:2:17	./.:.:2	./.:.:0	./.:.:0	./.:.:0	1/1:255:411:406:0:405:99.75%:5.2256E-243:0:60:0:0:175:230	1/1:255:352:345:2:343:99.42%:3.8488E-202:17:69:1:1:153:190	1/1:255:411:358:1:356:99.44%:1.3916E-211:32:61:0:1:206:150	1/1:255:417:398:0:398:100%:8.4874E-239:0:59:0:0:257:141	1/1:255:381:368:0:364:98.91%:2.3957E-218:0:63:0:0:219:145
chr17	7579472	.	G	C	.	PASS	ADP=158;WT=0;HET=0;HOM=6;NC=6;bior.Clinvar.ClinicalSignificance=Benign|Uncertain_significance;bior.Clinvar.RCVaccession=RCV000144668|RCV000013144|RCV000034639|RCV000079202|RCV000132165;bior.Clinvar.PhenotypeIDs=|GeneReviews:NBK1311|MedGen:C1835398|OMIM:151623|Orphanet:ORPHA524|MedGen:C0027672|MedGen:CN169374|MedGen:CN221809;bior.Clinvar.Guidelines=-;bior.Clinvar.ReviewStatus=classified_by_multiple_submitters;bior.ExAC.Info.AC=83571;bior.ExAC.Info.AN=126650;bior.ExAC.Info.AF=0.660;bior.ExAC.Info.AC_Het=26245;bior.ExAC.Info.AC_Hom=28558;bior.hgmd_2014.2.CLASS=DFP;bior.hgmd_2014.2.PHEN=Lung_cancer|_association_with;bior.hgmd_2014.2.OMIM_ID=191170;bior.hgmd_2014.2.PubMed=8625447;bior.cosmic68.Histology_subtype=NS;bior.dbSNP139.ID=rs1042522	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	1/1:105:19:19:0:19:100%:2.8292E-11:0:45:0:0:2:17	./.:.:2	./.:.:0	./.:.:0	./.:.:0	1/1:255:411:406:0:405:99.75%:5.2256E-243:0:60:0:0:175:230	1/1:255:352:345:2:343:99.42%:3.8488E-202:17:69:1:1:153:190	1/1:255:411:358:1:356:99.44%:1.3916E-211:32:61:0:1:206:150	1/1:255:417:398:0:398:100%:8.4874E-239:0:59:0:0:257:141	1/1:255:381:368:0:364:98.91%:2.3957E-218:0:63:0:0:219:145
chr17	7579520	.	T	C	.	PASS	ADP=163;WT=7;HET=2;HOM=1;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/1:57:117:117:99:18:15.38%:1.8802E-6:40:76:41:58:11:7	0/0:18:24:24:20:4:16.67%:5.461E-2:31:74:0:20:4:0	0/0:11:9:9:8:1:11.11%:5E-1:31:16:0:8:0:1	1/1:206:43:43:3:40:93.02%:2.287E-21:32:77:0:3:16:24	0/1:191:85:84:35:49:58.33%:7.0781E-20:44:76:9:26:27:22	0/0:723:398:398:397:1:0.25%:5E-1:33:16:8:389:0:1	0/0:673:360:360:360:0:0%:1E0:33:0:5:355:0:0	0/0:558:297:297:297:0:0%:1E0:33:0:3:294:0:0	0/0:568:304:304:304:0:0%:1E0:33:0:7:297:0:0	0/0:595:317:317:317:0:0%:1E0:33:0:6:311:0:0
chr17	37868262	.	C	T	.	PASS	ADP=251;WT=8;HET=1;HOM=0;NC=3;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=7.892e-06;bior.ExAC.Info.AC_Het=2;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:280:150:150:150:0:0%:1E0:76:0:68:82:0:0	./.:.:1	0/1:80:345:344:318:26:7.56%:9.1226E-9:76:58:176:142:18:8	0/0:201:109:108:108:0:0%:1E0:76:0:50:58:0:0	0/0:115:61:61:61:0:0%:1E0:74:0:32:29:0:0	0/0:854:455:455:455:0:0%:1E0:57:0:90:365:0:0	0/0:936:499:499:499:0:0%:1E0:51:0:76:423:0:0	0/0:872:466:466:466:0:0%:1E0:56:0:114:352:0:0	0/0:876:467:467:467:0:0%:1E0:55:0:100:367:0:0	0/0:861:472:472:471:1:0.21%:5E-1:55:39:95:376:0:1
chr17	37880967	.	C	A	.	PASS	ADP=253;WT=8;HET=2;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:4	0/0:630:367:365:362:3:0.82%:1.2449E-1:69:32:1:361:0:3	0/0:159:111:111:107:4:3.6%:6.0807E-2:75:32:1:106:0:4	0/0:748:480:475:466:9:1.89%:1.8799E-3:53:33:1:465:0:9	0/0:1188:665:657:655:2:0.3%:2.4981E-1:38:33:0:655:0:2	0/1:116:625:623:585:38:6.1%:2.0332E-12:38:32:0:585:0:38	0/0:565:301:301:301:0:0%:1E0:75:0:9:292:0:0	0/0:34:23:23:22:1:4.35%:5E-1:76:33:0:22:0:1	0/0:103:73:73:70:3:4.11%:1.2241E-1:75:33:0:70:0:3	0/0:377:213:212:211:1:0.47%:5E-1:75:77:7:204:0:1	0/1:49:197:197:181:16:8.12%:1.1112E-5:74:32:8:173:0:16
chr18	48584500	.	C	G	.	PASS	ADP=147;WT=8;HET=2;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:22:10:10:4:6:60%:5.418E-3:78:33:1:3:0:6	0/0:694:389:381:380:1:0.26%:5E-1:64:15:114:266:0:1	0/0:685:373:366:366:0:0%:1E0:66:0:123:243:0:0	0/0:591:315:315:315:0:0%:1E0:71:0:122:193:0:0	0/0:681:368:363:363:0:0%:1E0:68:0:126:237:0:0	0/0:440:273:269:265:4:1.49%:6.1802E-2:67:33:91:174:0:4	0/0:25:13:13:13:0:0%:1E0:72:0:9:4:0:0	./.:.:6	0/0:17:10:10:10:0:0%:1E0:76:0:2:8:0:0	0/0:14:8:8:8:0:0%:1E0:71:0:7:1:0:0	0/1:23:25:25:18:7:28%:4.8126E-3:74:33:5:13:0:7
chr18	48604672	.	A	G	.	PASS	ADP=367;WT=9;HET=1;HOM=0;NC=2;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=7.892e-06;bior.ExAC.Info.AC_Het=1;bior.ExAC.Info.AC_Hom=0	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:1251:668:668:668:0:0%:1E0:37:0:1:667:0:0	0/0:33:17:17:17:0:0%:1E0:38:0:2:15:0:0	0/0:1007:539:538:538:0:0%:1E0:35:0:2:536:0:0	0/0:1149:626:626:625:1:0.16%:5E-1:35:16:4:621:0:1	0/0:253:136:136:136:0:0%:1E0:35:0:0:136:0:0	0/0:760:524:524:507:15:2.86%:2.7558E-5:45:45:79:428:6:9	0/1:111:522:522:486:36:6.9%:7.7905E-12:47:41:51:435:4:32	0/0:589:405:405:393:12:2.96%:2.2477E-4:61:50:176:217:2:10	0/0:745:460:460:452:7:1.52%:7.6346E-3:53:56:119:333:4:3	0/0:840:519:519:511:8:1.54%:3.8015E-3:47:58:118:393:4:4
chr18	48604702	.	C	A	.	PASS	ADP=448;WT=7;HET=3;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:911:682:663:638:24:3.62%:4.8207E-8:28:17:1:637:0:24	0/1:146:667:523:475:47:8.99%:2.4031E-15:30:18:4:471:0:47	0/1:113:664:601:564:37:6.16%:4.1085E-12:29:17:2:562:0:37	0/0:866:665:629:606:23:3.66%:9.7134E-8:29:17:4:602:0:23	0/1:126:667:565:524:41:7.26%:2.142E-13:30:17:2:522:0:41	0/0:813:536:525:514:11:2.1%:4.6312E-4:43:18:81:433:0:11	0/0:793:534:527:514:13:2.47%:1.1326E-4:44:16:54:460:0:13	0/0:649:406:400:394:6:1.5%:1.5333E-2:62:17:159:235:0:6	0/0:563:443:436:416:20:4.59%:7.6313E-7:53:17:88:328:0:20	0/0:784:526:510:498:11:2.16%:4.6234E-4:44:17:118:380:0:11
chr18	48604705	.	G	T	.	PASS	ADP=484;WT=7;HET=3;HOM=0;NC=2	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:1035:684:684:668:16:2.34%:1.3963E-5:33:19:1:667:0:16	0/1:241:669:669:591:77:11.51%:6.4735E-25:31:18:4:587:0:77	0/1:151:666:666:616:49:7.36%:7.094E-16:33:21:2:614:0:49	0/0:912:668:668:642:25:3.74%:2.37E-8:34:19:4:638:0:25	0/1:202:670:670:605:65:9.7%:5.3031E-21:32:18:2:603:0:65	0/0:855:538:537:527:9:1.68%:1.8881E-3:46:21:81:446:0:9	0/0:962:536:536:533:2:0.37%:2.4977E-1:46:18:54:479:0:2	0/0:673:408:406:401:5:1.23%:3.0865E-2:61:18:158:243:0:5	0/0:733:454:454:447:7:1.54%:7.6326E-3:53:23:93:354:0:7	0/0:771:527:527:512:15:2.85%:2.7585E-5:46:19:120:392:0:15
chr19	1220321	.	T	C	.	PASS	ADP=58;WT=0;HET=0;HOM=5;NC=7;bior.dbSNP139.ID=rs2075606	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:1	./.:.:0	./.:.:0	1/1:76:14:14:0:14:100%:2.4927E-8:0:72:0:0:7:7	./.:.:0	./.:.:0	1/1:255:90:90:3:87:96.67%:1.4258E-48:77:70:2:1:44:43	1/1:255:62:62:0:62:100%:6.5755E-37:0:74:0:0:41:21	1/1:255:195:195:0:195:100%:9.8214E-117:0:72:0:0:99:96	1/1:255:339:339:0:339:100%:2.6031E-203:0:75:0:0:162:177	./.:.:0
chr19	1221229	.	G	T	.	PASS	ADP=512;WT=10;HET=1;HOM=0;NC=1;bior.cosmic68.Histology_subtype=adenocarcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/1:23:9:9:3:6:66.67%:4.5249E-3:64:32:1:2:0:6	0/0:1234:673:672:671:1:0.15%:5E-1:36:18:4:667:1:0	0/0:1247:666:665:665:0:0%:1E0:36:0:1:664:0:0	0/0:973:520:520:520:0:0%:1E0:47:0:45:475:0:0	0/0:1251:668:667:667:0:0%:1E0:36:0:2:665:0:0	0/0:425:288:288:280:8:2.78%:3.7185E-3:69:32:37:243:0:8	0/0:1251:670:668:668:0:0%:1E0:36:0:2:666:0:0	0/0:1247:667:665:665:0:0%:1E0:36:0:2:663:0:0	0/0:1251:669:668:668:0:0%:1E0:36:0:3:665:0:0	0/0:1244:664:663:663:0:0%:1E0:36:0:6:657:0:0	0/0:1223:668:667:665:1:0.15%:5E-1:36:37:1:664:0:1
chr19	17945638	.	G	A	.	PASS	ADP=5;WT=2;HET=0;HOM=1;NC=9;bior.ExAC.Info.AC=14;bior.ExAC.Info.AN=126702;bior.ExAC.Info.AF=1.105e-04;bior.ExAC.Info.AC_Het=15;bior.ExAC.Info.AC_Hom=0;bior.dbSNP139.ID=rs202171305	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	./.:.:0	0/0:40:22:22:22:0:0%:1E0:69:0:14:8:0:0	0/0:21:12:12:12:0:0%:1E0:50:0:11:1:0:0	./.:.:2	1/1:172:35:35:2:33:94.29%:5.9366E-18:77:77:1:1:20:13	./.:.:0
chr19	17947972	.	G	C	.	PASS	ADP=272;WT=7;HET=0;HOM=1;NC=4;bior.dbSNP139.ID=rs200582253	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:112:59:59:59:0:0%:1E0:76:0:59:0:0:0	./.:.:3	./.:.:0	./.:.:2	1/1:29:9:9:2:7:77.78%:1.1312E-3:75:32:2:0:0:7	0/0:8:8:8:7:1:12.5%:5E-1:75:34:4:3:0:1	0/0:1255:669:669:669:0:0%:1E0:37:0:665:4:0:0	0/0:1111:606:606:605:1:0.17%:5E-1:38:33:604:1:0:1	0/0:1205:656:656:655:1:0.15%:5E-1:37:39:650:5:1:0	0/0:1227:668:668:667:1:0.15%:5E-1:37:39:662:5:1:0	0/0:1109:591:591:591:0:0%:1E0:38:0:589:2:0:0
chr20	57484585	.	C	T	.	PASS	ADP=454;WT=8;HET=3;HOM=0;NC=1;bior.ExAC.Info.AC=1;bior.ExAC.Info.AN=126704;bior.ExAC.Info.AF=7.892e-06;bior.ExAC.Info.AC_Het=1;bior.ExAC.Info.AC_Hom=0;bior.cosmic68.Histology_subtype=endometrioid_carcinoma	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	0/0:426:227:227:227:0:0%:1E0:75:0:111:116:0:0	0/0:1251:675:668:668:0:0%:1E0:37:0:3:665:0:0	0/0:969:543:539:537:2:0.37%:2.4977E-1:45:27:48:489:0:2	0/0:853:457:456:456:0:0%:1E0:55:0:122:334:0:0	0/0:1247:669:665:665:0:0%:1E0:37:0:3:662:0:0	0/0:861:467:460:460:0:0%:1E0:54:0:83:377:0:0	0/0:673:477:471:456:15:3.18%:2.7251E-5:53:59:104:352:4:11	0/1:115:404:401:363:37:9.23%:3.0403E-12:65:56:141:222:11:26	0/1:92:546:540:510:30:5.56%:6.1552E-10:47:41:72:438:2:28	0/1:114:550:546:509:37:6.78%:3.8708E-12:46:47:66:443:7:30	0/0:606:488:482:458:24:4.98%:4.4445E-8:52:65:86:372:15:9
chr22	24176287	.	G	A	.	PASS	ADP=13;WT=4;HET=1;HOM=1;NC=6;bior.ExAC.Info.AC=12759;bior.ExAC.Info.AN=121340;bior.ExAC.Info.AF=0.105;bior.ExAC.Info.AC_Het=4877;bior.ExAC.Info.AC_Hom=575;bior.cosmic68.Histology_subtype=acute_lymphoblastic_leukaemia;bior.dbSNP139.ID=rs5030613	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:14:8:8:8:0:0%:1E0:76:0:8:0:0:0	./.:.:0	0/0:127:67:67:67:0:0%:1E0:75:0:67:0:0:0	0/0:47:26:26:26:0:0%:1E0:74:0:26:0:0:0	./.:.:1	0/1:48:24:24:11:13:54.17%:1.2938E-5:76:75:11:0:13:0	./.:.:0	./.:.:0	1/1:105:19:19:0:19:100%:2.8292E-11:0:77:0:0:19:0	0/0:25:14:14:14:0:0%:1E0:74:0:13:1:0:0
chr22	24176287	.	G	A	.	PASS	ADP=13;WT=4;HET=1;HOM=1;NC=6;bior.ExAC.Info.AC=12759;bior.ExAC.Info.AN=121340;bior.ExAC.Info.AF=0.105;bior.ExAC.Info.AC_Het=4877;bior.ExAC.Info.AC_Hom=575;bior.cosmic68.Histology_subtype=plasma_cell_myeloma;bior.dbSNP139.ID=rs5030613	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:14:8:8:8:0:0%:1E0:76:0:8:0:0:0	./.:.:0	0/0:127:67:67:67:0:0%:1E0:75:0:67:0:0:0	0/0:47:26:26:26:0:0%:1E0:74:0:26:0:0:0	./.:.:1	0/1:48:24:24:11:13:54.17%:1.2938E-5:76:75:11:0:13:0	./.:.:0	./.:.:0	1/1:105:19:19:0:19:100%:2.8292E-11:0:77:0:0:19:0	0/0:25:14:14:14:0:0%:1E0:74:0:13:1:0:0
chr22	24176287	.	G	A	.	PASS	ADP=13;WT=4;HET=1;HOM=1;NC=6;bior.ExAC.Info.AC=12759;bior.ExAC.Info.AN=121340;bior.ExAC.Info.AF=0.105;bior.ExAC.Info.AC_Het=4877;bior.ExAC.Info.AC_Hom=575;bior.cosmic68.Histology_subtype=plasma_cell_myeloma;bior.dbSNP139.ID=rs5030613	GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR	./.:.:0	./.:.:0	0/0:14:8:8:8:0:0%:1E0:76:0:8:0:0:0	./.:.:0	0/0:127:67:67:67:0:0%:1E0:75:0:67:0:0:0	0/0:47:26:26:26:0:0%:1E0:74:0:26:0:0:0	./.:.:1	0/1:48:24:24:11:13:54.17%:1.2938E-5:76:75:11:0:13:0	./.:.:0	./.:.:0	1/1:105:19:19:0:19:100%:2.8292E-11:0:77:0:0:19:0	0/0:25:14:14:14:0:0%:1E0:74:0:13:1:0:0
